10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2020

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from         to         

Commission File Number: 001-37785

Reata Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware	11-3651945
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
5320 Legacy Drive   Plano, Texas	75024
(Address of principal executive offices)	(Zip Code)

(972) 865-2219

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Common Stock, Par Value $0.001 Per Share	RETA	NASDAQ Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes  ☒    No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes ☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, an emerging growth company, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No ☒

As of August 5, 2020, the registrant had 28,559,247 shares of Class A common stock, $0.001 par value per share, and 5,045,092 shares of Class B common stock, $0.001 par value per share, outstanding.

TABLE OF CONTENTS

		Page
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS		1
DEFINED TERMS		3
PART I.	FINANCIAL INFORMATION
Item 1.	Financial Statements (Unaudited)	4
	Consolidated Balance Sheets	4
	Consolidated Statements of Operations	5
	Consolidated Statements of Stockholders’ Equity (Deficit)	6
	Consolidated Statements of Cash Flows	7
	Notes to Unaudited Consolidated Financial Statements	8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	34
Item 4.	Controls and Procedures	35
PART II.	OTHER INFORMATION
Item 1.	Legal Proceedings	35
Item 1A.	Risk Factors	35
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	35
Item 3.	Defaults Upon Senior Securities	35
Item 4.	Mine Safety Disclosures	36
Item 5.	Other Information	36
Item 6.	Exhibits	37
Signatures		38

i

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties.  We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws.  In this Quarterly Report on Form 10-Q, all statements, other than statements of historical or present facts, including statements regarding our future financial condition, future revenues, projected costs, prospects, business strategy, and plans and objectives of management for future operations, are forward-looking statements.  In some cases, you can identify forward-looking statements by terminology such as “believe,” “will,” “may,” “might,” “estimate,” “continue,” “anticipate,” “intend,” “target,” “project,” “model,” “should,” “would,” “plan,” “expect,” “predict,” “could,” “seek,” “goals,” “potential,”  and similar terms or expressions that concern our expectations, strategy, plans, or intentions.  These forward-looking statements include, but are not limited to, statements about:

• our expectations regarding the timing, costs, conduct, and outcome of our clinical trials, including statements regarding the timing of the initiation and availability of data from such trials;

• the timing and likelihood of regulatory filings and approvals for our product candidates;

• whether regulatory authorities determine that additional trials or data are necessary in order to accept a new drug application for review and/or approval;

• our ability to obtain funding for our operations, including funding necessary to complete further development and commercialization of our product candidates;

• our plans to research, develop, and commercialize our product candidates;

• the commercialization of our product candidates, if approved;

• the rate and degree of market acceptance of our product candidates;

• our expectations regarding the potential market size and the size of the patient populations for our product candidates, if approved for commercial use, and the potential market opportunities for commercializing our product candidates;

• the success of competing therapies that are or may become available;

• our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates;

• our ability to license additional intellectual property relating to our product candidates and to comply with our existing license agreements;

• our ability to maintain and establish relationships with third parties, such as contract research organizations, suppliers, and distributors;

• our ability to maintain and establish collaborators with development, regulatory, and commercialization expertise;

• our ability to attract and retain key scientific or management personnel;

• our ability to grow our organization and increase the size of our facilities to meet our anticipated growth;

• the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing;

• our expectations related to the use of our available cash;

• our ability to develop, acquire, and advance product candidates into, and successfully complete, clinical trials;

1

• the initiation, timing, progress, and results of future preclinical studies and clinical trials, and our research and development programs;

• the impact of governmental laws and regulations and regulatory developments in the United States and foreign countries;

• developments and projections relating to our competitors and our industry;

• the impact of the coronavirus disease (COVID-19) on our clinical trials, our supply chain, and our operations; and

• other risks and uncertainties, including those described under the heading “Risk Factors” included in our most recent Annual Report on Form 10-K for the year ended December 31, 2019, filed with the U.S. Securities and Exchange Commission (SEC) on February 19, 2020, as supplemented by our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, filed with the SEC on May 11, 2020.

Any forward-looking statements in this Quarterly Report on Form 10-Q reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements.

You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect.  Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

2

DEFINED TERMS

Unless the context requires otherwise, references to “Reata,” “the Company,” “we,” “us,” or “our” in this Quarterly Report on Form 10-Q refer to Reata Pharmaceuticals, Inc. and its subsidiaries.  We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below.

Abbreviated Term	Defined Term
AbbVie	AbbVie Inc.
ADPKD	Autosomal dominant polycystic kidney disease
ASU	Accounting Standards Update
Bardoxolone	Bardoxolone methyl
BXLS	Blackstone Life Sciences, LLC
CARES Act	Coronavirus Aid, Relief, and Economic Security Act
CKD	Chronic kidney disease
COVID-19	Coronavirus disease
CRO	Contract research organization
eGFR	Estimated glomerular filtration rate
ESKD	End stage kidney disease
Exchange Act	Securities Exchange Act of 1934
FA	Friedreich’s ataxia
FARA	Friedreich’s Ataxia Research Alliance
FASB	Financial Accounting Standards Board
FDA	United States Food and Drug Administration
FSGS	Focal segmental glomerulosclerosis
GFR	Glomerular filtration rate
IgAN	IgA nephropathy
IST	Investigator-Sponsored Trial
KKC	Kyowa Kirin Co., Ltd.
mFARS	Modified Friedreich’s Ataxia Rating Scale
NDA	New Drug Application
NYU	New York University Grossman School of Medicine
PDUFA	Prescription Drug User Fee Act
Registrational trial	An adequate and well-controlled trial designed to be sufficient to apply for regulatory approval of a drug candidate, although notwithstanding the Company’s design a regulatory agency may determine that further clinical studies or data are required
Sarbanes-Oxley Act	The Sarbanes-Oxley Act of 2002
SEC	U.S. Securities and Exchange Commission
T1D CKD	Type 1 diabetic CKD
T2D CKD	Type 2 diabetic CKD

3

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

Reata Pharmaceuticals, Inc.

Consolidated Balance Sheets

(in thousands, except share data)

	June 30, 2020			December 31, 2019
	(unaudited)
Assets
Cash and cash equivalents	$	610,419		$	664,324
Prepaid expenses and other current assets		7,830			4,952
Income tax receivable		22,218			—
Total current assets		640,467			669,276
Property and equipment, net		4,267			2,996
Other assets		7,670			10,148
Total assets	$	652,404		$	682,420
Liabilities and stockholders’ equity
Accounts payable		11,263			1,908
Accrued direct research liabilities		16,689			23,774
Other current liabilities		14,545			11,631
Current portion of payable to collaborators		—			150,000
Current portion of deferred revenue		4,688			4,701
Total current liabilities		47,185			192,014
Other long-term liabilities		6,940			6,982
Term loan, net of debt issuance costs		—			155,017
Liability related to sale of future royalties, net		294,234			—
Payable to collaborators, net of current portion		70,055			66,862
Deferred revenue, net of current portion		2,363			4,688
Total noncurrent liabilities		373,592			233,549
Commitments and contingencies
Stockholders’ equity:
Common stock A, $0.001 par value:    500,000,000 shares authorized; issued and outstanding – 28,526,532 and    27,878,550 at June 30, 2020 and December 31, 2019, respectively		29			28
Common stock B, $0.001 par value:    150,000,000 shares authorized; issued and outstanding – 5,058,319 and    5,318,157 shares at June 30, 2020 and December 31, 2019, respectively		5			5
Additional paid-in capital		1,058,606			967,317
Accumulated deficit		(827,013	)		(710,493	)
Total stockholders’ equity		231,627			256,857
Total liabilities and stockholders’ equity	$	652,404		$	682,420

See accompanying notes.

4

Reata Pharmaceuticals, Inc.

Unaudited Consolidated Statements of Operations

(in thousands, except share and per share data)

	Three Months Ended						Six Months Ended
	June 30						June 30
	2020			2019			2020			2019
Collaboration revenue
License and milestone	$	1,169		$	7,813		$	2,338		$	15,539
Other revenue		1,904			20			2,088			64
Total collaboration revenue		3,073			7,833			4,426			15,603
Expenses
Research and development		36,783			29,554			84,436			55,668
General and administrative		16,600			11,706			37,387			21,744
Depreciation		284			232			562			401
Total expenses		53,667			41,492			122,385			77,813
Other income (expense), net		(16,990	)		(701	)		(20,804	)		(1,301	)
Loss before taxes on income		(67,584	)		(34,360	)		(138,763	)		(63,511	)
(Benefit from) provision for taxes on income		(3	)		20			(22,243	)		23
Net loss	$	(67,581	)	$	(34,380	)	$	(116,520	)	$	(63,534	)
Net loss per share—basic and diluted	$	(2.03	)	$	(1.14	)	$	(3.51	)	$	(2.12	)
Weighted-average number of common shares used in    net loss per share basic and diluted		33,265,778			30,069,048			33,243,931			29,950,241

See accompanying notes.

5

Reata Pharmaceuticals, Inc.

Unaudited Consolidated Statements of Stockholders’ Equity (Deficit)

(in thousands, except share and per share data)

	Three Months Ended June 30, 2020
	Common Stock A				Common Stock B					Additional Paid-In		Total Accumulated			Total Stockholders’
	Shares		Amount		Shares			Amount		Capital		Deficit			Equity
Balance at March 31, 2020		28,166,652	$	28		5,070,271		$	5	$	988,046	$	(759,432	)	$	228,647
Net loss		—		—		—			—		—		(67,581	)		(67,581	)
Compensation expense    related to stock options		—		—		—			—		14,796		—			14,796
Exercise of options		—		—		7,135			—		365		—			365
Conversion of common stock    Class B to Class A		19,087		—		(19,087	)		—		—		—			—
Issuance of Common Stock		340,793		1		—			—		55,399		—			55,400
Balance at June 30, 2020		28,526,532	$	29		5,058,319		$	5	$	1,058,606	$	(827,013	)	$	231,627

	Six Months Ended June 30, 2020
	Common Stock A				Common Stock B					Additional Paid-In		Total Accumulated			Total Stockholders’
	Shares		Amount		Shares			Amount		Capital		Deficit			Equity
Balance at December 31, 2019		27,878,550	$	28		5,318,157		$	5	$	967,317	$	(710,493	)	$	256,857
Net loss		—		—		—			—	$	—		(116,520	)		(116,520	)
Compensation expense    related to stock options		—		—		—			—	$	34,104		—			34,104
Exercise of options		—		—		47,351			—	$	1,786		—			1,786
Conversion of common stock    Class B to Class A		307,189		—		(307,189	)		—	$	—		—			—
Issuance of Common Stock		340,793		1		—			—	$	55,399		—			55,400
Balance at June 30, 2020		28,526,532	$	29		5,058,319		$	5	$	1,058,606	$	(827,013	)	$	231,627

	Three Months Ended June 30, 2019
	Common Stock A				Common Stock B					Additional Paid-In		Total Accumulated			Total Stockholders’
	Shares		Amount		Shares			Amount		Capital		Deficit			(Deficit)
Balance at March 31, 2019		24,403,477	$	24		5,639,666		$	6	$	444,837	$	(449,477	)	$	(4,610	)
Net loss		—		—		—			—		—		(34,380	)		(34,380	)
Compensation expense    related to stock options		—		—		—			—		4,483		—			4,483
Exercise of options		—		—		54,791			—		1,034		—			1,034
Conversion of common stock    Class B to Class A		62,930		—		(62,930	)		—		—		—			—
Balance at June 30, 2019		24,466,407	$	24		5,631,527		$	6	$	450,354	$	(483,857	)	$	(33,473	)

	Six Months Ended June 30, 2019
	Common Stock A				Common Stock B					Additional Paid-In		Total Accumulated			Total Stockholders’
	Shares		Amount		Shares			Amount		Capital		Deficit			Equity (Deficit)
Balance at December 31, 2018		24,000,683	$	24		5,728,175		$	6	$	435,452	$	(420,323	)	$	15,159
Net loss		—		—		—			—		—		(63,534	)		(63,534	)
Compensation expense    related to stock options		—		—		—			—		8,710		—			8,710
Exercise of options		—		—		369,076			—		6,085		—			6,085
Conversion of common stock    Class B to Class A		465,724		—		(465,724	)		—		—		—			—
Other shareholder    transactions		—		—		—			—		107		—			107
Balance at June 30, 2019		24,466,407	$	24		5,631,527		$	6	$	450,354	$	(483,857	)	$	(33,473	)

See accompanying notes.

6

Reata Pharmaceuticals, Inc.

Unaudited Consolidated Statements of Cash Flows

(in thousands)

	Six Months Ended
	June 30
	2020			2019
Operating activities
Net loss	$	(116,520	)	$	(63,534	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		562			401
Amortization of debt issuance costs and implied interest		4,163			678
Non-cash interest expense on liability related to sale of future royalty		664			—
Stock-based compensation expense		34,104			8,710
Loss on extinguishment of debt		11,183			—
Changes in operating assets and liabilities:
Income tax receivable		(22,218	)		—
Prepaid expenses and other current assets and other assets		(1,815	)		(2,271	)
Accounts payable		9,355			312
Accrued direct research, other current, and long-term liabilities		(4,247	)		9,802
Payable to collaborators		(150,000	)		—
Deferred revenue		(2,338	)		(15,539	)
Net cash used in operating activities		(237,107	)		(61,441	)
Investing activities
Purchases of property and equipment		(384	)		(2,092	)
Net cash used in investing activities		(384	)		(2,092	)
Financing activities
Proceeds from issuance of common stock, net		55,399			—
Payments on long-term debt		(167,170	)		—
Exercise of options		1,786			6,085
Proceeds from sale of future royalties, net		293,571			107
Net cash provided by financing activities		183,586			6,192
Net decrease in cash and cash equivalents		(53,905	)		(57,341	)
Cash and cash equivalents at beginning of year		664,324			337,790
Cash and cash equivalents at end of period	$	610,419		$	280,449
Supplemental disclosures
Cash paid for interest	$	8,021		$	4,153
Non-cash activity:
Right-of-use assets obtained in exchange for lease obligations	$	—		$	8,981
Purchases of equipment in accounts payable, accrued direct research, other current, and long-term liabilities	$	1,448		$	170

See accompanying notes.

7

Reata Pharmaceuticals, Inc.

Notes to Unaudited Consolidated Financial Statements

1. Description of Business

The Company’s mission is to identify, develop, and commercialize innovative therapies that change patients’ lives for the better.  The Company focuses on small-molecule therapeutics with novel mechanisms of action for the treatment of severe, life-threatening diseases with few or no approved therapies.  The Company’s lead programs are in rare forms of chronic kidney disease (CKD) and a rare neurological disease.  The Company announced positive topline data from registrational trials for both of its lead product candidates, bardoxolone methyl (bardoxolone) in patients with CKD caused by Alport syndrome, and omaveloxolone in patients with a neurological disorder called Friedreich’s ataxia (FA).  Both bardoxolone and omaveloxolone activate the transcription factor Nrf2 to normalize mitochondrial function, restore redox balance, and resolve inflammation.  Because mitochondrial dysfunction, oxidative stress, and inflammation are features of many diseases, the Company believes bardoxolone and omaveloxolone have many potential clinical applications.  Reata possesses exclusive, worldwide rights to develop, manufacture and commercialize bardoxolone, omaveloxolone, and our next-generation Nrf2 activators, excluding certain Asian markets for bardoxolone in certain indications, which are licensed to Kyowa Kirin Co., Ltd. (KKC).

The Company’s consolidated financial statements include the accounts of all majority-owned subsidiaries.  Accordingly, the Company’s share of net earnings and losses from these subsidiaries is included in the consolidated statements of operations.  Intercompany profits, transactions, and balances have been eliminated in consolidation.

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements.  In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.  Operating results for the six months ended June 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020.  The consolidated balance sheet at December 31, 2019, has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements.  For further information, refer to the annual consolidated financial statements and footnotes thereto of the Company.

Summary of Significant Accounting Policies

The significant accounting policies used in preparation of these condensed consolidated financial statements for the three and six months ended June 30, 2020 are consistent with those discussed in Note 2 to the consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, except as noted below with respect to the Company’s liability related to sale of future royalties and as noted within the “Recent Accounting Pronouncements – Recently Adopted Accounting Pronouncements” section.

Liability Related to Sale of Future Royalties

On June 10, 2020, the Company entered into a Development and Commercialization Funding Agreement with an affiliate of Blackstone Life Sciences, LLC (BXLS) that provides funding for the development and commercialization of bardoxolone for the treatment of CKD caused by Alport syndrome, autosomal dominant polycystic kidney disease (ADPKD), and certain other rare CKD indications in return for future royalties (Development Agreement).  The Company accounted for the Development Agreement as a sale of future revenues resulting in a debt classification, primarily because the Company has significant continuing involvement in generating the future revenue on which the royalties are based. The debt will be amortized under the effective interest rate method and, accordingly, the Company is recognizing non-cash interest expense over the estimated term of the Development Agreement. The liability related to sale of future royalties, and the debt amortization, are based

8

on the Company’s current estimate of future royalties expected to be paid over the estimated term of the Development Agreement. The Company will periodically assess the expected royalty payments and, if materially different than its previous estimate, will prospectively adjust and recognize the related non-cash interest expense. The transaction costs associated with the liability will be amortized to non-cash interest expense over the estimated term of the Development Agreement. See Note 5, Liability Related to Sale of Future Royalties, of Notes to Consolidated Financial Statements contained in this Quarterly Report on Form 10-Q.

Fair Value Measurements

The Company categorizes its financial instruments measured at fair value into a three-level fair value hierarchy that prioritizes the inputs used in determining the fair value of the asset or liability. The three levels of the fair value hierarchy are as follows:

• Level 1 - Financial instruments that have values based on unadjusted quoted prices for identical assets or liabilities in an active market which the Company has the ability to access at the measurement date

• Level 2 - Financial instruments that have values based on quoted market prices in markets where trading occurs infrequently or that have values based on quoted prices of instruments with similar attributes in active markets.

• Level 3 - Financial instruments that have values based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset.

The Company has determined the fair value of the liability related to the sale of future royalties is based on the Company’s current estimates of future royalties expected to be paid to BXLS, over the life of the arrangement, which are considered Level 3. See Note 5, Liability Related to Sale of Future Royalties, of Notes to Consolidated Financial Statements contained in this Quarterly Report on Form 10-Q.

Recently Adopted Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board (FASB) issued Topic 842, amended by ASU 2018-11, Leases (Topic 842): Targeted Improvements. The new guidance requires a lessee to recognize assets and liabilities for all leases with lease terms of more than 12 months and provide additional disclosures. Topic 842 requires adoption using a modified retrospective transition approach with either 1) transition provisions at the beginning of the earliest comparative period with its cumulative adjustment recognized to retained earnings at the beginning of the earliest period presented or 2) a cumulative-effect adjustment recognized to the opening balance of retained earnings on the adoption.  We adopted this standard on January 1, 2019, using the cumulative-effect adjustment approach. We elected the package of practical expedients in transition for leases that commenced prior to January 1, 2019 whereby these contracts were not reassessed or reclassified from their previous assessment as of December 31, 2018.

In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808) (ASU 2018-18).  This update provides clarification on the interaction between Revenue from Contracts with Customers (Topic 606) and Collaborative Arrangements (Topic 808) including the alignment of unit of account guidance between the two topics.  This update is effective in fiscal years, including interim periods, beginning after December 15, 2019, and early adoption is permitted.  The Company adopted this standard on January 1, 2020 and its adoption did not have a material impact on the Company’s consolidated financial statements and related disclosure.

In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. This update requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to defer and recognize as an asset. This guidance should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. The Company adopted this standard on January 1, 2020 and its adoption did not have material impact to the Company’s consolidated financial statements and related disclosure.

9

3. Collaboration Agreements

AbbVie

In September 2010, the Company entered into a license agreement with AbbVie Inc. (AbbVie) (the AbbVie License Agreement) for an exclusive license to develop and commercialize bardoxolone in the Licensee Territory (as defined in the AbbVie License Agreement).

In December 2011, the Company entered into a collaboration agreement with AbbVie (the AbbVie Collaboration Agreement) to jointly research, develop, and commercialize the Company’s portfolio of second and later generation oral Nrf2 activators.

On October 9, 2019, the Company and AbbVie entered into an Amended and Restated License Agreement (the Reacquisition Agreement) pursuant to which the Company reacquired the development, manufacturing, and commercialization rights concerning its proprietary Nrf2 activator product platform originally licensed to AbbVie in the AbbVie License Agreement and the AbbVie Collaboration Agreement.  In exchange for such rights, the Company agreed to pay AbbVie $330.0 million, of which $100.0 million was paid as of December 31, 2019, $150.0 million was paid on June 30, 2020, and $80.0 million will be payable on November 30, 2021.  Additionally, the Company will pay AbbVie an escalating, low single-digit royalty on worldwide net sales, on a product-by-product basis, of omaveloxolone and certain next-generation Nrf2 activators. The Company recognized interest expense related to the Reacquisition Agreement of approximately $1.6 million and $0 million, during the three months ended June 30, 2020 and 2019, respectively, and $3.2 million and $0 million, during the six months ended June 30, 2020 and 2019, respectively.  As of June 30, 2020, the Company’s payable to collaborators was $80.0 million, with a present value of $70.1 million.  

The execution of the Reacquisition Agreement ended our performance obligations under the AbbVie Collaboration Agreement and included the write off of the remaining related deferred revenue balance, after which no further revenue was recognized.  Accordingly, there was no revenue recognized in 2020.  The Company recognized revenue related to the AbbVie Collaboration Agreement totaling approximately $6.6 million and $13.2 million during the three and six months ended June 30, 2019, respectively. The deferred revenue balance was $0 million as of June 30, 2020.

KKC

In December 2009, the Company entered into an exclusive license with KKC (the KKC Agreement) to develop and commercialize bardoxolone in the licensed territory.  The Company received a nonrefundable, up-front license fee of $35.0 million in 2009 and regulatory milestones totaling $45.0 million in 2010, 2012, and 2018 and could receive additional regulatory milestones of $52.0 million and commercial milestones of $140.0 million, as well as tiered royalties ranging from the low teens to the low 20 percent range, depending on the country of sale and the amount of annual net sales, on net sales by KKC in the licensed territory.  

The up-front payment and regulatory milestones are accounted for as a single unit of accounting.  Revenue is being recognized ratably through December 2021, which is the estimated minimum period that is needed to complete the deliverables under the terms of the KKC Agreement.  The Company began recognizing revenue related to the up-front payment upon execution of the KKC Agreement. The Company recognized collaboration revenue totaling approximately $1.2 million during each of the three months ended June 30, 2020 and 2019 and $2.3 million during each of the six months ended June 30, 2020 and 2019.  As of June 30, 2020, the Company recorded deferred revenue totaling approximately $7.1 million of which approximately $4.7 million is reflected as the current portion of deferred revenue.

4. Term Loan

On October 9, 2019, the Company entered into the First Amendment to the Amended and Restated Loan and Security Agreement (the Amended Restated Loan Agreement).  Under the Amended Restated Loan Agreement, the Term A Loan principal amount was $80.0 million, and the Term B Loan availability was increased from $45.0 million to $75.0 million (collectively with the Term A Loan, the Term Loans).  On December 20, 2019, the Company borrowed $75.0 million under the Term B Loan resulting in a principal balance of the Term Loans of $155.0 million.

10

On June 24, 2020, the Company paid off the total outstanding balance of the Term Loans prior to the maturity date.  The payoff consisted of (i) the outstanding principal balance of $155.0 million, (ii) exit fees of $6.7 million, which has been partially accrued up to the date of repayment, (iii) prepayment fees of $5.4 million, and (iv) accrued and unpaid interest of $1.0 million. At the time of payoff, all liabilities and obligations under the Amended Restated Loan Agreement were terminated. In connection with the payoff of the Term Loans, the Company recorded a loss on extinguishment of debt of $11.2 million in the three and six months ended June 30, 2020.

5. Liability Related to Sale of Future Royalties

On June 24, 2020, the Company closed on the Development Agreement with BXLS.  The Development Agreement includes a $300.0 million payment by an affiliate of BXLS in return for various percentage royalty payments on worldwide net sales of bardoxolone, once approved in the United States or certain specified European countries, by Reata and its licensees, other than KKC.  The royalty percentage will initially be in the mid-single digits and, in future years, can vary between higher-mid single digit percentages to low-single digit percentages depending on various milestones, including indication approval dates, cumulative royalty payments, and cumulative net sales.  Pursuant to the Development Agreement, we have granted BXLS a security interest in substantially all of our assets.

In addition, concurrent with the Development Agreement, the Company entered into a common stock purchase agreement (Purchase Agreement) with affiliates of BXLS to sell an aggregate of 340,793 shares of the Company’s Class A common stock at $146.72 per share for a total of $50.0 million.

The Company concluded that there were two units of accounting for the consideration received, comprised of the liability related to the sale of future royalties and the common shares.  The Company allocated the $300.0 million from the Development Agreement and $50.0 million from the Purchase Agreement between the two units of accounting on a relative fair value basis at the time of the transaction. The Company allocated $294.2 million, which includes $0.8 million in transaction costs incurred, in transaction consideration to the liability, and $55.5 million to the common shares.  The Company determined the fair value of the common shares based on the closing stock price on the June 24, 2020, the closing date of the Development Agreement. The effective interest rate under the Development Agreement, including transaction costs, is approximately 13.7%.

The following table shows the activity within the liability related to sale of future royalties for the six months ended June 30, 2020:

	Liability Related to Sale of Future Royalties
	(in thousands)
Transaction date balance	$	294,454
Non-cash interest expense recognized, net of transaction cost amortization		664
Balance at June 30, 2020		295,118
Less: Unamortized transaction cost		(884	)
Carrying value at June 30, 2020	$	294,234

6. Other Income (Expense), Net

	Three Months Ended						Six Months Ended
	June 30						June 30
	2020			2019			2020			2019
Other income (expense), net
Investment income	$	501		$	1,705		$	2,555		$	3,502
Interest expense		(5,644	)		(2,413	)		(11,512	)		(4,810	)
Non-cash interest expense on liability    related to sale of future royalty		(664	)		—			(664	)		—
Other income (expense)		—			7			—			7
Loss on extinguishment of debt		(11,183	)		—			(11,183	)		—
Total other income (expense), net	$	(16,990	)	$	(701	)	$	(20,804	)	$	(1,301	)

11

Investment Income

Interest income consists primarily of interest generated from our cash and cash equivalents.

Interest Expense

Interest expense consists primarily of interest on our borrowing activities under our loan agreements and the imputed interest from amount due to AbbVie under the Reacquisition Agreement.

Non-Cash Interest Expense on Liability Related to Sale of Future Royalties

Non-cash interest expense consists of recognition of interest expense based on the Company’s current estimate of future royalties expensed to be paid over the estimated term of the Development Agreement.

Other Income (Expense)

Other income (expense) consists primarily of gains and losses on foreign currency exchange and sales of assets.

Loss on Extinguishment of Debt

In June 2020, the Company paid off the Term Loans and recorded a loss on the extinguishment of debt of $11.2 million, which consisted primarily of prepayment fees, exit fees and unamortized debt issuance costs.

7. Leases

The Company’s headquarters are located in Plano, Texas, where it leases approximately 122,000 square feet of office space.  The Company leases additional office and laboratory space of approximately 34,890 square feet located in Irving, Texas. The lease terms for the Irving and Plano offices extend through October 31, 2022 with an option to renew up to six months and through April 30, 2022 with four successive three-month-period renewal options, respectively.  

The Company has an additional lease of a single-tenant, build-to-suit building of approximately 327,400 square feet of office and laboratory space located in Plano, Texas with an initial lease term of 16 years.  The Company entered into the lease agreement on October 15, 2019 (the Lease Agreement), and at the Company’s option, it may renew the lease for two consecutive five-year renewal periods or one ten-year renewal period.  The Company does not have control of the space or the construction prior to completion of construction.  Therefore, no right-of-use or lease liabilities were recorded in connection with the Lease Agreement as of June 30, 2020.  Under the First Amendment to the Lease Agreement executed in May 2020, the landlord will fund the Company’s leasehold improvements up to $31.3 million, of which the Company has recorded a leasehold incentive obligation of approximately $1.7 million as other long-term liabilities as of June 30, 2020.

At June 30, 2020, the weighted average incremental borrowing rate and the weighted average remaining lease term for the operating leases held by the Company were 9.6% and 2.3 years, respectively.  During the three and six months ended June 30, 2020, cash paid for amounts included for the measurement of lease liabilities was $1.0 million and $1.9 million, respectively. During the three and six months ended June 30, 2020 the Company recorded operating lease expense of $1.0 million and $1.9 million, respectively.  The Company has elected to net the amortization of the right-of-use assets and the reduction of the lease liabilities principal in accrued direct research and other current and long-term liabilities in the consolidated statements of cash flows.

Supplemental balance sheet information related to the Company’s operating leases is as follows:

	Balance Sheet Classification	As of June 30, 2020
		(in thousands)
Non-current right-of-use assets	Other assets	$	7,653
Current lease liabilities	Other current liabilities		3,452
Non-current lease liabilities	Other long-term liabilities		5,212

12

Maturities of lease liabilities by fiscal year for the Company’s operating leases:

	As of June 30, 2020
	(in thousands)
2020 (remaining six months)	$	2,063
2021		4,142
2022		3,500
Total lease payments		9,705
Less: Imputed interest		(1,041	)
Present value of lease liabilities	$	8,664

8. Income Taxes

On March 27, 2020, the United States enacted the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act).  The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and to provide assistance to individuals, families, and businesses affected by COVID-19.  Accordingly, under its provisions, for the six months ended June 30, 2020, the Company recognized a tax benefit and receivable of $22.1 million associated with the ability to carryback an applicable prior year’s net operating losses to a preceding year to generate a refund.

For the three months ended June 30, 2020, the Company’s effective tax rate was a benefit of 0.0% compared to 0.0% for the three months ended June 30, 2019.  The Company’s effective tax rate for the three months ended June 30, 2020 varies with the statutory rate primarily due to valuation allowances on deferred taxes.  For the six months ended June 30, 2020, the Company’s effective tax rate was a benefit of 16.0% compared to 0.0% for the six months ended June 30, 2019.  The Company’s effective tax rate for the six months ended June 30, 2020 varies with the statutory rate primarily due to the favorable impact associated with the CARES Act and changes in the valuation allowance related to certain deferred tax assets generated or utilized in the applicable period.  The Company’s deferred tax assets have been fully offset by a valuation allowance at June 30, 2020, and the Company expects to maintain this valuation allowance until there is sufficient evidence that future earnings can be achieved, which is uncertain at this time.  

9. Stock-Based Compensation

The following table summarizes stock-based compensation expense reflected in the consolidated statements of operations:

	Three Months Ended June 30				Six Months Ended June 30
	2020		2019		2020		2019
	(in thousands)
Research and development	$	7,527	$	1,659	$	19,044	$	3,350
General and administrative		7,269		2,824		15,060		5,360
	$	14,796	$	4,483	$	34,104	$	8,710

13

Restricted Stock Units (RSUs)

The following table summarizes RSUs as of June 30, 2020, under the Second Amended and Restated Long Term Incentive Plan (LTIP Plan) agreement and standalone option agreements:

	Number of RSUs		Weighted-Average Grant Date Fair Value
Outstanding at January 1, 2020		50,000	$	72.70
Granted		24,751	$	184.00
Vested		—	$	—
Forfeited		—	$	—
Outstanding at June 30, 2020		74,751	$	109.55

As of June 30, 2020, the performance targets for the performance-based RSUs have not been met. Accordingly, the fair value related to these performance-based RSUs of approximately $4.2 million has not been recognized. During the quarter ended June 30, 2020, the Company recognized $0.3 million in compensation expense related to time-based RSUs.

Stock Options  

The following table summarizes stock option activity as of June 30, 2020, and changes during the six months ended June 30, 2020, under the LTIP and standalone option agreements:

	Number of Options			Weighted-Average Exercise Price
Outstanding at January 1, 2020		4,038,949		$	41.24
Granted		973,999		$	203.19
Exercised		(47,351	)	$	37.51
Forfeited		(171,917	)	$	94.68
Outstanding at June 30, 2020		4,793,680		$	72.27
Exercisable at June 30, 2020		2,240,699		$	33.31

Stock-based compensation expense for the three and six months ended June 30, 2020, included accelerated recognition of expense due to modifications of outstanding stock options as a result of the death of an executive and employees who entered into consulting agreements at the termination of employment, which were considered to be non-substantive services. Accordingly, the Company recognized $2.9 million and $10.0 million for the three and six months ended June 30, 2020, respectively.

As of June 30, 2020, the Company has approximately 303,000 shares of performance-based stock options for which the performance targets have not been met.  Accordingly, the fair value related to these performance-based stock options of approximately $34.1 million has not been recognized.

The total intrinsic value of all outstanding options and exercisable options at June 30, 2020 was $448.7 million and $278.2 million, respectively.

14

10. Net Loss per Share

The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders:

	Three Months Ended June 30						Six Months Ended June 30
	2020			2019			2020			2019
	(in thousands, except share and per share data)
Numerator
Net loss	$	(67,581	)	$	(34,380	)	$	(116,520	)	$	(63,534	)
Denominator
Weighted-average number of common shares    used in net loss per share – basic		33,265,778			30,069,048			33,243,931			29,950,241
Dilutive potential common shares		—			—			—			—
Weighted-average number of common shares    used in net loss per share – diluted		33,265,778			30,069,048			33,243,931			29,950,241
Net loss per share – basic	$	(2.03	)	$	(1.14	)	$	(3.51	)	$	(2.12	)
Net loss per share – diluted	$	(2.03	)	$	(1.14	)	$	(3.51	)	$	(2.12	)

The number of weighted average options that were not included in the diluted earnings per share calculation because the effect would have been anti-dilutive represented 4,793,680 and 3,845,874 shares as of June 30, 2020 and 2019, respectively.

15

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes and other financial information appearing in this Quarterly Report on Form 10-Q.  Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, operations, and product candidates, includes forward-looking statements that involve risks and uncertainties.  Factors that may cause actual results to differ materially from current expectations include, among other things, those described under the heading “Risk Factors” and discussed elsewhere in this Quarterly Report on Form 10-Q.

Overview

We are a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies that change patients’ lives for the better.  We concentrate on small-molecule therapeutics with novel mechanisms of action for the treatment of severe, life-threatening diseases with few or no approved therapies.  Our lead programs are in rare forms of chronic kidney disease (CKD) and a rare neurological disease.  We have announced positive topline data from registrational trials for both of our lead product candidates, bardoxolone methyl (bardoxolone) in patients with CKD caused by Alport syndrome and omaveloxolone in patients with a neurological disorder called Friedreich’s ataxia (FA).  Both bardoxolone and omaveloxolone activate the transcription factor Nrf2 to normalize mitochondrial function, restore redox balance, and resolve inflammation.  Because mitochondrial dysfunction, oxidative stress, and inflammation are features of many diseases, we believe bardoxolone and omaveloxolone have many potential clinical applications.  We possess exclusive, worldwide rights to develop, manufacture, and commercialize bardoxolone, omaveloxolone, and our next-generation Nrf2 activators, excluding certain Asian markets for bardoxolone in certain indications, which are licensed to KKC.

Regulatory Update

Bardoxolone for CKD Caused by Alport Syndrome

Following the announcement of positive, year one data from the Phase 3 CARDINAL study of bardoxolone in patients with CKD caused by Alport syndrome in November 2019, we have been engaged in discussions with the U.S. Food and Drug Administration (FDA) regarding the Year 1 efficacy and safety results.  We have had a Type C meeting where the FDA expressed concerns with basing an NDA for accelerated approval on the Year 1 data and recommended that we consider submitting the NDA with Year 2 data based, in part, on the assumption that there would not be much delay in NDA submission.  Following the Type C meeting, we provided written responses, and engaged in follow up informal meetings, that we believe addressed the FDA comments regarding the Year 1 results.  Accordingly, we recently requested and were granted a pre-NDA meeting by the FDA to discuss the NDA submission content and plans.

Our plan has been, and continues to be, to submit the NDA for bardoxolone in Alport syndrome during fourth quarter of 2020 for accelerated approval based on the one-year data from the Phase 3 portion of CARDINAL.  If the second-year results are available during an acceptable time frame, we may be able to submit the second-year data to the NDA during the review process and before the FDA makes a determination about accelerated approval.  This may extend the PDUFA date, but could also result in consideration of full approval, rather than accelerated approval.  Alternatively, the FDA could recommend that we wait for the second-year data from CARDINAL to file the NDA.  This would permit us to file for full approval but would delay the filing until the first quarter of 2021 compared to our current guidance of filing by the end of this year.  This timing assumes that we can complete the activities necessary to provide the Year 2 data to the FDA on a timely basis and is, of course, subject to uncertainty resulting from the COVID-19 pandemic.  As a result of the measures taken in response to the pandemic, and based on current operational metrics, at this time we believe that the timeline for Year 2 data availability is unlikely to be affected by COVID-19.

Omaveloxolone for Friedreich’s Ataxia

Following the announcement of the positive data from the MOXIe Part 2 study in October 2019, we have planned, subject to discussion with regulatory authorities, to proceed with a submission for marketing approval of

16

omaveloxolone for the treatment of FA in the United States.  We recently completed a Type C meeting in which the FDA provided us with guidance that it does not have any concerns with the reliability of the modified Friedreich’s Ataxia Rating Scale (mFARS) primary endpoint results in the MOXIe Part 2 study.  Nevertheless, the FDA is not convinced that the MOXIe Part 2 results will support a single study approval without additional evidence that lends persuasiveness to the results.  In preliminary comments for the meeting, the FDA stated that we will need to conduct a second pivotal trial that confirms the mFARS results of the MOXIe Part 2 study with a similar magnitude of effect.  

In response to the preliminary comments, the Friedreich’s Ataxia Research Alliance (FARA), key FA clinicians, and we provided the FDA with information to demonstrate that it will be difficult to conduct an additional, prospective clinical trial in FA because of the very slow progression rate of FA, the limited number of FA patients available for clinical research, the small number of clinical trial investigators who can conduct the mFARS exam, and the impact of the COVID-19 pandemic on the ability to conduct neuroscience clinical trials.  Thus, conducting an additional pivotal study would result in a long delay in the availability of a potentially effective therapy to patients with a progressive, life-threatening disease with no treatment options.  The FDA acknowledged the unmet need of patients with FA, reiterated its commitment to facilitate the development of omaveloxolone within the constraints of the regulatory standards, and emphasized its willingness to consider all available options to meet the regulatory standards.  The FDA also acknowledged that launching a new, neuroscience clinical trial now may not be possible because of the COVID-19 pandemic.

At the Type C meeting, to address the FDA’s requirement, FARA, key opinion leaders, and Reata proposed a second study (the “crossover study”) to provide additional evidence of effectiveness.  The study would measure the effect of omaveloxolone on mFARS in patients who were previously randomized to placebo in the MOXIe Part 2 study and are being treated with omaveloxolone in the MOXIe open-label extension study.  The FDA acknowledged that a study like the proposed crossover study could provide important additional information and asked us to submit a design for the crossover study for their consideration.

If the FDA accepts this approach, we expect to complete the crossover study as early as the fourth quarter of this year.  Assuming that the FDA views the crossover study data as sufficiently positive to provide confirmatory evidence, our plan would be to submit an NDA during the first quarter of 2021.  If the FDA rejects the proposal or if the data are not supportive, we will evaluate whether it is feasible to conduct a second pivotal study in FA patients as suggested by the FDA.  Regardless of the interaction with the FDA, we plan to pursue marketing approval outside of the United States.

Second Quarter 2020 Key Developments

Strategic Investment from Blackstone Life Sciences

On June 24, 2020, we closed a Development and Commercialization Funding Agreement (Development Agreement) with an affiliate of Blackstone Life Sciences, LLC (BXLS) that provides funding for the development and commercialization of bardoxolone for the treatment of CKD caused by Alport syndrome, autosomal dominant polycystic kidney disease (ADPKD), and certain other rare CKD indications. The Development Agreement includes a $300 million payment by the Blackstone affiliate in return for various percentage royalty payments on worldwide net sales of bardoxolone by Reata and its licensees, other than KKC.  The royalty percentage will initially be in the mid-single digits and in future years can vary between higher-mid single digit percentages to low-single digit percentages depending on various milestones, including indication approval dates, cumulative royalty payments, and cumulative net sales. Pursuant to the Development Agreement, we have granted BXLS a security interest in substantially all of our assets.

In addition, affiliates of BXLS paid us an aggregate of $50.0 million to purchase an aggregate of 340,793 shares of our Class A common stock, par value $0.001 per share, at $146.72 per share.

In connection with the closing of the Development Agreement, we fully paid off our senior loan with Oxford Finance LLC and Silicon Valley Bank that included $155.0 million in principal and $12.1 million in exit and prepayment fees.

17

FALCON Trial Enrollment Resumed

In March 2020, we temporarily paused enrollment of new patients in the global Phase 3 FALCON trial of bardoxolone in patients with ADPKD due to the emergence of COVID-19 as a global public health threat. We expect to enroll a total of approximately 300 patients worldwide.  We began to lift the screening hold in FALCON in June 2020, and currently, all sites are able to screen patients and approximately half are able to randomize patients. The first patients have now reached the second year of the trial. The measures we implemented to the conduct of FALCON in response to COVID-19 have been effective, and we anticipate no meaningful impact on data integrity due to COVID-19.

Adjustments to Operations Due to COVID-19

Beginning in the first quarter of 2020, in accordance with recommendations from local, state, and national health authorities, we implemented and continue to enforce work-from-home measures and additional safety protocols to protect employees and the broader community and to ensure business continuity.  These measures include restricting on-site staff to only those required to execute their job responsibilities and limiting the number of staff working in our research and development laboratory.  We also continue to limit in-person meetings and business travel.  We will continue to monitor this dynamic situation closely and will take additional measures as required to preserve the safety of our employees and the broader community.

CARDINAL and EAGLE Trials Adapted for Continuity

The Phase 3 CARDINAL trial of bardoxolone in patients with CKD caused by Alport syndrome is fully enrolled and ongoing.  As previously announced, we are in the process of completing the Year 2 portion of our CARDINAL Phase 3 study.  As COVID-19 emerged as a pandemic with serious public health implications during the first quarter of 2020, we undertook a series of measures to protect the health and safety of patients and health care workers involved in our ongoing clinical studies, while maintaining the conduct of our studies in accordance with guidance provided by the FDA and the European Medicines Agency.  For example, we have implemented the use of at-home visits as an alternative to in-clinic visits when necessary to collect blood draws and to assess patient safety.  We also arranged for home delivery of the study drug to patients.  

At this time, approximately 60% of the 157 patients randomized to the CARDINAL Phase 3 cohort have completed the Year 2 final off-treatment visit.  The last study visits are anticipated to occur during the fourth quarter of 2020, which is consistent with our pre-COVID-19 timeline.  Currently, almost all sites are allowing on-site or remote monitoring.  

Patients who participated in the CARDINAL study may be eligible to enroll in an open-label extension study known as EAGLE.  We are implementing procedures for the conduct of EAGLE that are similar to those being used in CARDINAL to ensure continued access to bardoxolone and appropriate safety monitoring.

MOXIe Extension Study Advanced with Modifications

The MOXIe Part 2 trial was completed prior to the onset of the COVID-19 pandemic.  Patients who participated in MOXIe Part 1 or 2 were eligible to enroll in an open-label extension portion of the study.  We are implementing procedures for the conduct of the MOXIe extension study that are similar to those being used in our other ongoing studies to ensure continued access to omaveloxolone and appropriate safety monitoring.

BARCONA Study of Bardoxolone in Patients with COVID-19

Researchers at NYU Grossman School of Medicine (NYU) are initiating an Investigator-Sponsored Trial (IST), known as BARCONA, to study the effect of bardoxolone in patients suffering from COVID-19.  Serious complications of COVID-19 are caused by excessive, systemic inflammation, which can result in dysfunction of the lungs, kidneys, and other organs.  Acute kidney injury has been reported to occur in up to 28% of all hospitalized COVID-19 patients, and in up to 72% of patients who do not survive COVID-19.  Bardoxolone and its analogs have demonstrated anti-inflammatory activity in animal models of acute lung and kidney injury, have increased survival in models of systemic inflammation, suppress replication of several types of viruses and have shown improvements in kidney function in multiple clinical trials that enrolled over 3,000 patients with various forms of chronic kidney disease.  

18

The Phase 2 BARCONA study is a randomized, placebo-controlled, double-blind trial that will enroll 40 patients with a primary endpoint of safety and treatment duration of up to 29 days in hospitalized patients.  Major exclusion criteria include patients who are intubated and on invasive mechanical ventilation for three or more days, prior hospitalization for heart failure, or estimated glomerular filtration rate (eGFR) <30 ml/min/1.73 m².  To further mitigate any safety risk, enrollment will be paused after enrollment of the initial five patients to assess safety.  As with all trials conducted at NYU, the trial will be overseen by a Data Safety Monitoring Board that meets every other week.

We were involved in the design of the trial, have a representative on the study’s executive steering committee, and are providing drug supply, as requested by NYU.  Any further enrollment in a potential Phase 3 trial will be gated based on an assessment of Phase 2 safety and activity, as well as feasibility of conducting a Phase 3 trial.

Background: Our Programs

The following chart outlines each of our programs by indication and phase:

In addition, KKC, our strategic collaborator in CKD, is currently conducting its registrational trial of bardoxolone in diabetic (type 1 and 2) CKD in Japan.  KKC completed patient enrollment in this trial in June 2019 and expects to have topline data in the first half of 2022.

NYU has initiated an IST (Phase 2/3 trial) of bardoxolone in COVID-19 patients called BARCONA.  

*The CARDINAL study reported one-year data in November 2019 and is an ongoing two-year study.

**See discussion above under “Regulatory Update-Omaveloxolone for Friedreich's Ataxia”.

Programs in CKD

We are developing bardoxolone for the treatment of patients with certain rare forms of CKD.  CKD is characterized by a progressive worsening in the rate at which the kidney filters waste products from the blood, called the glomerular filtration rate (GFR). When GFR gets too low, patients develop end-stage kidney disease (ESKD) and require dialysis or a kidney transplant to survive.  Dialysis leads to a reduced quality of life and increases the likelihood of serious and life-threatening complications.  The five-year survival rate for hemodialysis patients is only approximately 42%.

Estimated glomerular filtration rate (eGFR) is an estimate of GFR that nephrologists use to track the decline in kidney function and progression of CKD.  In 11 separate CKD clinical trials, bardoxolone has been shown to improve eGFR in patients with diverse etiologies of CKD.  We believe that bardoxolone treatment has the potential

19

to delay or prevent GFR declines that cause the need for dialysis or a transplant in patients with Alport syndrome, ADPKD, and other rare forms of CKD.

Bardoxolone in CKD Caused by Alport Syndrome

We are developing bardoxolone for the treatment of patients with CKD caused by Alport syndrome, ADPKD, and other rare forms of CKD that, in the aggregate, affect more than 700,000 patients in the United States.  

Alport syndrome is a rare, genetic form of CKD caused by mutations in the genes encoding type IV collagen, which is a major structural component of the glomerular basement membrane in the kidney.  The kidneys of patients with Alport syndrome progressively lose the capacity to filter waste products out of the blood, which can lead to ESKD and the need for chronic dialysis treatment or a kidney transplant.  Alport syndrome affects both children and adults.  In patients with the most severe forms of the disease, approximately 50% progress to dialysis by age 25, 90% by age 40, and nearly 100% by age 60.  According to the Alport Syndrome Foundation, Alport syndrome affects approximately 30,000 to 60,000 people in the United States.  There are currently no approved therapies to treat CKD caused by Alport syndrome.

In November 2019, we announced that the Phase 3 portion of the CARDINAL study of bardoxolone in patients with CKD caused by Alport syndrome met its primary and key secondary Year 1 endpoints.  After 48 weeks of treatment, patients treated with bardoxolone had a statistically significant improvement compared to placebo in mean eGFR of 9.50 mL/min/1.73 m² (p<0.0001).  At Week 52, after 48 weeks of treatment and four weeks of off-treatment period, patients treated with bardoxolone had a statistically significant improvement compared to placebo in mean eGFR of 5.14 mL/min/1.73 m² (p=0.0012), while patients in the placebo arm of CARDINAL lost an average of 6.1 mL/min/1.73 m².  The retained benefit of kidney function during the off-treatment period is a key regulatory endpoint for the CARDINAL and FALCON studies.  Based on these positive results, and subject to discussions with regulatory authorities, we plan to proceed with the submission of regulatory filings this year for marketing approval in the United States.

Bardoxolone in ADPKD

ADPKD is a rare and serious hereditary form of CKD caused by a genetic defect in PKD1 or PKD2 genes leading to the formation of fluid-filled cysts in the kidneys and other organs.  Cyst growth can cause the kidneys to expand up to five to seven times their normal volume, leading to pain and progressive loss of kidney function.  ADPKD affects both men and women of all racial and ethnic groups and is the leading inheritable cause of kidney failure with an estimated diagnosed population of 140,000 patients in the United States.  Despite current standard of care treatment, an estimated 50% of ADPKD patients progress to ESKD and require dialysis or a kidney transplant by 60 years of age.

In a Phase 2 study called PHOENIX, bardoxolone demonstrated a statistically significant increase from baseline in mean eGFR of 9.3 mL/min/1.73 m² (p<0.0001) after 12 weeks of treatment in 31 patients with ADPKD.  Available historical data for 29 of these patients showed an average annual decline in eGFR of 4.8 mL/min/1.73 m² in the three-year period prior to study entry.  The United States Food and Drug Administration (FDA) has provided us with written guidance that, in patients with ADPKD, an analysis of eGFR during the off-treatment period demonstrating an improvement versus placebo after one year of bardoxolone treatment may support accelerated approval, and an improvement versus placebo after two years of treatment may support full approval.  In May 2019, we began enrollment in FALCON, an international, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial studying the safety and efficacy of bardoxolone in approximately 300 patients with ADPKD.  The enrollment of new patients was temporarily paused in March of 2020 due to safety concerns related to the COVID-19 global pandemic, and the screening hold in FALCON was lifted in June 2020 at some sites.  The trial will enroll a broad range of patients from 18 to 70 years old with an eGFR between 30 to 90 mL/min/1.73 m².  

Bardoxolone in Other Rare Forms of CKD

Three additional rare forms of CKD were studied in PHOENIX, including IgA nephropathy (IgAN), type 1 diabetic CKD (T1D CKD), and focal segmental glomerulosclerosis (FSGS).  In each of these Phase 2 cohorts, bardoxolone demonstrated a statistically significant increase from baseline in mean eGFR after 12 weeks of treatment.  We plan to pursue each of these rare and serious forms of CKD as commercial indications.

20

The FDA has granted orphan drug designation to bardoxolone for the treatment of Alport syndrome and ADPKD, and the European Commission has granted orphan drug designation to bardoxolone for the treatment of Alport syndrome.

Historical Development of Bardoxolone

Prior to our CARDINAL Phase 3 trial, clinical trials enrolling over 2,000 patients exposed to bardoxolone have demonstrated consistent, clinically meaningful improvement in kidney function across several disease states as measured by eGFR and other markers of kidney function.  Specifically, we have observed statistically significant increases in eGFR in all Phase 2 and Phase 3 clinical trials in numerous patient populations treated with bardoxolone, including patients with CKD caused by type 2 diabetes (T2D CKD), Alport syndrome, ADPKD, IgAN, T1D CKD, and FSGS.  

We believe these data, in addition to the CARDINAL Phase 3 one-year data, support the potential for bardoxolone to delay or prevent dialysis, kidney transplant, and death in patients with Alport syndrome and other forms of CKD.  

Additional observations from the prior clinical trials of bardoxolone include the following:

• Statistically significant increases in directly-measured GFR using the “gold standard” inulin clearance method, improvements in creatinine clearance, and reduction in the levels of blood waste products filtered by the kidney.  

• Sustained improvement in kidney function in long-term trials:  

o In the Phase 2 portion of CARDINAL, bardoxolone treatment produced a statistically significant increase from baseline in mean eGFR of 10.4 mL/min/1.73 m² (p<0.0001) after 48 weeks of treatment, which, based on historical data available for 22 of the patients prior to enrolling in the trial, represents a recovery of over two years of average decline in kidney function.  

o In two large, placebo-controlled clinical studies (BEAM and BEACON) in patients with T2D CKD, statistically significant increases in mean eGFR of 14.9 mL/min/1.73 m² (p<0.001) and 5.6 mL/min/1.73 m² (p<0.001), respectively, were sustained for at least one year.

• Reduction in risk of adverse kidney outcomes, suggesting that bardoxolone treatment preserves kidney function and may delay the onset of kidney failure in patients with T2D and stage 4 CKD:

o In BEACON, patients randomized to bardoxolone were significantly less likely to experience adverse kidney outcomes as defined by a composite endpoint consisting of ≥30% decline from baseline in eGFR, eGFR <15 mL/min/1.73 m², or ESKD events (HR=0.48, p<0.0001).  

o In BEACON, bardoxolone treatment resulted in a decreased number of kidney-related SAEs and ESKD events.  

• Statistically significant improvement in eGFR during the off-treatment period in BEAM, BEACON, the Phase 2 portion of CARDINAL at one year, and the Phase 3 portion of CARDINAL at one year.  

o The FDA has provided guidance to us and other sponsors that clinical trials with an eGFR benefit versus placebo during the off-treatment period may support approval in certain rare forms of CKD.  The FDA has provided guidance to us that, in patients with CKD caused by Alport syndrome or ADPKD, an eGFR benefit versus placebo during the off-treatment period after one year of bardoxolone treatment may support accelerated approval and after two years of bardoxolone treatment may support full approval.

o We believe the eGFR benefit during the off-treatment period observed in these clinical trials demonstrates that bardoxolone treatment improved the structure of the kidney, modified the course of the disease, and may prevent or delay kidney failure and the need for dialysis or a kidney transplant.

Programs in Neurological Diseases

Omaveloxolone in FA

21

We are developing omaveloxolone for the treatment of patients with FA, an inherited, debilitating, and degenerative neuromuscular disorder that is typically diagnosed during adolescence and typically leads to premature death.  Patients with FA experience progressive loss of coordination, muscle weakness, and fatigue, which commonly progresses to motor incapacitation and wheelchair reliance.  Symptoms generally occur in children, with patients requiring a wheelchair by their teens or early 20s.  FA affects approximately 5,000 children and adults in the United States and 22,000 individuals globally.  There are currently no approved therapies to treat FA.

In October 2019, we announced that the registrational part 2 portion of the MOXIe Phase 2 trial of omaveloxolone in patients with FA met its primary endpoint of change in mFARS relative to placebo after 48 weeks of treatment.  Patients treated with omaveloxolone (150 mg/day) demonstrated a statistically significant, placebo-corrected 2.40 point mean improvement (decrease) in mFARS after 48 weeks of treatment (p=0.014).  Patients treated with omaveloxolone demonstrated improvement in every subcategory measured under mFARS.  Omaveloxolone treatment was generally reported to be well-tolerated.  The FDA and the European Commission have granted orphan drug designation to omaveloxolone for the treatment of FA.  

As discussed above under “Regulatory Update-Omaveloxolone for Friedreich’s Ataxia,” the FDA will consider whether a crossover study of omaveloxolone using placebo patients from MOXIe Part 2 who were crossed over to omaveloxolone treatment in the MOXIe extension study could serve as additional confirmatory evidence.  If the FDA accepts the proposal, we could have completed data from the crossover study in the fourth quarter of this year.  Assuming that the crossover study data are sufficiently positive to provide confirmatory evidence, our plan would be to submit an NDA during the first quarter of 2021.  If the FDA rejects the proposal or if the data are not supportive, we will evaluate whether it is feasible to conduct a second pivotal study on FA patients as suggested by the FDA.  Regardless of the interaction with the FDA, we plan to pursue marketing approval outside of the United States.

Omaveloxolone in Other Potential Indications

In addition, we have observed compelling activity of omaveloxolone and our other Nrf2 activators in preclinical models of Parkinson’s disease, dementia, epilepsy, Huntington’s disease, and amyotrophic lateral sclerosis (ALS), and we plan to pursue the development of omaveloxolone and our other Nrf2 activators for one or more of these diseases.

RTA 901 in Neurodegeneration and Neuroprotection Diseases

We are also developing RTA 901 in neurological indications.  RTA 901 is the lead product candidate from our Hsp90 modulator program.  We have observed favorable activity of RTA 901 in a range of preclinical models of neurological disease, including models of diabetic neuropathy, neuroinflammation, and neuropathic pain.  We have completed a Phase 1 trial to evaluate the safety, tolerability, and pharmacokinetic profile of RTA 901 administered orally, once-daily in healthy adult volunteers, and no safety or tolerability concerns were reported.  We plan to continue development for RTA 901 in neurological diseases, such as diabetic neuropathy.  We are the exclusive licensee of RTA 901 and have worldwide commercial rights.

Other Clinical Programs

In addition, we are developing RTA 1701, the lead product candidate from our proprietary series of RORγt inhibitors, for the potential treatment of a broad range of autoimmune, inflammatory, and fibrotic diseases.  We have completed a Phase 1 trial to evaluate the safety, tolerability, and pharmacokinetic profile of RTA 1701 in healthy adult volunteers.  No safety or tolerability concerns were reported, and we observed an acceptable pharmacokinetic profile.  We plan to continue development for RTA 1701 in autoimmune, inflammatory, or fibrotic diseases.  We retain all rights to our RORγt inhibitors, which are not subject to any existing commercial collaborations.

22

Corporate Overview

To date, we have focused most of our efforts and resources on developing our product candidates and conducting preclinical studies and clinical trials.  We have historically financed our operations primarily through revenue generated from our collaborations with AbbVie and KKC, from sales of our securities, with secured loans, and most recently from a strategic financing from BXLS.  We have not received any payments or revenue from collaborations other than nonrefundable upfront, milestone, and cost sharing payments from our collaborations with AbbVie and KKC, from the Development Agreement with BXLS, and from reimbursements of expenses under the terms of our agreement with KKC.  We have incurred losses in each year since our inception, other than in 2014. As of June 30, 2020, we had $610.4 million of cash and cash equivalents and an accumulated deficit of $827.0 million. We continue to incur significant research and development and other expenses related to our ongoing operations.  Despite contractual product development commitments and the potential to receive future payments from KKC, we anticipate that we will continue to incur losses for the foreseeable future, and we anticipate that our losses will increase as we continue our development of, seek regulatory approval for, and potential commercialization of our product candidates.  If we do not successfully develop and obtain regulatory approval of our existing product candidates or any future product candidates and effectively manufacture, market, and sell any products that are approved, we may never generate revenue from product sales.  Furthermore, even if we do generate revenue from product sales, we may never again achieve or sustain profitability on a quarterly or annual basis.  Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ equity and working capital.  Our failure to become and remain profitable could depress the market price of our Class A common stock and could impair our ability to raise capital, expand our business, diversify our product offerings, or continue our operations.

Financial Operations Overview

Revenue

Our revenue to date has been generated primarily from licensing fees received under our collaborative license agreements and reimbursements for expenses.  We currently have no approved products and have not generated any revenue from the sale of products to date.  In the future, we may generate revenue from product sales, royalties on product sales, reimbursements for collaboration services under our current collaboration agreements, or license fees, milestones, or other upfront payments if we enter into any new collaborations or license agreements.  We expect that our future revenue will fluctuate from quarter to quarter for many reasons, including the uncertain timing and amount of any such payments and sales.

Our license and milestone revenue has been generated primarily from the KKC Agreement, the AbbVie License Agreement, and the AbbVie Collaboration Agreement and consists of upfront payments and milestone payments.  License revenue recorded with respect to the KKC Agreement, the AbbVie License Agreement, and the AbbVie Collaboration Agreement consists solely of the recognition of deferred revenue.  Under our revenue recognition policy, collaboration revenue associated with upfront, non-refundable license payments received under our license and collaboration agreements are deferred and recognized ratably over the expected term of the performance obligations under each agreement.  Under the Reacquisition Agreement, we no longer have performance obligations under the AbbVie License Agreement and the AbbVie Collaboration Agreement.  We only expect to recognize revenue under the KKC Agreement, which extends through 2021.

Research and Development Expenses

The largest component of our total operating expenses has historically been our investment in research and development activities, including the clinical development of our product candidates.  From our inception through June 30, 2020, we have incurred a total of $859.4 million in research and development expense, a majority of which relates to the development of bardoxolone and omaveloxolone.  We expect our research and development expense to continue to increase in the future as we advance our product candidates through clinical trials and expand our product candidate portfolio.  The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and we consider the active management and development of our clinical pipeline to be crucial to our long-term success.  The actual probability of success for each product candidate and preclinical

23

program may be affected by a variety of factors, including the safety and efficacy data for product candidates, investment in the program, competition, manufacturing capability, and commercial viability.

Research and development expenses include:

• expenses incurred under agreements with clinical trial sites that conduct research and development activities on our behalf;

• expenses incurred under contract research agreements and other agreements with third parties;

• employee and consultant-related expenses, which include salaries, benefits, travel, and stock-based compensation;

• laboratory and vendor expenses related to the execution of preclinical and non-clinical studies and clinical trials;

• the cost of acquiring, developing, manufacturing, and distributing clinical trial materials;

• the cost of development, scale up, and process validation activities to support product registration; and

• facilities, depreciation, and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance, and other supply costs.

Research and development costs are expensed as incurred.  Costs for certain development activities such as clinical trials are highly judgmental and are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and our clinical sites.

We base our expense accruals related to clinical trials on our estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and contract research organizations (CROs) that conduct and manage clinical trials on our behalf.  The financial terms of these agreements vary from contract to contract and may result in uneven payment flows.  Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones.  In accruing costs, we estimate the time period over which services will be performed and the level of effort to be expended in each period.  If we do not identify costs that we have begun to incur or if we underestimate or overestimate the level of services performed or the costs of these services, our actual expenses could differ from our estimates.

To date, we have not experienced material changes in our estimates of accrued research and development expenses after a reporting period.  However, due to the nature of estimates, we cannot assure you that we will not make changes to our estimates in the future as we become aware of additional information about the status or conduct of our clinical trials and other research activities.

Currently, KKC has allowed us to conduct clinical studies of bardoxolone in certain rare forms of kidney diseases in Japan and has reimbursed us the majority of the costs for our CARDINAL study in Japan and is paying for the costs of a certain number of patients as the in-country caretaker in our FALCON study in Japan.  We reduced our expenses by $0.0 million and $0.3 million for KKC’s share of CARDINAL costs for the six months ended June 30, 2020 and 2019, respectively.

The following table summarizes our research and development expenses incurred:

	Three Months Ended June 30				Six Months Ended June 30
	2020		2019		2020		2019
	(unaudited; in thousands)
Bardoxolone methyl	$	9,736	$	10,713	$	23,653	$	19,393
Omaveloxolone		8,313		5,676		14,942		11,479
RTA 901		750		719		1,961		1,055
RTA 1701		479		653		1,874		982
Other research and development expenses		17,505		11,793		42,006		22,759
Total research and development expenses	$	36,783	$	29,554	$	84,436	$	55,668

24

The program-specific expenses summarized in the table above include costs that we directly allocate to our product candidates.  Our other research and development expenses include research and development salaries, benefits, stock-based compensation and preclinical, research, and discovery costs, which we do not allocate on a program-specific basis.

General and Administrative Expenses

General and administrative expenses consist primarily of employee-related expenses for executive, operational, finance, legal, compliance, and human resource functions.  Other general and administrative expenses include personnel expense, facility-related costs, professional fees, accounting and legal services, depreciation expense, other external services, and expenses associated with obtaining and maintaining our intellectual property rights.

We anticipate that our general and administrative expenses will increase in the future as we prepare for our potential commercialization of our product candidates.  We have also incurred, and anticipate incurring in the future, increased expenses associated with being a public company, including exchange listing and SEC requirements, director and officer insurance premium, legal, audit and tax fees, compliance with the Sarbanes-Oxley Act, regulatory compliance programs, and investor relations costs.  Additionally, if and when we believe the first regulatory approval of one of our product candidates appears likely, we anticipate an increase in payroll and related expenses as a result of our preparation for commercial operations, especially for the sales and marketing of our product candidates.

Other Income (Expense), Net

Other income (expense) includes interest and gains earned on our cash and cash equivalents, interest expense on term loans, amortization of debt issuance costs, imputed interest on long term payables, loss on extinguishment of debt, foreign currency exchange gains and losses, gains and losses on sales of assets, and non-cash interest expense on liability related to the sale of future royalties.

(Benefit from) Provision for Taxes on Income

Provision for taxes on income consists of net loss, taxed at federal tax rates and adjusted for certain permanent differences.  We maintain a full valuation allowance against our net deferred tax assets.  Changes in this valuation allowance also affect the tax provision.

Results of Operations

Comparison of the Three Months Ended June 30, 2020 and 2019 (unaudited)

The following table sets forth our results of operations for the three months ended June 30:

	2020			2019			Change $			Change %
	(in thousands)
Collaboration revenue
License and milestone	$	1,169		$	7,813		$	(6,644	)		(85	)
Other revenue		1,904			20			1,884		**
Total collaboration revenue		3,073			7,833			(4,760	)		(61	)
Expenses
Research and development		36,783			29,554			7,229			24
General and administrative		16,600			11,706			4,894			42
Depreciation		284			232			52			22
Total expenses		53,667			41,492			12,175			29
Other income (expense), net		(16,990	)		(701	)		(16,289	)	**
Loss before taxes on income		(67,584	)		(34,360	)		(33,224	)		(97	)
(Benefit from) provision for taxes on income		(3	)		20			(23	)		(115	)
Net loss	$	(67,581	)	$	(34,380	)	$	(33,201	)		(97	)
** Percentage not meaningful

25

Revenue

License and milestone revenue represented approximately 38% and 100% of total revenue for the three months ended June 30, 2020 and 2019, respectively, and consisted primarily of the recognition of deferred revenue.  License and milestone revenue decreased by $6.6 million or 85% during the three months ended June 30, 2020, compared to the three months ended June 30, 2019, primarily due to the Reacquisition Agreement in October 2019, which ended our performance obligations under the AbbVie Collaboration Agreement and resulted in the writing off of the related remaining deferred revenue balance, after which no further revenue was recognized.  Total revenue of $1.2 million was recognized during the three months ended June 30, 2020 from deferred revenue related to the KKC Agreement.

Other revenue increased by $1.9 million for the three months ended June 30, 2020, compared to the three months ended June 30, 2019. The increase was primarily due to $1.6 million in revenue recognized for reimbursements of expenses from KKC.  

The following table summarizes the sources of our revenue for the three months ended June 30:

	2020		2019
	(in thousands)
License and milestone
AbbVie Collaboration Agreement	$	—	$	6,644
KKC Agreement		1,169		1,169
Total license and milestone		1,169		7,813
Other revenue		1,904		20
Total collaboration revenue	$	3,073	$	7,833

Expenses

The following table summarizes our expenses, as a percentage of total expenses, for the three months ended June 30:

	2020		% of Total Expenses			2019		% of Total Expenses
	(in thousands)
Research and development	$	36,783		68	%	$	29,554		71	%
General and administrative		16,600		31	%		11,706		28	%
Depreciation		284		1	%		232		1	%
Total expenses	$	53,667				$	41,492

Research and Development Expenses

Research and development expenses increased by $7.2 million, or 24%, for the three months ended June 30, 2020, compared to the three months ended June 30, 2019.  The increase was primarily due to $8.5 million in increased personnel-related expenses related to the growth of our development activities and accelerated recognition of stock-based compensation expense from employees who entered into consulting agreements at the termination of employment; $1.6 million in increased manufacturing costs to support product registration offset by a decrease in clinical study expenses related to stopping the CATALYST study and its extension study; and $2.3 million in decreased medical affairs expenses.

Research and development expenses, as a percentage of total expenses, was 68% and 71% for the three months ended June 30, 2020 and 2019, respectively.  The decrease of 3% was primarily due to a proportionately larger increase in general and administrative expenses, which includes personnel and stock-based compensation expenses and rent and office expenses to support growth in our development and commercial readiness activities.

General and Administrative Expenses

General and administrative expenses increased by $4.9 million, or 42%, for the three months ended June 30, 2020, compared to the three months ended June 30, 2019. The increase was primarily due to $6.1 million in increased personnel and stock-based compensation expenses, offset by a decrease of $0.6 million in marketing and commercialization expenses.

26

General and administrative expenses, as a percentage of total expenses, was 31% and 28%, for the three months ended June 30, 2020 and 2019, respectively.  The increase of 3% was primarily due to a proportionately larger increase in general and administrative expenses, compared to research and development expenses.

Other Income (Expense), Net

Other income (expense), net increased by $16.3 million for the three months ended June 30, 2020, compared to the three months ended June 30, 2019.  The increase was primarily due to $11.2 million from loss on debt extinguishment, $3.2 million of additional interest expense attributable to additional borrowings under the Term B Loan drawn in December 2019 and the payable due to collaborator related to the Reacquisition Agreement in October 2019, and $1.2 million in decreased investment income due to declining interest rates.

(Benefit from) Provision for Taxes on Income

Benefit from taxes on income was immaterial for the three months ended June 30, 2020 and 2019.

Comparison of the Six Months Ended June 30, 2020 and 2019 (unaudited)

The following table sets forth our results of operations for the six months ended June 30:

	2020			2019			Change $			Change %
	(in thousands)
Collaboration revenue
License and milestone	$	2,338		$	15,539		$	(13,201	)		(85	)
Other revenue		2,088			64			2,024		**
Total collaboration revenue		4,426			15,603			(11,177	)		(72	)
Expenses
Research and development		84,436			55,668			28,768			52
General and administrative		37,387			21,744			15,643			72
Depreciation		562			401			161			40
Total expenses		122,385			77,813			44,572			57
Other income (expense), net		(20,804	)		(1,301	)		(19,503	)	**
Loss before taxes on income		(138,763	)		(63,511	)		(75,252	)		(118	)
(Benefit from) provision for taxes on income		(22,243	)		23			(22,266	)	**
Net loss	$	(116,520	)	$	(63,534	)	$	(52,986	)		(83	)
** Percentage not meaningful

Revenue

License and milestone revenue represented approximately 53% and 100% of total revenue for the six months ended June 30, 2020, and 2019, respectively, and consisted primarily of the recognition of deferred revenue.  License and milestone revenue decreased by $13.2 million or 85% during the six months ended June 30, 2020, compared to the six months ended June 30, 2019, primarily due to the Reacquisition Agreement in October 2019, which ended our performance obligations under the AbbVie Collaboration Agreement and resulted in the writing off of the related remaining deferred revenue balance, after which no further revenue was recognized.  Total revenue of $2.3 million was recognized during the six months ended June 30, 2020 from deferred revenue related to the KKC Agreement.

Other revenue increased by $2.0 million for the six months ended June 30, 2020, compared to the six months ended June 30, 2019. The increase was primarily due to $1.6 million in revenue recognized for reimbursements of expenses from KKC.  

27

The following table summarizes the sources of our revenue for the six months ended June 30:

	2020		2019
	(in thousands)
License and milestone
AbbVie Collaboration Agreement	$	—	$	13,214
KKC Agreement		2,338		2,325
Total license and milestone		2,338		15,539
Other revenue		2,088		64
Total collaboration revenue	$	4,426	$	15,603

Expenses

The following table summarizes our expenses, as a percentage of total expenses, for the six months ended June 30:

	2020		% of Total Expenses			2019		% of Total Expenses
	(in thousands)
Research and development	$	84,436		69	%	$	55,668		71	%
General and administrative		37,387		30	%		21,744		28	%
Depreciation		562		1	%		401		1	%
Total expenses	$	122,385				$	77,813

Research and Development Expenses

Research and development expenses increased by $28.8 million, or 52%, for the six months ended June 30, 2020, compared to the six months ended June 30, 2019.  The increase was primarily due to $21.7 million in increased personnel-related expenses related to the growth of our development activities and accelerated recognition of stock-based compensation expense as a result of the death of an executive and employees who entered into consulting agreements at the termination of employment; $9.9 million in increased manufacturing costs to support product registration and increased clinical, clinical pharmacology, and toxicity study expenses to support our registrational programs, as well as our RTA 901 and RTA 1701 programs, which were offset by a decrease in clinical study expenses related to stopping the CATALYST study and its extension study; and $2.7 million in decreased medical affairs and research expenses.

Research and development expenses, as a percentage of total expenses, was 69% and 71% for the six months ended June 30, 2020 and 2019, respectively.  The decrease of 2% was primarily due to a proportionately larger increase in general and administrative expenses, which includes personnel and stock-based compensation expenses and rent and office expenses to support growth in our development and commercial readiness activities.

General and Administrative Expenses

General and administrative expenses increased by $15.6 million, or 72%, for the six months ended June 30, 2020, compared to the six months ended June 30, 2019.  The increase was primarily due to $14.2 million in increased personnel and stock-based compensation expenses, $0.6 million in increased insurance expenses, and $0.5 million in increased marketing and commercialization expenses.

General and administrative expenses, as a percentage of total expenses, was 30% and 28%, for the six months ended June 30, 2020 and 2019, respectively.  The increase of 2% was primarily due to a proportionately larger increase in general and administrative expenses, compared to research and development expenses.

Other Income (Expense), Net

Other income (expense), net increased by $19.5 million for the six months ended June 30, 2020, compared to the six months ended June 30, 2019.  The increase was primarily due to $11.2 million from loss on debt extinguishment, $6.7 million of additional interest expense attributable to additional borrowings under the Term B Loan drawn in December 2019 and the payable due to collaborator related to the Reacquisition Agreement in October 2019, and $1.0 million in decreased investment income due to declining interest rates.

28

(Benefit from) Provision for Taxes on Income

Benefit from taxes on income increased by $22.2 million for the six months ended June 30, 2020, compared to the six months ended June 30, 2019.  The increase was primarily due to a tax refund we have filed for under the provisions of the CARES Act.

Liquidity and Capital Resources

Since our inception, we have funded our operations primarily through collaboration and license agreements, the sale of preferred and common stock, secured loans, and the sale of future royalties.  Through June 30, 2020, we have raised gross cash proceeds of $476.6 million through the sale of convertible preferred stock and $780.0 million from payments under license and collaboration agreements. We also obtained $944.7 million in net proceeds from our initial public offering, follow-on offerings, and the sale of our Class A common stock under the Purchase Agreement, and $299.0 million in net proceeds from the sale of future royalties under the Development Agreement.  We also obtained $151.6 million in net proceeds from our Amended Restated Loan Agreement, which we paid off in June 2020.  We have not generated any revenue from the sale of any products.  As of June 30, 2020, we had available cash and cash equivalents of approximately $610.4 million.  Our cash and cash equivalents are invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation.

Cash Flows

The following table sets forth the primary sources and uses of cash for each of the six months ended June 30:

	2020			2019
	(in thousands)
Net cash (used in) provided by:
Operating activities	$	(237,107	)	$	(61,441	)
Investing activities		(384	)		(2,092	)
Financing activities		183,586			6,192
Net change in cash and cash equivalents	$	(53,905	)	$	(57,341	)

Operating Activities

Net cash used in operating activities was $237.1 million for the six months ended June 30, 2020, consisting primarily of a net loss of $116.5 million adjusted for non-cash items including stock-based compensation expense of $34.1 million, loss on extinguishment of debt of $11.2 million, depreciation and amortization expense of $4.7 million, and a net increase in operating assets and liabilities of $171.3 million.  The significant items in the change in operating assets that impacted our use of cash in operations were an increase in income tax receivable of $22.2 million and a decrease in payable to collaborators of $150.0 million for a payment made on June 30, 2020 under the Reacquisition Agreement.

Net cash used in operating activities was $61.4 million for the six months ended June 30, 2019, consisting primarily of a net loss of $63.5 million adjusted for non-cash items including stock-based compensation expense of $8.7 million, depreciation and amortization expense of $1.1 million, and a net decrease in operating assets and liabilities of $7.7 million.  The significant items in the change in operating assets that impacted our use of cash in operations include increases in accrued direct research and other current and long-term liabilities of $9.8 million due to activities related to clinical trials and personnel-related activities, an increase in prepaid expenses and other current assets of $3.2 million due to increases in prepaid subscriptions and insurance premiums, and decreases in amounts earned or due from collaboration agreements of $0.9 million and deferred revenue of $15.5 million.  The decrease in deferred revenue is due to the ratable recognition of revenue over the expected term of the performance obligations under our collaboration agreements with AbbVie and KKC, which resulted in recognition of $15.5 million of license and milestone revenue.

29

Investing Activities

Net cash used in investing activities of $0.4 million and $2.1 million for the six months ended June 30, 2020 and 2019, respectively, were primarily due to capital expenditures in connection with an expansion of our office space and purchase of property and equipment.

Financing Activities

Net cash provided by financing activities was $183.6 million for the six months ended June 30, 2020, primarily due to $55.4 million and $293.6 million in funding received from the Purchase Agreement and Development Agreement with BXLS, respectively, and $1.8 million from options exercised, offset by $167.2 million to pay off our Term Loans.

Net cash provided by financing activities was $6.2 million for the six months ended June 30, 2019, were primarily due to option exercises.

Operating Capital Requirements

To date, we have not generated any revenue from product sales.  We do not know when or whether we will generate any revenue from product sales.  We do not expect to generate significant revenue from product sales unless and until we obtain regulatory approval of and commercialize one or more of our current or future product candidates.  We anticipate that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our product candidates, and begin to commercialize any approved products.  We are subject to all the risks related to the development and commercialization of novel therapeutics, and we may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect our business.  We continue to incur additional costs associated with operating as a public company.  We anticipate that we will need substantial additional funding in connection with our continuing operations.

On June 24, 2020, we closed on the Development Agreement and Purchase Agreement, each dated June 10, 2020, under which certain Blackstone entities paid us an aggregate of $350.0 million in exchange for future royalties on bardoxolone and an aggregate of 340,793 shares of our Class A common stock at $146.72 per share.

On June 24, 2020, we paid off our Term Loans with Oxford Finance LLC and Silicon Valley Bank, which included payments for principal of $155.0 million, prepayment fees of $5.4 million, exit fees of $6.7 million, and accrued and unpaid interest of $1.0 million.

On March 27, 2020, the United States enacted the CARES Act.  Under its provisions, for the six months ended June 30, 2020, we recognized a tax benefit and receivable of $22.1 million associated with the ability to carryback an applicable prior year’s net operating losses to a preceding year to generate a refund.  

On November 18, 2019, we closed a follow-on underwritten public offering of 2,760,000 shares of our Class A common stock for gross proceeds of $505.1 million.  Net proceeds to us from the offering were approximately $491.9 million, after deducting underwriting discounts and commissions and offering expenses.

On October 15, 2019, we entered into the Lease Agreement, relating to the lease of approximately 327,400 square feet of office and laboratory space located in Plano, Texas.  The term of the Lease is estimated to commence mid-2022, when construction is completed, and continue for 16 years, with up to 10 years of extension at our option.  The initial annual base rent will be determined based on the project cost, subject to an initial annual cap of approximately $13.3 million, which may increase in certain circumstances.  Beginning in the third lease year, the base rent will increase 1.95% per annum each year.  In addition to the annual base rent, we will pay for taxes, insurance, utilities, operating expenses, assessments under private covenants, maintenance and repairs, certain capital repairs and replacements, and building management fees.

On October 9, 2019, we and AbbVie entered into the Reacquisition Agreement pursuant to which we reacquired the development, manufacturing, and commercialization rights concerning our proprietary Nrf2 activator product platform originally licensed to AbbVie in the AbbVie License Agreement and the AbbVie Collaboration Agreement.  In exchange for such rights, we will pay AbbVie $330.0 million, of which $100.0 million was paid as of December 31, 2019, $150.0 million was paid on June 30, 2020, and $80.0 million is payable on November 30,

30

2021.  We will also pay AbbVie an escalating, low single-digit royalty on worldwide net sales, on a product-by-product basis, of omaveloxolone and an identified list of certain next-generation Nrf2 activators.  The termination of our deferred revenue balance will not have an impact on our cash flow.

In November 2017, we entered into an at-the-market equity offering sales agreement with Stifel, Nicolaus & Company, Incorporated, that established a program pursuant to which it may offer and sell up to $50.0 million of its Class A common stock from time to time in at-the-market transactions.  In November 2019, we suspended the program in connection with the November 2019 equity offering, which remains suspended until we notify Stifel otherwise.  To date, no sales have been made under our at-the-market offering program.

Our longer term liquidity requirements will require us to raise additional capital, such as through additional equity, debt, or royalty financings or collaboration arrangements.  Our future capital requirements will depend on many factors, including the receipt of milestones under our KKC Agreement and the timing of our expenditures related to clinical trials.  We believe our existing cash and cash equivalents will be sufficient to enable us to fund our operations through the end of 2023.  However, we anticipate opportunistically raising additional capital before that time through equity offerings, collaboration or license agreements, additional debt, or royalty financings in order to maintain adequate capital reserves.  In addition, we may choose to raise additional capital at any time for the further development of our existing product candidates and may also need to raise additional funds sooner to pursue other development activities related to additional product candidates.  Decisions about the timing or nature of any financing will be based on, among other things, our perception of our liquidity and of the market opportunity to raise equity, debt, or royalty financing.  Additional securities may include common stock, preferred stock, or debt securities.  We may explore strategic collaborations or license arrangements for any of our product candidates.  If we do explore any arrangements, there can be no assurance that any agreement will be reached, and we may determine to cease exploring a potential transaction for any or all of the assets at any time.  If an agreement is reached, there can be no assurance that any such transaction would provide us with a material amount of additional capital resources.

Until we can generate a sufficient amount of revenue from our product candidates, if ever, we expect to finance future cash needs through public or private equity or debt offerings, commercial loans, royalty financings, and collaboration or license transactions.  The outbreak of COVID-19 has caused significant disruption of global financial markets, which may reduce our ability to access capital, which could negatively affect our liquidity.  Additional capital may not be available on reasonable terms, if at all.  If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back, or discontinue the development or commercialization of one or more of our product candidates.  If we raise additional funds through the issuance of additional equity or debt securities, it could result in dilution to our existing stockholders or increased fixed payment obligations, and any such securities may have rights senior to those of our common stock.  If we incur indebtedness or obtain royalty financing, we could become subject to covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell, or license intellectual property rights, and other operating restrictions that could adversely affect our ability to conduct our business, and any such debt or royalty financing could be secured by some or all of our assets.  Any of these events could significantly harm our business, financial condition, and prospects.  For a description of the numerous risks and uncertainties associated with product development and raising additional capital, see “Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2019 and in the Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, under “Part II, Item 1A. Risk Factors.”

Our forecast of the period through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors.  We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect.  Our future funding requirements, both near- and long-term, will depend on many factors, including, but not limited to:

• the scope, rate of progress, results, and cost of our clinical trials, preclinical testing, and other activities related to the development of our product candidates;

• the number and characteristics of product candidates that we pursue;

• the costs of development efforts for our product candidates that are not subject to reimbursement from our collaborator;

31

• the costs necessary to obtain regulatory approvals, if any, for our product candidates in the United States and other jurisdictions, and the costs of post-marketing studies that could be required by regulatory authorities in jurisdictions where approval is obtained;

• the continuation of our existing collaboration with KKC and entry into new collaborations and the receipt of any collaboration payments;

• the time and unreimbursed costs necessary to commercialize products in territories in which our product candidates are approved for sale;

• the revenue from any future sales of our products for which we are entitled to a profit share, royalties, and milestones;

• the level of reimbursement or third-party payor pricing available to our products;

• the costs of obtaining third-party commercial supplies of our products, if any, manufactured in accordance with regulatory requirements;

• the costs associated with any potential loss or corruption of our information or data in a cyberattack on our computer systems or those of our suppliers, vendors, or collaborators who store or transmit our data;

• the costs associated with being a public company;

• any additional costs we incur associated with the COVID-19 pandemic; and

• the costs we incur in the filing, prosecution, maintenance, and defense of our patent portfolio and other intellectual property rights.

If we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition, and results of operations could be materially adversely affected.

Contractual Obligations and Commitments

As of June 30, 2020, there have been no material changes, outside of the ordinary course of business, in our outstanding contractual obligations from those disclosed within “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, as contained in our Annual Report on Form 10-K for year ended December 31, 2019, except for those discussed below.

Below are our contractual obligations as of June 30, 2020 (unaudited):

	Payments due by period
	Less than 1 year		1 to 3 years		4 to 5 years		Total
	(in thousands)
Operating lease obligations (1)	$	3,787	$	5,918	$	—	$	9,705
Payable to collaborators		—		80,000		—		80,000
Total contractual obligations	$	3,787	$	85,918	$	—	$	89,705

(1) Total minimum future lease payments for the Plano build-to-suit lease have not commenced as of June 30, 2020. Therefore, such payments are not included in the consolidated financial statement, as we do not yet control the underlying assets.  The lease is expected to commence mid-2022 with initial lease term of 16 years.

The terms of the Development Agreement require us to pay potential future royalty payments based on product development success. The above table excludes such obligations as the amount and timing of such obligations are unknown or uncertain, which are further described in Note 5, Liability Related to Sale of Future Royalties, to Consolidated Financial Statements contained in this Quarterly Report on Form 10-Q.

32

Clinical Trials

As of June 30, 2020, we have several on-going clinical trials in various stages.  Under agreements with various CROs and clinical trial sites, we incur expenses related to clinical trials of our product candidates and potential other clinical candidates.  The timing and amounts of these disbursements are contingent upon the achievement of certain milestones, patient enrollment, and services rendered or as expenses are incurred by the CROs or clinical trial sites.  Therefore, we cannot estimate the potential timing and amount of these payments, and they have been excluded from the table above.

Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles.  The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our financial statements.  On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue recognition, accrued research and development expenses, income taxes, and stock-based compensation.  We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.  Actual results may differ from these estimates under different assumptions or conditions.

Our significant accounting policies are described in Note 2 of Part I, Item 1 of this Quarterly Report on Form 10-Q and in Part I, Item 7, “Critical Accounting Policies and Significant Judgments and Estimates” in our Annual Report on Form 10-K for the year ended December 31, 2019. During the three months ended June 30, 2020, we entered into the Development Agreement with an affiliate of BXLS.  As a result, we recorded a liability related to sale of future royalties that are based on our current estimate of future royalties expected to be paid over the estimated term of the Development Agreement and non-cash interest expense over the estimated term of the Development Agreement.  There have been no other changes to our critical accounting policies and estimates since our Annual Report on Form 10-K for the year ended December 31, 2019.

Off-Balance Sheet Arrangements

Since our inception, we have not had any relationships with unconsolidated organizations or financial partnerships, such as structured finance or special purpose entities, that would have been established for the purpose of facilitating off-balance sheet arrangements, and we have not engaged in any other off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

Recent Accounting Pronouncements

For a discussion of recent accounting pronouncements, please see Note 2 of Notes to Consolidated Financial Statements contained in this Quarterly Report on Form 10-Q.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are exposed to market risks in the ordinary course of our business.  These market risks are principally limited to interest rate fluctuations.  We had cash and cash equivalents of $610.4 million at June 30, 2020, consisting primarily of funds in operating cash accounts.  The primary objective of our investment activities is to preserve principal and liquidity while maximizing income without significantly increasing risk.  We do not enter into investments for trading or speculative purposes.  Due to the short-term nature of our investment portfolio, we do not believe an immediate increase of 100 basis points in interest rates would have a material effect on the fair market value of our portfolio, and accordingly we do not expect a sudden change in market interest rates to affect materially our operating results or cash flows.

We contract with research, development, and manufacturing organizations and investigational sites globally.  Generally, these contracts are denominated in United States dollars.  However, we may be subject to fluctuations in

33

foreign currency rates in connection with agreements not denominated in United States dollars.  We do not hedge our foreign currency exchange rate risk.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2020.  The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported, within the time periods specified in the SEC’s rules and forms.  Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.  Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.  Based on the evaluation of our disclosure controls and procedures as of June 30, 2020, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.  

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act, during the three months ended June 30, 2020, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings.

We are not currently subject to any material legal proceedings.

Item 1A. Risk Factors.

In addition to other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors and other cautionary statements described under the heading “Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2019, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, which could materially affect our businesses, financial condition, or future results.  Additional risks and uncertainties currently unknown to us, or that we currently deem to be immaterial, also may materially adversely affect our business, financial condition, or future results.  There have been no material changes in our risk factors from those described in the Annual Report on Form 10-K for the year ended December 31, 2019 and the Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None, except as previously reported on a Current Report on Form 8-K.

Item 3. Defaults Upon Senior Securities.

None.

34

Item 4. Mine Safety Disclosures.

None.

Item 5. Other Information.

None.

35

Item 6. Exhibits.

Exhibit Number	Description
3.1	Thirteenth Amended and Restated Certificate of Incorporation, dated May 11, 2016 (incorporated by reference to Exhibit 3.7 to the Company’s Form S-1 (File No. 333-208843), filed with the SEC on May 16, 2016).
3.2	Second Amended and Restated Bylaws, dated as of December 7, 2016 (incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K (File No. 001-37785), filed with the SEC on December 7, 2016).
10.1*	First Amendment to Lease Agreement, dated as of May 27, 2020.
10.2†#*	Common Stock Purchase Agreement between the Company and BXLS V – River L.P, dated as of June 10, 2020.
10.3†#*	Development and Commercialization Funding Agreement between the Company and BXLS V – River L.P, dated as of June 10, 2020.
10.4+*	Fourth Amended and Restated Non-Employee Director Compensation Policy, dated as of June 10, 2020.
10.5+	Indemnification Agreement by and between the Company and Martin W. Edwards, dated as of August 3, 2020 (incorporated by reference to Exhibit 10.1 to the Company's Form 8-K (File No. 001-37785), filed with the SEC on July 31, 2020).
31.1*	Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**	Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**	Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*	Inline XBRL Instance Document
101.SCH*	Inline XBRL Taxonomy Extension Schema Document
101.CAL*	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed herewith.

** Furnished herewith.

+ Indicates management contract or compensatory plan.

† Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule or exhibit will be furnished to the Securities and Exchange Commission upon request.

# Information in this exhibit identified by brackets is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is not material and would likely cause competitive harm to the Company if publicly disclosed. An unredacted copy of this exhibit will be furnished to the Securities and Exchange Commission on a supplemental basis upon request.

36

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 10, 2020	REATA PHARMACEUTICALS, INC.
	By:	/s/ J. Warren Huff
	Name:	J. Warren Huff
	Title:	Chief Executive Officer and President

By:	/s/ Manmeet S. Soni
Name:	Manmeet S. Soni
Title:	Chief Operating Officer, Chief Financial Officer, and Executive Vice President

37

EX-10.1

Exhibit 10.1

FIRST AMENDMENT TO LEASE AGREEMENT

THIS FIRST AMENDMENT TO LEASE AGREEMENT (this “Amendment”) is made and entered into as of this 27 day of May, 2020, by and between TC LEGACY PHASE I VENTURE, LLC, a Delaware limited liability company (“Landlord”), and REATA PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).

RECITALS

A.Landlord and Tenant entered into a certain Lease Agreement dated October 15, 2019 (the "Lease").  Unless otherwise defined herein, terms used herein with initial capital letters shall have the same meanings assigned to such terms in the Lease.

B. Landlord and Tenant now wish to amend the Lease as described below.

NOW, THEREFORE, in consideration of the premises and the mutual covenants herein contained, Landlord and Tenant hereby amend the Lease as follows:

1. The Improvement Allowance is hereby increased by $5,737,530 to $31,337,530.

2. The guaranteed maximum price payable to the General Contractor under the Construction Contract for the construction of the Base Building Improvements is $83,561,648.

3. Tenant acknowledges that the Base Building Improvements will not include the finish work for the lobby of the Building and that such work shall be performed as part of the Tenant Improvements and that the allowance for such finish work which was described in the Design Intent Narrative is no longer applicable.

4. As modified by this Amendment, the Lease remains in full force and effect.

5. This Amendment may be separately executed in any number of counterparts, each of which will be an original, but all of which, taken together, will be deemed to constitute one and the same instrument.  Any signature page to any counterpart may be detached from such counterpart without impairing the legal effect of the signatures thereon and thereafter attached to another counterpart identical thereto except having attached to it additional signature pages.  If this Amendment is transmitted by facsimile machine, electronic mail, or other electronic transmission, it shall be treated for all purposes as an original document.  Additionally, the signature of any party on this Amendment transmitted by way of a facsimile machine, electronic mail, or other electronic transmission shall be considered for all purposes as an original signature.  Any such transmitted document shall be considered to have the same binding legal effect as an original document.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

Joinder of Lender

EXECUTED AND DELIVERED as of the date and year first above written.

LANDLORD:

TC LEGACY PHASE I VENTURE, LLC,

a Delaware limited liability company

By:      TC Legacy Phase I Member, LLC, a Delaware

limited liability company, its Managing Member

By: TCDFW Office Development, Inc., its sole member

                    By: /s/ Scott A. Krikorian

Print: Scott A. Krikorian

Title: President and CEO

TENANT:

REATA PHARMACEUTICALS, INC.,

a Delaware corporation

By: /s/ Manmeet S. Soni

Print: Manmeet S. Soni

Its:  Chief Financial Officer

EX-10.2

Exhibit 10.2

Execution Version

COMMON STOCK PURCHASE AGREEMENT

BY AND BETWEEN

REATA PHARMACEUTICALS, INC.

AND

BXLS V – River  L.P.

AND

BXLS FAMILY INVESTMENT PARTNERSHIP (CYM) V- ESC L.P.

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

TABLE OF CONTENTS

Article I. DEFINITIONS 1

Section 1.01 Definitions1

Article II. SALE AND PURCHASE 4

Section 2.01 Sale and Purchase4

Section 2.02 Consideration4

Section 2.03 Closing4

Section 2.04 Joint and Several Obligations4

Article III. REPRESENTATIONS AND WARRANTIES OF REATA PHARMACEUTICALS, INC. 5

Section 3.01 Authority5

Section 3.02 Capitalization and Valid Issuance of Purchased Shares5

Section 3.03 Reata SEC Documents6

Section 3.04 Independent Registered Public Accounting Firm6

Section 3.05 No Material Adverse Effect7

Section 3.06 Litigation7

Section 3.07 No Contravention7

Section 3.08 Approvals7

Section 3.09 Investment Company Status7

Section 3.10 Offering7

Section 3.11 Certain Fees8

Section 3.12 Internal Controls and Procedures8

Section 3.13 No Undisclosed Liabilities8

Section 3.14 No Undisclosed Events or Circumstances8

Article IV. REPRESENTATIONS AND WARRANTIES OF BXLS 8

Section 4.01 Authority8

Section 4.02 Investment9

Section 4.03 Accredited Investor Status9

Section 4.04 Receipt of Information9

Section 4.05 Restricted Securities9

Section 4.06 Certain Fees9

Section 4.07 Reliance Upon BXLS’s Representations and Warranties10

Section 4.08 Residence10

Section 4.09 Legend10

Article V. COVENANTS 10

Section 5.01 Taking of Necessary Action10

Section 5.02 Facilitation of Sales Pursuant to Rule 14411

Section 5.03 Registration Rights11

i

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

Article VI. CLOSING CONDITIONS 14

Section 6.01 Conditions to the Closing14

Section 6.02 Reata Deliveries16

Section 6.03 BXLS Deliveries16

Article VII. INDEMNIFICATION, COSTS AND EXPENSES 17

Section 7.01 Indemnification by Reata17

Section 7.02 Indemnification by BXLS18

Section 7.03 Indemnification Procedure18

Article VIII. MISCELLANEOUS 19

Section 8.01 Survival of Provisions19

Section 8.02 No Waiver; Modifications in Writing19

Section 8.03 Binding Effect; Assignment20

Section 8.04 Notices20

Section 8.05 Removal of Legend21

Section 8.06 Amendments; No Waiver22

Section 8.07 Severability22

Section 8.08 Entire Agreement23

Section 8.09 Counterparts23

Section 8.10 Construction23

Section 8.11 Termination23

Exhibits

Exhibit AReata Officer’s Certificate

Exhibit BOpinion of Reata Counsel

ii

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

COMMON STOCK PURCHASE AGREEMENT

This COMMON STOCK PURCHASE AGREEMENT, dated as of June 10, 2020 (this “Agreement”), is entered into by and between REATA PHARMACEUTICALS, INC., a Delaware corporation (“Reata”), BXLS V – River L.P., (“BXLS V”), a limited partnership organized and existing under the laws of Delaware, and BXLS Family Investment Partnership (CYM) V – ESC L.P., a limited partnership organized and existing under the laws of Delaware (together with BXLS V, collectively, “BXLS” and each, a “BXLS Entity”) (each, a “Party” and collectively, the “Parties”).

WHEREAS, pursuant to that certain Development and Commercialization Funding Agreement, dated as of the date hereof (the “Development Agreement”), Reata has agreed to sell to BXLS, and BXLS has agreed to purchase from Reata, an aggregate of 340,793 shares  of Class A common stock of Reata, par value $0.001 per share (the “Purchased Shares”), in accordance with the provisions of this Agreement.

NOW THEREFORE, in consideration of the mutual covenants and agreements set forth herein and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

Article I.
DEFINITIONS

Section 1.01Definitions

.  As used in this Agreement, and unless the context requires a different meaning, the following terms have the meanings indicated:

“Action” against a Person means any lawsuit, action, proceeding, investigation or complaint before any Governmental Authority, mediator or arbitrator.

“Affiliate” means, with respect to a specified Person, a business entity, directly or indirectly controlling, controlled by or under direct or indirect common control with such specified Person.  For purposes of this definition, “control” (including, with correlative meanings, “controlling”, “controlled by”, and “under common control with”) means ownership of 50% or more of the voting interest in the applicable Person, and in the case of a partnership, control of the general partner.

“Agreement” has the meaning specified in the introductory paragraph.

“Business Day” means a day that is not a Saturday, Sunday or a U.S. federal holiday.  For the avoidance of doubt, solely with respect to any notice or other communication required to be given or delivered hereunder, limitations on the operations of commercial banks due to the outbreak of a contagious disease, epidemic or pandemic (including COVID-19), or any quarantine, shelter-in-place or similar or related directive, will not prevent a day that would otherwise be a Business Day hereunder from so being a Business Day.

“BXLS” has the meaning specified in the introductory paragraph.

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

“BXLS Material Adverse Effect”means any material adverse effect on (i) the ability of BXLS to carry out its business as of the date of this Agreement or to meet its obligations under the Operative Documents on a timely basis or (ii) the ability of BXLS to consummate the transactions under any Operative Document.

“BXLS Related Parties” shall have the meaning specified in Section 7.01.

“Class A Common Stock” shall have the meaning specified in Section 3.02(a).

“Class B Common Stock” shall have the meaning specified in Section 3.02(a).

“Common Share Price” shall have the meaning specified in Section 2.02.

“Closing” shall have the meaning specified in Section 2.03.

“Closing Date” shall have the meaning specified in Section 2.03.

“Commission” means the United States Securities and Exchange Commission.

“Exchange Act” means the Securities Exchange Act of 1934 and the rules and regulations of the Commission promulgated thereunder.

“GAAP” means generally accepted accounting principles in the United States of America in effect from time to time.

“Governmental Authority” means, with respect to a particular Person, the country, state, county, city and political subdivisions in which such Person or such Person’s Property is located or which exercises valid jurisdiction over any such Person or such Person’s Property, and any court, agency, department, commission, board, bureau or instrumentality of any of them and any monetary authority that exercises valid jurisdiction over any such Person or such Person’s Property. Unless otherwise specified, all references to Governmental Authority herein shall mean a Governmental Authority having jurisdiction over, where applicable, Reata or any of its Property or BXLS.

“Indemnified Party” shall have the meaning specified in Section 7.03.

“Indemnifying Party” shall have the meaning specified in Section 7.03.

“Law” means any federal, state, local or foreign order, writ, injunction, judgment, settlement, award, decree, statute, law, rule or regulation.

“LTIP” means the Second Amended and Restated Long-Term Incentive Plan of Reata Pharmaceuticals, Inc.

“NASDAQ” means The NASDAQ Stock Market LLC.

2

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

“Operative Documents”means, collectively, this Agreement, and any and all other agreements or instruments executed and delivered by the Parties hereunder or thereunder, or any amendments, supplements, continuations or modifications thereto.

“Parties” means Reata and BXLS.

“Person” means any individual, corporation, company, voluntary association, partnership, joint venture, trust, limited liability company, unincorporated organization or government or any agency, instrumentality or political subdivision thereof, or any other form of entity.

“Property” means any interest in any kind of property or asset, whether real, personal or mixed, or tangible or intangible.

“Purchase Price” shall have the meaning specified in Section 2.02.

“Purchased Shares” has the meaning specified in the introductory paragraph.

“Preferred Stock” shall have the meaning specified in Section 3.02(a).

“Reata” has the meaning specified in the introductory paragraph.

“Reata Financial Statements” means the financial statement or statements described or referred to in Section 3.03.

“Reata Material Adverse Effect” means any material adverse effect on (i) the assets, liabilities, financial condition, business, operations or affairs of Reata, measured against those assets, liabilities, financial condition, business, operations or affairs reflected in the Reata SEC Documents filed with the Commission prior to the date of this Agreement, (ii) the ability of Reata, to carry out its business as of the date of this Agreement or to meet its obligations under the Operative Documents on a timely basis, or (iii) the ability of Reata to consummate the transactions under any Operative Document.

“Reata SEC Documents” shall have the meaning specified in Section 3.03.

“Registration Expenses” means all expenses incident to Reata’s performance under or compliance with this Agreement to effect the registration of the reoffer and resale of the Purchased Shares on the Registration Statement pursuant to Section 5.03(a), including, without limitation, all registration, filing, and securities exchange listing fees, all registration, filing, qualification and other fees and expenses of complying with securities or “Blue Sky” laws, fees of the Financial Industry Regulatory Authority, fees of transfer agents and registrars, all word processing, duplicating and printing expenses, any transfer taxes, the fees and disbursements of counsel and independent public accountants for Reata, and the fees and reasonable disbursements of counsel for BXLS, but excluding taxes on any resale of the Purchased Shares.

“Registration Statement” shall have the meaning specified in Section 5.03.

“Registration Statement End Date” means [***].

“Registration Statement Start Date” means [***].

3

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

“Representatives” of any Person means the Affiliates, officers, directors, managers, employees, agents, counsel, accountants, investment bankers, investment advisers, members and other representatives of such Person.

“Securities Act” means the Securities Act of 1933 and the rules and regulations of the Commission promulgated thereunder.

“Subsidiary” has the meaning specified in Rule 405 of the rules and regulations promulgated under the Securities Act.

“Underwritten Offering” means an offering (including an offering pursuant to a registration statement filed with the Commission) which may require Reata to engage in marketing efforts, enter into agreements with banks or broker dealers, or deliver comfort letters or negative assurances letters, including, without limitation, an offering in which shares of Class A Common Stock are sold to an underwriter on a firm commitment basis for reoffering to the public or an offering that is a “bought deal” with one or more investment banks.

Article II.
SALE AND PURCHASE

Section 2.01Sale and Purchase

.  Subject to the terms and conditions hereof, Reata hereby agrees to issue and sell to each BXLS Entity, and each BXLS Entity hereby agrees to purchase from Reata, the Purchased Shares set forth opposite such entity’s name on Schedule of Investors, and each BXLS Entity agrees to pay Reata the Common Share Price for such Purchased Shares.  

Section 2.02Consideration

.  The amount per Purchased Share that BXLS will pay to Reata to purchase each share of Class A Common Stock (the “Common Share Price”) shall be$146.7169385, for an aggregate purchase price of $50,000,105.62 (the “Purchase Price”).

Section 2.03Closing

.  Subject to the terms and conditions hereof, including satisfaction or waiver of the applicable conditions set forth in Article VI, the consummation of the purchase and sale of the Purchased Shares hereunder (the “Closing”) shall take place on the Closing Date (as defined in the Development Agreement) or such other date as mutually agreed by the Parties (the date of such closing, the “Closing Date”) via electronic exchange of the Operative Documents and the closing deliverables contemplated hereby and thereby against wireless transfer of immediately available funds. Unless otherwise provided herein, all proceedings to be taken and all documents to be executed and delivered by all parties at the Closing will be deemed to have been taken and executed simultaneously, and no proceedings will be deemed to have been taken or documents executed or delivered until all have been taken, executed or delivered.

Section 2.04Joint and Several Obligations

.  The obligations of each BXLS Entity under any Operative Document are joint and several with the obligations of any other BXLS Entity.

4

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

Article III.REPRESENTATIONS AND WARRANTIES OF REATA PHARMACEUTICALS, INC.

Reata represents and warrants to BXLS as follows:

Section 3.01Authority

.

(a)Reata is a corporation duly formed, legally existing and in good standing under the laws of the State of Delaware, with corporate power and authority to own its properties and conduct the businesses in which it is currently engaged, and Reata is duly qualified to do business as a foreign corporation in good standing in all other jurisdictions in which its ownership or lease of property or the conduct of its business requires such qualification, except where the failure to be duly qualified or in good standing would not, individually or in the aggregate, reasonably be expected to have a Reata Material Adverse Effect.

(b)Reata has the requisite corporate power and authority to enter into the Operative Documents and, assuming due authorization, execution and delivery by BXLS, the Operative Documents constitute, or will constitute, legal and valid obligations binding upon Reata, enforceable in accordance with their terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization and other laws of general applicability relating to or affecting creditors’ rights and by general principles of equity.

(c)Reata is not a party to any agreement that would prevent it from fulfilling its obligations under the Operative Documents or that otherwise conflicts with the provisions of the Operative Documents, in each case in any material respect.

Section 3.02Capitalization and Valid Issuance of Purchased Shares

.

(a)The authorized capital stock of Reata consists of (i) 100,000,000 shares of preferred stock, par value $0.001 per share (“Preferred Stock”), (ii) 500,000,000 shares of Class A common stock, par value $0.001 per share (“Class A Common Stock”), and (iii) 150,000,000 shares of Class B common stock, par value $0.001 per share (“Class B Common Stock”). As of the close of business on June 9, 2020, there were (i) 28,183,552 shares of Class A Common Stock outstanding, (ii) 5,058,319 shares of Class B Common Stock outstanding, (iii) no shares of Preferred Stock outstanding, (iii) 4,807,293 shares of Class B Common Stock issuable upon the exercise of outstanding stock options issued as of June 9, 2020, pursuant to the LTIP or stand-alone option agreements, and (iv) 73,701 shares of Class B Common Stock issuable upon vesting of restricted stock units issued pursuant to the LTIP.

(b)There are no preemptive rights or other similar rights with respect to the Purchased Shares; and none of the outstanding shares of capital stock of Reata have been issued in violation of any preemptive or similar rights of any security holder.

(c)Except as described or disclosed in the Reata SEC Documents, Reata has no equity compensation plans that contemplate the issuance of shares of Class A Common Stock or Class B Common Stock (or securities convertible into or exchangeable for shares of Class A Common Stock or Class B Common Stock). No indebtedness having the right to vote (or

5

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

convertible into or exchangeable for securities having the right to vote) on any matters on which Reata’s stockholders may vote is issued or outstanding. Except as described or disclosed in the Reata SEC Documents there are no outstanding (i) securities or obligations of Reataconvertible into or exchangeable for any capital stock of Reata, (ii) warrants, rights or options to subscribe for or purchase from Reata any such capital stock or any such convertible or exchangeable securities or obligations, or (iii) obligations of Reata to issue or sell any shares of capital stock, any such convertible or exchangeable securities or obligations or any such warrants, rights or options.

(d)The Purchased Shares have been duly authorized by Reata and, when issued and delivered to BXLS against payment therefor in accordance with the terms of this Agreement, will be validly issued, fully paid and nonassessable and will be free of any and all liens, encumbrances, security interests, equities, charges or claims and restrictions on transfer, other than restrictions on transfer under applicable state and federal securities Laws and other than such liens, encumbrances, security interests, equities, charges or claims as are created by BXLS.

(e)Reata’s currently outstanding shares of Class A Common Stock are listed on the NASDAQ. Reata is not in violation of the listing requirements of the NASDAQ and has no knowledge of any facts that are reasonably expected to lead to delisting or suspension of its Class A Common Stock from the NASDAQ in the foreseeable future.

Section 3.03Reata SEC Documents

.  Reata has timely filed with the Commission all reports, schedules and statements required to be filed by it under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act in the twelve months preceding the date of this Agreement (all such documents filed on or prior to the date of this Agreement, collectively the “Reata SEC Documents”).  The Reata SEC Documents, at the time filed  (except to the extent corrected by a subsequently filed Reata SEC Document filed prior to the date of this Agreement), (i) did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading, and (ii) complied in all material respects with the applicable requirements of the Exchange Act. Reata’s audited or unaudited financial statements and any notes thereto or schedules included therein (the “Reata Financial Statements”), at the time filed with the Reata SEC Documents, (x) complied as to form in all material respects with applicable accounting requirements and with the published rules and regulations of the Commission with respect thereto, (y) were prepared in accordance with GAAP applied on a consistent basis during the periods involved (except as may be indicated in the notes thereto or, in the case of unaudited statements, as permitted by Form 10-Q of the Commission), and (z) together with the related “Management’s Discussion and Analysis of Financial Condition and Results of Operations” fairly present (subject in the case of unaudited statements to normal, recurring and year-end audit adjustments) in all material respects the consolidated financial position of Reata as of the dates thereof and the consolidated results of its operations and cash flows for the periods then ended.  

Section 3.04Independent Registered Public Accounting Firm

. Ernst & Young LLP, which has certified certain financial statements of Reata, is an independent public accounting firm with respect to Reata within the applicable rules and regulations adopted by the Commission and

6

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

the Public Company Accounting Oversight Board (United States) and as required by the Exchange Act.

Section 3.05No Material Adverse Effect

.  Except for the transactions contemplated by this Agreement and the Development Agreement, since March 31, 2020 to the date of this Agreement, there has been no (i) event or occurrence that has had or would reasonably be expected to have a Reata Material Adverse Effect, (ii) acquisition or disposition of any material asset by Reata or any contract or arrangement therefor, otherwise than for fair value in the ordinary course of business, (iii) material change in Reata’s accounting principles, practices or methods, or (iv) incurrence of material indebtedness.

Section 3.06Litigation

.  As of the date hereof, except as set forth in the Reata SEC Documents, there is no Action pending or, to the knowledge of Reata, threatened against Reata or any of its respective officers, directors or Properties, which would, individually or in the aggregate, reasonably be expected to have a Reata Material Adverse Effect or which challenges the validity of this Agreement, the other Operative Documents or the Development Agreement, or which would reasonably be expected to adversely affect or restrict Reata’s ability to consummate the transactions contemplated by the Operative Documents or the Development Agreement.

Section 3.07No Contravention

. The execution, delivery and performance by Reata of the Operative Documents have been duly authorized by all necessary corporate or other organizational action, and do not and will not (a) contravene the terms of any of Reata’s organizational documents; (b) conflict with or result in any breach or contravention of, or the creation of (or the requirement to create) any lien or encumbrance under, or require any payment to be made under (i) any contractual obligation to which Reata is a party or affecting Reata, or the properties of Reata or any Subsidiary, or (ii) any order, injunction, writ or decree of any governmental authority or any arbitral award to which Reata or its property is subject; or (c) violate any applicable Law, except in the case of this Section 3.07(b) and (c) with respect to any conflict, breach, violation, or payment, to the extent that such conflict, breach, violation, or payment would not, individually or in the aggregate, reasonably be expected to have a Reata Material Adverse Effect.

Section 3.08Approvals

.  No authorization, consent, approval, waiver, license, qualification or written exemption from, nor any filing, declaration, qualification or registration with, any Governmental Authority or any other Person is required in connection with the execution, delivery or performance by Reata of any of the Operative Documents, except (a) such as have been obtained, (b) such as have been made or as may be required under the Exchange Act or under state or foreign securities or “Blue Sky” laws, or (c) where the failure to receive such authorization, consent, approval, waiver, license, qualification or written exemption from, or to make such filing, declaration, qualification or registration would not, individually or in the aggregate, reasonably be expected to have a Reata Material Adverse Effect.

Section 3.09Investment Company Status

.  Reata is not, and after giving effect to the transactions contemplated by the Operative Documents will not be, an “investment company” as defined in the Investment Company Act of 1940, as amended.

7

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

Section 3.10Offering

.  Assuming the accuracy of the representations and warranties of BXLS contained in this Agreement, the issuance and sale of the Purchased Shares pursuant to this Agreement is exempt from registration requirements of the Securities Act, and neither Reata nor, to the knowledge of Reata, any authorized Representative acting on its behalf has taken or will take any action hereafter that would cause the loss of such exemption.

Section 3.11Certain Fees

.  No fees or commissions will be payable by BXLS to brokers, finders, or investment bankers engaged by Reata or its Affiliates with respect to the sale of any of the Purchased Shares or the consummation of the transactions contemplated by this Agreement.

Section 3.12Internal Controls and Procedures

.Reata maintains disclosure controls and procedures as such terms are defined in, and required by, Rule 13a-15 and Rule 15d-15 under the Exchange Act. Such disclosure controls and procedures were effective at the reasonable assurances level as of the latest date of management’s evaluation of such disclosure controls and procedures as set forth in the Reata SEC Documents to ensure that all material information required to be disclosed by Reata in the reports that it files or furnishes under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Commission. Reata maintains a system of internal controls over financial reporting sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; and (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP.

Section 3.13No Undisclosed Liabilities

. Reata does not have any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on Reata’s balance sheet (including the notes thereto) in conformity with GAAP and are not disclosed in the Reata SEC Documents, other than (a) those incurred in the ordinary course of Reata’s business since March 31, 2020, (b) those which, individually or in the aggregate, do not or would not reasonably be expected to have a Reata Material Adverse Effect, and (c) those arising under the Operative Documents or the Development Agreement.

Section 3.14No Undisclosed Events or Circumstances

. Except for the transactions contemplated by this Agreement and the Development Agreement, no event or circumstance has occurred or exists with respect to Reata or its business, properties, operations or financial condition, which, under applicable Law has required public disclosure or announcement by Reata but which has not been so publicly disclosed or announced and which event or circumstance, individually or in the aggregate, would have a Reata Material Adverse Effect.  

Article IV.
REPRESENTATIONS AND WARRANTIES OF BXLS

Each BXLS Entity, jointly and severally, represents and warrants to Reata as follows:

Section 4.01Authority

.

(a)Such BXLS Entity has the requisite limited liability company power and authority to enter into the Operative Documents and, assuming due authorization, execution and

8

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

delivery by Reata, the Operative Documents constitute, or will constitute, legal and valid obligations binding upon such BXLS Entity, enforceable in accordance with their terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization and other laws of general applicability relating to or affecting creditors’ rights and by general principles of equity.

(b)Such BXLS Entity is not a party to any agreement that would prevent it from fulfilling its obligations under the Operative Documents or that otherwise conflicts with the provisions of the Operative Documents, in each case in any material respect.

Section 4.02Investment

. Such BXLS Entity represents and warrants to, and covenants and agrees with, Reata that the Purchased Shares are being acquired for its own account, not as a nominee or agent, and with no intention of distributing the Purchased Shares or any part thereof, and that such BXLS Entity has no present intention of selling or granting any participation in or otherwise distributing the same in any transaction in violation of the securities laws of the United States of America or any State, without prejudice, however, to such BXLS Entity’s right at all times to sell or otherwise dispose of all or any part of the Purchased Shares under a registration statement under the Securities Act and applicable state securities laws or under an exemption from such registration available thereunder (including, without limitation, if available, Rule 144 promulgated thereunder). If such BXLS Entity should in the future decide to dispose of any of its Purchased Shares, such BXLS Entity understands and agrees that it may do so only in compliance with the Securities Act and applicable state securities law, as then in effect, or in the manner contemplated by any registration statement pursuant to which such securities are being offered, and that stop-transfer instructions to that effect will be in effect with respect to such securities.

Section 4.03Accredited Investor Status

. Such BXLS Entity is an “accredited investor” within the meaning of Rule 501(a) of Regulation D promulgated by the Commission pursuant to the Securities Act and by reason of its business and financial experience it has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Purchased Shares, is able to bear the economic risk of such investment and, at the present time, would be able to afford a complete loss of such investment.

Section 4.04Receipt of Information

. Such BXLS Entity has (i) had access to the Reata SEC Documents, (ii) has had access to Reata’s electronic data room associated with the transactions contemplated by this Agreement and the Development Agreement, and (iii) has been provided a reasonable opportunity to ask questions of and receive answers from Representatives of Reata regarding the business and operations of Reata.

Section 4.05Restricted Securities

. Such BXLS Entity understands that the Purchased Shares are characterized as “restricted securities” under the federal securities Laws inasmuch as they are being acquired from Reata in a transaction not involving a public offering and that under such laws and applicable regulations such securities may be resold without registration under the Securities Act only in certain limited circumstances. In this connection, such BXLS Entity represents that it is knowledgeable with respect to Rule 144 of the Commission promulgated under the Securities Act.

9

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

Section 4.06Certain Fees

. No fees or commissions will be payable by Reata to brokers, finders, or investment bankers engaged by such BXLS Entity or its Affiliates with respect to the sale of any of the Purchased Shares or the consummation of the transactions contemplated by this Agreement.

Section 4.07Reliance Upon BXLS’s Representations and Warranties

. Such BXLS Entity understands and acknowledges that the Purchased Shares are being offered and sold in reliance on a transactional exemption from the registration requirements of federal and state securities laws, and that Reata is relying in part upon the truth and accuracy of the representations, warranties, agreements, acknowledgments and understandings of such BXLS Entity set forth in this Agreement in (i) concluding that the issuance and sale of the Purchased Shares is a “private offering” and, as such, is exempt from the registration requirements of the Securities Act, and (ii) determining the applicability of such exemptions and the suitability of such BXLS Entity to purchase the Purchased Shares.

Section 4.08Residence

. Such BXLS Entity is a resident only of the state of Massachusetts for purposes of applicable securities or “Blue Sky” laws of the states of the United States.

Section 4.09Legend

. Such BXLS Entity understands that the book entry evidencing the Purchased Shares will bear substantially the following legend:  

These securities have not been registered under the Securities Act of 1933 (the “Securities Act”). These securities may not be sold or offered for sale except pursuant to an effective registration statement under the Securities Act or pursuant to an exemption from registration thereunder, in each case in accordance with all applicable securities laws of the states or other jurisdictions, and in the case of a transaction exempt from registration, such securities may only be transferred if the transfer agent for such securities has received documentation satisfactory to it that such transaction does not require registration under the Securities Act.

Article V.
COVENANTS

Section 5.01Taking of Necessary Action

. Each of the Parties hereto shall use its commercially reasonable efforts promptly to take or cause to be taken all action and promptly to do or cause to be done all things necessary, proper or advisable under applicable Law and regulations to consummate and make effective the transactions contemplated by this Agreement.  Without limiting the foregoing, Reata shall use its commercially reasonable efforts to make all filings and obtain all consents of any Governmental Authority that may be necessary or, in the reasonable opinion of the other party, as the case may be, advisable for the consummation of the transactions contemplated by the Operative Documents, and shall, on or before the Closing Date, take such action as the Company shall reasonably determine is necessary in order to obtain an

10

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

exemption for or to qualify the Purchased Shares for sale to BXLS under applicable securities or “Blue Sky” laws of the states of the United States (or to obtain an exemption from such qualification), and shall provide evidence of any such action so taken to the BXLS on or prior to the Closing Date. Reata shall make all filings and reports relating to the offer and sale of the Purchased Shares required under applicable securities or “Blue Sky” laws of the states of the United States following the Closing Date.

Section 5.02Facilitation of Sales Pursuant to Rule 144

. For one year following the Closing Date, Reata shall timely file the reports required to be filed by it under the Exchange Act or the Securities Act (including the reports under Sections 13 and 15(d) of the Exchange Act referred to in subparagraph (c)(1) of Rule 144)  to the extent required from time to time to enable BXLS to sell the Purchased Shares without registration under the Securities Act within the limitations of the exemption provided by Rule 144.

Section 5.03Registration Rights

. From the Registration Statement Start Date until the Registration Statement End Date:

(a)Reata shall use commercially reasonable efforts to register the reoffer and resale of the Purchased Shares by BXLS under the Securities Act on a continuous basis on a Registration Statement on Form S-3 (as may be supplemented or amended, the “Registration Statement”) within [***] after Reata’s public disclosure of all material non-public information (i) that is required to be disclosed in the Registration Statement and (b) that the board of directors or the Chief Executive Officer of Reata reasonably determines (a “Delay Determination”) that the disclosure of which at the time would, absent the delay provided by this Section 5.03(a), require disclosure of material information that Reata has a bona fide business purpose for preserving as confidential, including the status of its current discussions with the FDA regarding the regulatory pathway for the use of bardoxolone methyl in the treatment of patients with chronic kidney disease caused by Alport syndrome (CARDINAL trial) and the use of omaveloxolone for the treatment of patients with Friedreich’s ataxia (MOXIe trial), and to cause the Registration Statement to be declared effective by the Commission, if applicable. For avoidance of doubt, such registration may be done by way of Reata filing a prospectus supplement to the base prospectus contained in Reata’s registration statement on Form S-3 (Reg. No. 333-226289) under Rule 424 of the Securities Act, provided that such registration statement is then effective under the Securities Act. In the event of a Delay Determination, Reata shall as promptly as practicable (and thereafter, as long as such Delay Determination remains in effect, on the same day of the month as the original Delay Determination was made, or if no such day exists in such month, on the last day of such month) certify to BXLS that a Delay Determination has been made and, upon written request by BXLS, provide details of the circumstances then existing which shall have resulted in the Delay Determination (or the continuation of same, as the case may be). In the event that Registration Statement on Form S-3 is not available for the registration of the resale of Purchased Shares, Reata shall (i) register the resale of the Purchased Shares on another appropriate form reasonably acceptable to BXLS and (ii) undertake to register the Purchased Shares on Form S-3 promptly after such form is available, provided that Reata shall maintain the effectiveness of the Registration Statement until such time as a Registration Statement on Form S-3 covering the Purchased Shares has been declared effective by the Commission. The “Plan of Distribution” relating to BXLS which is included in the Registration Statement shall not include distribution through an Underwritten

11

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

Offering, and Reata’s management shall not be required to participate in a roadshow or similar marketing effort in connection with any offering.

(b)Reata shall use commercially reasonable efforts to (i) keep the Registration Statement continuously effective under the Securities Act until the Registration Statement End Date, and (ii) avoid the issuance of, or, if issued, obtain the withdrawal of (A) any order suspending the effectiveness of a Registration Statement, or (B) any suspension of the qualification (or exemption from qualification) of any of the Purchased Shares for sale in any jurisdiction, as soon as practicable. Reata shall prepare and file with the Commission such amendments (including post-effective amendments) and supplements, to the Registration Statement and the prospectus used in connection therewith as may be necessary to keep the Registration Statement continuously effective until the Registration Statement End Date; (ii) cause the related Prospectus to be amended or supplemented by any required Prospectus supplement (subject to the terms of this Agreement), and, as so supplemented or amended, to be filed pursuant to Rule 424 under the Securities Act; (iii) respond as promptly as reasonably practicable to any comments received from the Commission with respect to the Registration Statement or any amendment thereto and, as promptly as reasonably practicable, provide BXLS true and complete copies of all correspondence from and to the Commission relating to the Registration Statement that pertains to BXLS as “Selling Stockholders” but not any comments that would result in the disclosure to BXLS of material and non-public information concerning Reata; and (iv) comply with the provisions of the Securities Act and the Exchange Act with respect to the disposition of all Purchased Shares covered by the Registration Statement; provided, however, that BXLS shall be responsible for the delivery of the relevant prospectus to the persons to whom BXLS sells any of the Purchased Shares (including in accordance with Rule 172 under the Securities Act), and BXLS agrees to dispose of Purchased Shares in compliance with the “Plan of Distribution” for BXLS described in the Registration Statement and otherwise in compliance with applicable federal and state securities laws. In the case of amendments and supplements to a Registration Statement which are required to be filed pursuant to this Agreement by reason of Reata filing a report on Form 10-K, Form 10-Q or Form 8-K or any analogous report under the Exchange Act, Reata shall have incorporated such report by reference into such Registration Statement, if applicable, or shall file such amendments or supplements with the Commission within [***] of when the Exchange Act report which created the requirement for Reata to amend or supplement such Registration Statement was filed.

(c)Not less than [***] prior to the filing of the Registration Statement, if applicable, or any prospectus or any amendment or supplement thereto related to BXLS (except for Annual Reports on Form 10-K, and Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any similar or successor reports or supplements made to update for any such report), Reata shall (i) furnish to BXLS copies of such Registration Statement, prospectus or amendment or supplement thereto, as proposed to be filed, which documents will be subject to the review of BXLS (it being acknowledged and agreed that if BXLS does not object to or comment on the aforementioned documents within such [***] then BXLS shall be deemed to have consented to and approved the use of such documents) and (ii) use commercially reasonable efforts to cause its officers and directors, counsel and independent registered public accountants to respond to such inquiries as shall be necessary, in the reasonable opinion of BXLS, to conduct a reasonable investigation within the meaning of the Securities Act. Reata shall not file any registration statement under the Securities Act or amendment or supplement thereto in a form to which BXLS

12

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

reasonably objects in good faith, provided that, Reata is notified of such objection in writing within the[***].

(d)Until the Registration Statement End Date, Reata shall notify BXLS (which notice shall, pursuant to clauses (iii) through (v) hereof, be accompanied by an instruction to suspend the use of the prospectus until the requisite changes have been made) as promptly as reasonably practicable (and, in the case of (i)(A) below, not less than [***] prior to such filing) and (if requested by any such person) confirm such notice in writing no later than [***] following the day: (i)(A) when a prospectus or any prospectus supplement or post-effective amendment to the Registration Statement is proposed to be filed; (B) when the Commission notifies Reata whether there will be a “review” of the Registration Statement and whenever the Commission comments in writing on the Registration Statement (in which case Reata shall provide to BXLS true and complete copies of all comments that pertain to BXLS as a “Selling Stockholder” or to the “Plan of Distribution” for BXLS and all written responses thereto, but not information that Reata believes would constitute material and non-public information); and (C) with respect to the Registration Statement or any post-effective amendment, when the same has become effective; (ii) of any request by the Commission or any other federal or state governmental authority for amendments or supplements to the Registration Statement or a prospectus contained therein or for additional information that pertains to BXLS as “Selling Stockholders” or the “Plan of Distribution” for BXLS; (iii) of the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of the Registration Statement or the initiation of any proceedings for that purpose; (iv) of the receipt by Reata of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Purchased Shares for sale in any jurisdiction, or the initiation or threatening of any proceeding for such purpose; (v) of the occurrence of any event or passage of time that makes the financial statements included in the Registration Statement ineligible for inclusion therein or any statement made in such Registration Statement or prospectus contained therein or any document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires any revisions to the Registration Statement, such prospectus or other documents so that, in the case of the Registration Statement or such prospectus, as the case may be, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus, form of prospectus or supplement thereto, in light of the circumstances under which they were made), not misleading, provided that, any and all such information shall remain confidential to BXLS until such information otherwise becomes public, unless disclosure by BXLS is required by law; and provided, further, that notwithstanding BXLS’s agreement to keep such information confidential, BXLS makes no acknowledgement that any such information is material, non-public information; provided, further, that Reata may not postpone or suspend the effectiveness of the Registration Statement under this Section 5.03(d) for more than [***].

(e)If requested by BXLS, Reata shall furnish to BXLS, without charge, at least one conformed copy of the Registration Statement and each amendment thereto and all exhibits to the extent requested by BXLS (including those previously furnished or incorporated by reference) promptly after the filing of such documents with the Commission; provided, that Reata shall have no obligation to provide any document pursuant to this clause that is available on the Commission’s EDGAR system.

13

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

(f)Prior to any resale of Purchased Shares by BXLS, Reata shall use its commercially reasonable efforts to register or qualify or cooperate with BXLS in connection with the registration or qualification (or exemption from the registration or qualification) of the Purchased Shares for the resale by BXLS under the securities or Blue Sky laws of such jurisdictions within the United States as BXLS reasonably requests in writing, to keep each registration or qualification (or exemption therefrom) effective until the Registration Statement End Date, and to do any and all other acts or things reasonably necessary to enable the disposition in such jurisdictions of the Purchased Shares covered by each Registration Statement; provided, that Reata shall not be required to qualify generally to do business in any jurisdiction where it is not then so qualified, subject Reata to any material tax in any such jurisdiction where it is not then so subject or file a general consent to service of process in any such jurisdiction.

(g)If requested by BXLS, Reata shall cooperate with BXLS to facilitate the timely preparation and delivery of the evidence of ownership representing Purchased Shares to a transferee pursuant to the Registration Statement, which evidence shall be free, to the extent permitted under law, of all restrictive legends, and to enable such Purchased Shares to be in such denominations and registered in such names as BXLS may reasonably request.

(h)BXLS shall furnish to Reata such information regarding BXLS, and the resale of the Purchased Shares under the Registration Statement, as Reata may reasonably request in writing and as shall be required in connection with the Registration Statement. With respect to information regarding BXLS furnished in writing to Reata by BXLS expressly for use in the Registration Statement, or to the extent that such information relates to BXLS or BXLS’s proposed method of distribution of the Purchased Shares and was reviewed and approved in writing by BXLS expressly for use in the Registration Statement, BXLS shall promptly notify Reata upon knowledge of the happening of any event as a result of which the Registration Statement includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading (in the case of any prospectus contained in such Registration Statement or documents incorporated therein by reference, in the light of the circumstances under which a statement is made); provided, that, any and all such information shall remain confidential to Reata until such information otherwise becomes public, unless disclosure by Reata is required by law.

(i)Reata shall pay all Registration Expenses incurred by Reata or BXLS.

Article VI.
CLOSING CONDITIONS

Section 6.01Conditions to the Closing

.

(a)Mutual Conditions.  The obligation of each Party to consummate the purchase and issuance and sale of the Purchased Shares shall be subject to the satisfaction on or prior to the Closing Date of each of the following conditions (any or all of which may be waived by a particular Party on behalf of itself in writing, in whole or in part, to the extent permitted by applicable Law):

14

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

(i)no Law shall have been enacted or promulgated, and no Action shall have been taken, by any Governmental Authority of competent jurisdiction which temporarily, preliminarily or permanently restrains, precludes, enjoins or otherwise prohibits the consummation of the transactions contemplated by this Agreement or makes the transactions contemplated by this Agreement illegal; and

(ii)there shall not be pending any suit, Action or proceeding by any Governmental Authority seeking to restrain, preclude, enjoin or prohibit the transactions contemplated by this Agreement.

(b)BXLS’s Conditions.  The respective obligation of BXLS to consummate the purchase of the Purchased Shares shall be subject to the satisfaction on or prior to the Closing Date of each of the following conditions (any or all of which may be waived by BXLS in writing, in whole or in part, to the extent permitted by applicable Law):

(i)Reata shall have performed and complied with the covenants and agreements contained in this Agreement and the Development Agreement that are required to be performed and complied with by Reata on or prior to the Closing (including, for avoidance of doubt, the condition in Section 4.2.2.2 of the Development Agreement shall have been satisfied);

(ii)the representations and warranties of Reata contained in this Agreement that are qualified by materiality or Reata Material Adverse Effect shall be true and correct when made and as of the Closing and all other representations and warranties shall be true and correct in all material respects when made and as of the Closing, in each case as though made at and as of the Closing  (except that representations made as of a specific date shall be required to be true and correct as of such date only);

(iii)no notice of delisting from the NASDAQ shall have been received by Reata with respect to the Class A Common Stock;

(iv)the Class A Common Stock shall not have been suspended by the Commission or the NASDAQ from trading on the NASDAQ nor shall suspension by the Commission or the NASDAQ have been threatened in writing by the Commission or the NASDAQ;

(v)no Reata Material Adverse Effect shall have occurred after the date of this Agreement and be continuing; and

(vi)Reata shall have delivered, or caused to be delivered, to BXLS at the Closing, Reata’s closing deliveries described in Section 6.02 of this Agreement.

(c)Reata’s Conditions.  The obligation of Reata to consummate the sale of the Purchased Shares to BXLS shall be subject to the satisfaction on or prior to the Closing of the following conditions (which may be waived by Reata in writing, in whole or in part, to the extent permitted by applicable Law):

15

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

(i)BXLS shall have performed and complied with the covenants and agreements contained in this Agreement and the Development Agreement that are required to be performed and complied with by BXLS on or prior to the Closing Date;

(ii)the representations and warranties of BXLS contained in this Agreement that are qualified by materiality or BXLS Material Adverse Effect shall be true and correct when made and as of the Closing and all other representations and warranties shall be true and correct in all material respects when made and as of the Closing, in each case as though made at and as of the Closing  (except that representations made as of a specific date shall be required to be true and correct as of such date only);

(iii)no BXLS Material Adverse Effect shall have occurred and be continuing; and

(iv)BXLS shall have delivered, or caused to be delivered, to Reata at the Closing, BXLS’s closing deliveries described in Section 6.03 of this Agreement.

Section 6.02Reata Deliveries

.  At the Closing, subject to the terms and conditions of this Agreement, Reata will deliver, or cause to be delivered, to BXLS:

(a)Evidence of the Purchased Shares credited to book-entry accounts for BXLS or their custodian maintained by the transfer agent of Reata, bearing the legend or restrictive notation set forth in Section 4.09, free and clear of all Liens, other than transfer restrictions under applicable federal and state securities laws;

(b)The Officer’s Certificate, dated the Closing Date, substantially in the form attached to this Agreement as Exhibit A.

(c)A certificate of the Secretary or Assistant Secretary of Reata, certifying as to (1) Reata’s Thirteenth Amended and Restated Certification of Incorporation (including a certification that same is then in effect unamended), (2) Reata’s Second Amended and Restated Bylaws (including a certification that same is then in effect unamended), (3) board resolutions (i) authorizing the execution and delivery of the Operative Documents and (ii) the consummation of the transactions contemplated thereby, including the issuance of the Purchased Shares, and (4) the incumbency of the officers authorized to execute the Operative Documents, setting forth the name and title and bearing the signatures of such officers;

(d)An opinion addressed to BXLS from Vinson & Elkins L.L.P., legal counsel to Reata, dated the Closing, in substantially the form of opinion attached to this Agreement as Exhibit B;

(e)A certificate of the Secretary of State of the State of Delaware, dated a recent date, to the effect that Reata is in good standing; and

16

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

(f)A receipt, dated the Closing Date, executed by Reata to the effect that Reata has received the Purchase Price for the Purchased Shares.

Section 6.03BXLS Deliveries

.  At the Closing, subject to the terms and conditions of this Agreement, BXLS will deliver, or cause to be delivered, to Reata:

(a)Payment to Reata of the Purchase Price by wire transfer(s) of immediately available funds to an account designated by Reata in writing at least two (2) Business Days (or such shorter period as shall be agreeable to all Parties hereto) prior to the Closing.

Article VII.
INDEMNIFICATION, COSTS AND EXPENSES

Section 7.01Indemnification by Reata

.  

(a)Reata agrees to indemnify BXLS, their respective Affiliates, investors and their respective members, officers, directors, employees and agents (collectively, “BXLS Related Parties”) from, and hold each of them harmless against, any and all Actions, suits, proceedings (including any investigations, litigation or inquiries), demands, and causes of action, and, in connection therewith, and promptly upon demand, pay or reimburse each of them for all reasonable costs, losses, liabilities, damages, or expenses of any kind or nature whatsoever, including, without limitation, the reasonable fees and disbursements of counsel and all other reasonable expenses incurred in connection with investigating, defending or preparing to defend any such matter (“Losses”) that may be incurred by them or asserted against or involve any of them as a result of, arising out of, or in any way related to the breach of any of the representations, warranties or covenants of Reata contained herein, provided such claim for indemnification relating to a breach of a representation or warranty is made prior to the expiration of such representation or warranty, and provided further, that no BXLS Related Party shall be entitled to recover special, consequential (including lost profits or diminution in value) or punitive damages, and provided further that the aggregate dollar amount of indemnification payable by Reata pursuant to this Section 7.01(a) shall not exceed [***].

(b)Reata shall, notwithstanding any termination of this Agreement, indemnify, defend and hold harmless the BXLS Related Parties from and against any and all Losses, as incurred, that arise out of or are based upon (i) any untrue or alleged untrue statement of a material fact contained in the Registration Statement, any related prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus or form of prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading, or (ii) any violation or alleged violation by Reata of the Securities Act, Exchange Act or any state securities law or any rule or regulation thereunder, in connection with the performance of its obligations under this Agreement, except insofar as (A) such untrue statements, alleged untrue statements, omissions or alleged omissions are based solely upon information regarding BXLS furnished in writing to Reata by BXLS expressly for use therein, or to the extent that such information relates to BXLS or BXLS’s proposed method of distribution of the Purchased Shares

17

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

and was reviewed and approved in writing by BXLS expressly for use in the Registration Statement, such prospectus or such form of Prospectus or in any amendment or supplement thereto or (B) to the extent that any such Losses arise out of BXLS’ failure to send or give a copy of the prospectus or supplement (as then amended or supplemented) related to the Registration Statement, if required, pursuant to Rule 172 under the Securities Act (or any successor rule) to the persons asserting an untrue statement or alleged untrue statement or alleged untrue statement or omission or alleged omission at or prior to the written confirmation of the sale of Purchased Shares to such person if such statement or omission was corrected in such prospectus or supplement. Reata shall notify BXLS promptly of the institution, threat or assertion of any proceeding arising from or in connection with the transactions contemplated by this Agreement of which Reata is aware. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of a BXLS Related Party and shall survive the transfer of the Purchased Shares by BXLS. In no event shall the aggregate dollar amount of indemnification payable by Reata pursuant to this Section 7.01(b) exceed [***].

Section 7.02Indemnification by BXLS

.  

(a)BXLS agrees to indemnify Reata, its Affiliates and its and their respective officers, directors, employees and agents (collectively, “Reata Related Parties”) from, and hold each of them harmless against, any and all Losses incurred by them or asserted against or involve any of them as a result of, arising out of, or in any way related to the breach of any of the representations, warranties or covenants of BXLS contained herein, provided such claim for indemnification relating to a breach of the representations and warranties is made prior to the expiration of such representations and warranties, and provided further, that no Reata Related Party shall be entitled to recover special, consequential (including lost profits or diminution in value) or punitive damages.

(b)BXLS shall indemnify and hold harmless the Reata Related Parties from and against all Losses arising out of any untrue or alleged untrue statement of a material fact contained in the Registration Statement, any related prospectus, or any form of prospectus, or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any such prospectus, or any form of prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading (i) to the extent that such untrue statements or omissions are contained in any information regarding BXLS furnished in writing to Reata by BXLS expressly for use therein or (ii) to the extent that such information relates to BXLS or its proposed method of distribution of Purchased Shares and was reviewed and approved in writing by BXLS expressly for use in the Registration Statement, such prospectus or such form of prospectus or in any amendment or supplement thereto. In no event shall the liability of BXLS hereunder be greater in amount than the dollar amount of the net proceeds received by BXLS upon the sale of the Purchased Shares giving rise to such indemnification obligation.

Section 7.03Indemnification Procedure

.  Promptly after any Reata Related Party or BXLS Related Party (hereinafter, the “Indemnified Party”) has received notice of any indemnifiable claim hereunder, or the commencement of any Action or proceeding by a third

18

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

person, which the Indemnified Party believes in good faith is an indemnifiable claim under this Agreement, the Indemnified Party shall give the indemnitor hereunder (the “Indemnifying Party”) written notice of such claim or the commencement of such Action or proceeding, but failure to so notify the Indemnifying Party will not relieve the Indemnifying Party from any liability it may have to such Indemnified Party hereunder except to the extent that the Indemnifying Party is materially prejudiced by such failure. Such notice shall state the nature and the basis of such claim to the extent then known.  The Indemnifying Party shall have the right to defend and settle, at its own expense and by its own counsel, any such matter as long as the Indemnifying Party pursues the same diligently and in good faith. If the Indemnifying Party undertakes to defend or settle, it shall promptly notify the Indemnified Party of its intention to do so, and the Indemnified Party shall cooperate with the Indemnifying Party and its counsel in all commercially reasonable respects in the defense thereof and the settlement thereof. Such cooperation shall include, but shall not be limited to, furnishing the Indemnifying Party with any books, records and other information reasonably requested by the Indemnifying Party and in the Indemnified Party’s possession or control.  Such cooperation of the Indemnified Party shall be at the cost of the Indemnifying Party.  After the Indemnifying Party has notified the Indemnified Party of its intention to undertake to defend or settle any such asserted liability, and for so long as the Indemnifying Party diligently pursues such defense, the Indemnifying Party shall not be liable for any additional legal expenses incurred by the Indemnified Party in connection with any defense or settlement of such asserted liability; provided, however, that the Indemnified Party shall be entitled (i) at its expense, to participate in the defense of such asserted liability and the negotiations of the settlement thereof and (ii) if (A) the Indemnifying Party has failed to assume the defense and employ counsel or (B) if the defendants in any such Action include both the Indemnified Party and the Indemnifying Party and counsel to the Indemnified Party shall have concluded that there may be reasonable defenses available to the Indemnified Party that are different from or in addition to those available to the Indemnifying Party or if the interests of the Indemnified Party reasonably may be deemed to conflict with the interests of the Indemnifying Party, then the Indemnified Party shall have the right to select a separate counsel and to assume such legal defense and otherwise to participate in the defense of such Action, with the expenses and fees of such separate counsel and other expenses related to such participation to be reimbursed by the Indemnifying Party as incurred.  Notwithstanding any other provision of this Agreement, the Indemnifying Party shall not settle any indemnified claim without the consent of the Indemnified Party, unless the settlement thereof imposes no liability or obligation on, and includes a complete release from liability of, the Indemnified Party.

Article VIII.
MISCELLANEOUS

Section 8.01Survival of Provisions

.  The representations and warranties set forth in this Agreement shall survive for a period of twelve (12) months following the Closing regardless of any investigation made by or on behalf of Reata or BXLS, except for those set forth in Sections 3.01, 3.02(a), 3.02(d), 3.08, 3.10 and 3.11, which shall survive indefinitely for duration of the relevant statute of limitations.  The covenants made in this Agreement or any other Operative Document shall survive the closing of the transactions described herein and remain operative and in full force and effect regardless of acceptance of any of the Purchased Shares and payment therefor and repayment, conversion, exercise or repurchase thereof. All indemnification

19

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

obligations of Reata and BXLS and the provisions of Article VII shall remain operative and in full force and effect unless such obligations are expressly terminated in a writing by the Parties, regardless of any purported general termination of this Agreement.

Section 8.02No Waiver; Modifications in Writing

.

(a)Delay. No failure or delay on the part of any party in exercising any right, power, or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right, power, or remedy preclude any other or further exercise thereof or the exercise of any right, power, or remedy. The remedies provided for herein are cumulative and are not exclusive of any remedies that may be available to a party at law or in equity or otherwise.

(b)Amendments and Waivers. Except as otherwise provided herein, no amendment, waiver, consent, modification, or termination of any provision of this Agreement or any other Operative Document shall be effective unless signed by each of the original signatories hereto or thereto affected by such amendment, waiver, consent, modification, or termination. Any amendment, supplement or modification of or to any provision of this Agreement or any other Operative Document, any waiver of any provision of this Agreement or any other Operative Document, and any consent to any departure by Reata from the terms of any provision of this Agreement or any other Operative Document shall be effective only in the specific instance and for the specific purpose for which made or given. Except where notice is specifically required by this Agreement, no notice to or demand on Reata in any case shall entitle Reata to any other or further notice or demand in similar or other circumstances.

Section 8.03Binding Effect; Assignment

.

(a)No Third Parties. Except as expressly provided in this Agreement, this Agreement shall not be construed so as to confer any right or benefit upon any Person other than the Parties to this Agreement, and their respective successors and permitted assigns.

(b)Assignment. All or any portion of BXLS’s Purchased Shares purchased pursuant to this Agreement may be sold, assigned or pledged by BXLS, subject to compliance with applicable securities laws and Section 5.01 of this Agreement. All or any portion of the rights but not the obligations of BXLS under this Agreement may be transferred to any Affiliate of BXLS but may not otherwise be transferred by BXLS without the prior written consent of Reata.

Section 8.04Notices

.  Any notice or other communication required or permitted to be given by either Party under this Agreement will be in writing and will be effective when delivered if delivered by fax, e-mail, hand, reputable courier service, or five (5) days after mailing if mailed by registered or certified mail, postage prepaid and return receipt requested, addressed to the other Party at the following addresses or such other address as may be designated by notice pursuant to this Section:

20

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

(a) If to BXLS:

BXLS V – River L.P.

c/o Blackstone Life Sciences

101 Main Street

Suite 1210

Cambridge, MA 02142

Attention: [***]

email: [***]

with copies to:

Blackstone Life Sciences – Legal Department

101 Main Street

Suite 1210

Cambridge, MA 02142

Attention: [***]

email: [***]

Morrison & Foerster LLP

755 Page Mill Road

Palo Alto, CA 94304-1018

Attention:  Michael O’Donnell

email: MichaelODonnell@MoFo.com

(b) If to Reata:

Reata Pharmaceuticals, Inc.

5320 Legacy Drive

Plano, TX 75024

Attention: Chief Financial Officer

email:  manmeet.soni@reatapharma.com

with copies to:

Reata Pharmaceuticals, Inc.

5320 Legacy Drive

Plano, TX 75024

Attention:  Chief Legal Officer

email:  mike.wortley@reatapharma.com

Cooley LLP

101 California Street, 5th Floor

San Francisco, MA 94111-5800

Attention: Mischi a Marca

email: gmamarca@cooley.com

21

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

Vinson & Elkins L.L.P.
2001 Ross Avenue, Suite 3900
Dallas, Texas 75201
Attention: Robert L. Kimball
email:  rkimball@velaw.com

or to such other address as Reata or BXLS may designate in writing. All notices and communications shall be deemed to have been duly given: at the time delivered by hand, if personally delivered; upon actual receipt if sent by certified mail, return receipt requested, or regular mail, if mailed; when receipt acknowledged, if sent via facsimile or electronic mail; and upon actual receipt when delivered to an air courier guaranteeing overnight delivery. Consistent with this provision, for all notices or other communication required or permitted to be given under this Agreement to or from BXLS, BXLS V shall act as the representative for both BXLS Entities.

Section 8.05Removal of Legend

.

(a)  In connection with a sale of Purchased Shares by BXLS in reliance on Rule 144, BXLS and its broker shall deliver to the transfer agent and Reata a customary seller’s and broker’s representation letter providing to the transfer agent and Reata any information Reata deems reasonably necessary to determine that the sale of the Purchased Shares is made in compliance with Rule 144, including, as may be appropriate, a certification that BXLS is not an affiliate of Reata (as defined in Rule 144) and regarding the length of time the Purchased Shares have been held. Upon receipt of such representation letter, Reata shall cause any restrictive legends with respect to the Purchased Shares (including the legend referred to in Section 4.09) to be removed, including promptly directing its transfer agent to remove the notation of such restrictive legend in BXLS’s book-entry account maintained by the transfer agent for such sold Purchased Shares and, if reasonably requested by BXLS, causing counsel to Reata to issue an opinion to such transfer agent authorizing the removal of such restrictive legends.

(b)At such time as BXLS is permitted to sell all the Purchased Shares pursuant to Rule 144 without volume or manner of sale restrictions and without the requirement that Reata comply with the reporting requirements of Rule 144(c)(i) (or any similar provision then in effect), and upon delivery by BXLS and its broker of customary seller’s and broker’s representation letters providing to the transfer agent and Reata any information Reata deems reasonably necessary to determine that the future sale of the Purchased Shares shall be made in compliance with Rule 144, including, as may be appropriate, a certification that BXLS is not an affiliate of Reata (as defined in Rule 144) and regarding the length of time the Purchased Shares have been held, Reata shall promptly direct its transfer agent to remove the notation of a restrictive legend in BXLS’s book-entry account maintained by the transfer agent for all the Purchased Shares, including the legend referred to in Section 4.09.

(c)Upon completion of the registration of the resale of the Purchased Shares pursuant to a prospectus under an effective registration statement, Reata shall promptly direct its transfer agent to remove the notation of a restrictive legend in BXLS’s book-entry account

22

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

maintained by the transfer agent for all Purchased Shares, including the legend referred to inSection 4.09.

Section 8.06Amendments; No Waiver

.  Unless otherwise specified herein, no amendment, supplement, or modification of this Agreement will be binding on either Party unless it is in writing and signed by both Parties. No delay or failure on the part of a Party in the exercise of any right under this Agreement or available at law or equity will be construed as a waiver of such right, nor will any single or partial exercise thereof preclude any other exercise thereof. All waivers must be in writing and signed by the Party against whom the waiver is to be effective. Any such waiver will constitute a waiver only with respect to the specific matter described in such writing and will in no way impair the rights of the Party granting such waiver in any other respect or at any other time.

Section 8.07Severability

.  If any provision (or portion thereof) of this Agreement is determined by a court or arbitration to be unenforceable as drafted by virtue of the scope, duration, extent, or character of any obligation contained herein, it is the Parties’ intention that such provision (or portion thereof) will be construed in a manner designed to effectuate the purposes of such provision to the maximum extent enforceable under such applicable Law. The Parties will enter into whatever amendment to this Agreement as may be necessary to effectuate such purposes.

Section 8.08Entire Agreement

.  This Agreement, along with the Operative Documents, contains the entire understanding of the Parties and supersedes, revokes, terminates, and cancels any and all other arrangements, understandings, agreements, term sheets, or representations and warranties, whether oral or written, between the Parties relating to the subject matter of this Agreement.

Section 8.09Counterparts

.  This Agreement will be executed in two (2) counterparts, one (1) for either Party, which, taken together, will constitute one and the same agreement. This Agreement will not be binding on the Parties or otherwise effective unless and until executed by both Parties. This Agreement and any Operative Document may be delivered by any Party by facsimile or other electronic transmission.

Section 8.10Construction

.   This Agreement has been negotiated by the Parties and their respective counsel. This Agreement will not be construed in favor of or against either Party by reason of the authorship of any provisions hereof.

Section 8.11Termination

.

(a)Notwithstanding anything herein to the contrary, this Agreement may be terminated at any time at or prior to the Closing by mutual agreement of the Parties.  

(b)Notwithstanding anything herein to the contrary, this Agreement shall automatically terminate at any time at or prior to the Closing:

(i)if a statute, rule, order, decree or regulation shall have been enacted or promulgated, or if any Action shall have been taken by any Governmental

23

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

Authority of competent jurisdiction that permanently restrains, permanently precludes, permanently enjoins or otherwise permanently prohibits the consummation of the transactions contemplated by this Agreement or makes the transactions contemplated by this Agreement illegal; or

(ii)if the Development Agreement is terminated prior to the Closing other than based on BXLS’s failure to pay the BXLS Development Payment (as defined in the Development Agreement) at or prior to the Closing.

(c)Notwithstanding anything herein to the contrary, this Agreement may be terminated at any time at or prior to the Closing, if BXLS shall have failed to pay the BXLS Development Payment (as defined in the Development Agreement) as required under the Development Agreement, provided, for avoidance of doubt, that all conditions under Sections 4.2.1 and 4.2.2 of the Development Agreement shall have been satisfied as of the date that Reata elects to exercise its right under this Section 8.11(c).

(d)In the event of the termination of this Agreement as provided in Section 8.11, this Agreement shall forthwith become null and void.  In the event of such termination, there shall be no liability under this Agreement on the part of any party hereto, except as set forth in Article VII of this Agreement; provided that nothing herein shall relieve any party from any liability or obligation under this Agreement with respect to any willful breach of this Agreement.

[Signature pages follow.]

24

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

IN WITNESS WHEREOF, the Parties hereto execute this Agreement, effective as of the date first above written.

REATA PHARMACEUTICALS, INC.

By: /s/ Manmeet S. Soni

Name: Manmeet S. Soni

Title: Chief Operating Officer, Chief Financial Officer and Executive Vice President

Signature Page to Common Stock Purchase Agreement

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

BXLS V – RIVER L.P.

By: Blackstone Life Sciences Advisors L.L.C. on

Behalf of BXLS V – River L.P.

By: /s/ Robert Liptak

Name: Robert Liptak

Title: Authorized Person

BXLS FAMILY INVESTMENT PARTNERSHIP (CYM) V – ESC L.P.

By: Blackstone Life Sciences V (CYM) AIV GP L.P.

By: BXLS V L.L.C., its general partner

By: /s/ Robert Liptak

Name: Robert Liptak

Title: Authorized Person

Signature Page to Common Stock Purchase Agreement

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

Exhibit A

Reata Officer’s Certificate

Omitted pursuant to Item 601(a)(5) of Regulation S-K.

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

Exhibit B

Opinion of Reata Counsel

Omitted pursuant to Item 601(a)(5) of Regulation S-K.

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

Schedule of Investors

Omitted pursuant to Item 601(a)(5) of Regulation S-K.

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

EX-10.3

Exhibit 10.3

Execution Version

DEVELOPMENT AND COMMERCIALIZATION FUNDING AGREEMENT

This Development and Commercialization Funding Agreement (“Agreement”), made effective as of June 10, 2020 (the “Effective Date”), is by and between Reata Pharmaceuticals Inc., a Delaware corporation (“Reata”), and BXLS V – River  L.P. (together with its successors and assigns, “BXLS”), a limited partnership organized and existing under the laws of Delaware (each, a “Party” and collectively, the “Parties”).

WHEREAS, BXLS is in the business of facilitating, among other things, the development and approval of pharmaceutical products and desires to provide financing for the development and commercialization of the Product (as hereafter defined) as a treatment for patients with chronic kidney disease associated with Alport syndrome (“ALPS”), autosomal dominant polycystic kidney disease (“ADPKD”) and associated indications, either alone or in combination with other treatments; and

WHEREAS, Reata has rights to the Product, is conducting clinical trials of the Product in patients with ALPS and ADPKD and would like to enter into an agreement with BXLS to enable BXLS to provide financing for the continued clinical development and commercialization of the Product.

NOW THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:  

Article 1

DEFINITIONS

1.1Defined Terms.  Initially capitalized terms will have the meaning ascribed to such terms in this Agreement, including the following terms which will have the following respective meanings:

1.1.1“AC” has the meaning ascribed to such term in Section 5.1.1.

1.1.2“AC Chairperson” has the meaning ascribed to such term in Section 5.1.2.

1.1.3“AC Representative(s)” has the meaning ascribed to such term in Section 5.1.1.

1.1.4“Account” is any “account” as defined in the UCC and includes, without limitation, all accounts receivable owing to Reata.

1.1.5“ADPKD” shall have the meaning set forth in the preamble.

1.1.6“Affiliate” means, with respect to a Person, a business entity under common control with, or controlling or controlled by, such Person, with “control” meaning direct or indirect ownership of 50% or more of the voting interest in the applicable Person, and in the case of a

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

partnership, control of the general partner.  Notwithstanding the foregoing, neither The Blackstone Group Inc. (“Blackstone”) nor any of its divisions, including Blackstone Life Sciences Advisors L.L.C., will be deemed to be an “Affiliate” of BXLS.

1.1.7“Alliance Manager” has the meaning ascribed to such term in Section 5.1.5.

1.1.8“ALPS” shall have the meaning set forth in the preamble.

1.1.9“Alternate Remediation Proposal” has the meaning ascribed to such term in Section 5.2.2.1.

1.1.10“Anti-Corruption Laws” means the US Foreign Corrupt Practices Act, as amended, the UK Bribery Act 2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money laundering or terrorism.

1.1.11“Applicable Law” means the applicable laws, statutes, rules, regulations, guidelines or other requirements of any Governmental Authorities (including any Regulatory Authorities), to the extent legally binding, that may be in effect from time to time in any country or regulatory jurisdiction of the Territory with respect to a given action or activity. For clarity, Applicable Laws will include, as applicable, (a) all laws, regulations and legally binding guidelines, including legally binding GCP, GLP, GMP and ICH guidelines applicable to the conduct of Clinical Trials, (b) all Anti-Corruption Laws, and (c) all applicable data protection and privacy laws, rules and regulations, including, to the extent applicable, the United States Department of Health and Human Services privacy rules under the Health Insurance Portability and Accountability Act of 1996 and the Health Information Technology for Economic and Clinical Health Act and the EU General Data Protection Regulation (2016/679) and similar laws covering the use and storage of personal health information or protected personally identifiable information.  

1.1.12“Approval” or “Approved” means (i) the full or accelerated approval of a new drug application (NDA) in the United States by the FDA, or (ii) approval of a marketing authorization application (MAA) in any of the EU5 by the EMA, in each case for the Product for ALPS or ADPKD.

1.1.13“Bardoxolone” has the meaning set forth in Exhibit A.

1.1.14“Bardoxolone IP” means all Intellectual Property that is specifically relating to the Product, and that is owned or otherwise Controlled by Reata.

1.1.15“Bardoxolone IP Collateral” means the Bardoxolone IP and the proceeds thereof (excluding any Accounts and Payment Intangibles arising out of, and proceeds of, the Kyowa Kirin License).  

1.1.16“Bardoxolone IP Proceeds Collateral” means with respect to any Accounts and Payment Intangibles (and proceeds thereof) arising out of the Bardoxolone IP Collateral, the portion thereof equal to the then-applicable Royalty Percentage applied to the Net Sales of the Product.

2

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

1.1.17“Business Day” means a day that is not a Saturday, Sunday or a US federal holiday.For the avoidance of doubt, solely with respect to any notice or other communication required to be given or delivered hereunder, limitations on the operations of commercial banks due to the outbreak of a contagious disease, epidemic or pandemic (including COVID-19), or any quarantine, shelter-in-place or similar or related directive, will not prevent a day that would otherwise be a Business Day hereunder from so being a Business Day.

1.1.18“BXLS” has the meaning ascribed to such term in the Preamble.

1.1.19“BXLS Background IP” has the meaning ascribed to such term in Section 11.1.1.

1.1.20“BXLS Collateral” has the meaning set forth in Section 7.2.  

1.1.21“BXLS Collateral Account” means the Deposit Account designated as such by Reata pursuant to Section 7.1 into which proceeds of Net Sales shall be deposited in accordance with Section 7.1.

1.1.22“BXLS Collateral Account Assets” means the BXLS Collateral Account and all assets on deposit in the BXLS Collateral Account and the proceeds from such assets on deposit.

1.1.23 “BXLS Development Payment” has the meaning set forth in Section 4.1

1.1.24“BXLS Improvement IP” means any data, results, information, analyses, discoveries, inventions and know-how that (a) is developed or generated solely by BXLS in the course of performing activities under this Agreement, and (b) was not generated with and does not otherwise disclose, use, incorporate, rely upon or specifically relate to the Product or any Confidential Information of Reata.

1.1.25“BXLS Indemnified Parties” has the meaning ascribed to such term in Section 12.1.2.

1.1.26“BXLS Security Period” means the time period commencing upon the Closing Date and ending immediately upon the earliest to occur of (a) such time as Cumulative Payments equal [***]% of the BXLS Development Payment, and (b) the termination of this Agreement pursuant to Article 14; provided, however, that after Cumulative Payments equal [***]% of the BXLS Development Payment, Reata may in its sole discretion terminate the BXLS Security Period by depositing into the BXLS Collateral Account, and/or establishing and maintaining in favor of BXLS a letter of credit in form and substance reasonably satisfactory to BXLS from a financial institution reasonably acceptable to BXLS in an amount equal to the greater of (i) the applicable Cumulative Payment Shortfall for the subsequent [***] period (based on amounts then expected to be deposited to the BXLS Collateral Account for the remaining portion of the current Calendar Year and the pro-rated amounts for the applicable portion of the subsequent Calendar Year) or (ii) the Product Payment projected to be payable by Reata as reasonably determined by

3

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

mutual agreement by Reata and BXLSfor the subsequent [***] period, which amount shall be updated on a quarterly basis to address any changes in such projected Product Payments or the Cumulative Payment Shortfall, as applicable, as reasonably determined by mutual agreement by Reata and BXLS.  Any such  cash on deposit in the BXLS Collateral Account and/or letter of credit (or replacement thereof), as applicable, shall be maintained until the earliest to occur of (a) such time as Cumulative Payments equal [***]% of the BXLS Development Payment, and (b) the termination of this Agreement pursuant to Article 14.

1.1.27“Calendar Quarter” means each successive period of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31; provided, that, the (a) the first Calendar Quarter shall begin on the Closing Date and end on the last day of the Calendar Quarter in which the Closing Date falls, and (b) the final Calendar Quarter shall end on the last day of the Term.

1.1.28“Calendar Year” means each successive period of twelve (12) months commencing on January 1 and ending on December 31; provided, that, (a) the first Calendar Year shall begin on the Closing Date and end on December 31 of the Calendar Year in which the Closing Date falls, and (b) the final Calendar Year shall end on the last day of the Term.

1.1.29“Change of Control” means, (a) a merger, reorganization or consolidation of such Party with a Third Party which results in the voting securities of such Party outstanding immediately prior thereto ceasing to represent, or being converted into or exchanged for voting securities that do not represent, at least 50% of the combined voting power of the voting securities of the surviving entity or the parent corporation of the surviving entity immediately after such merger, reorganization or consolidation, (b) a transaction in which a Third Party becomes the beneficial owner of 50% or more of the combined voting power of the outstanding securities of such Party or (c) the sale or other transfer of all or substantially all of such Party’s business or assets relating to the Product, provided that a Licensing Transaction shall not constitute a Change of Control and a Change of Control will not be deemed to have occurred in the event that the Third Party in any of the foregoing transactions is a venture capital fund, pension fund, investment fund, commercial or investment bank, insurance company, or similar financial institution, in each case that is not then a controlled Affiliate of a company engaged in the development and/or commercialization of pharmaceutical or biotechnology products.

1.1.30“Change of Control Event” means (i) a Change of Control of either Party or (ii) any assignment, transfer or sale by BXLS of all or substantially all of its rights to receive payments under this Agreement to any party other than an Affiliate of BXLS (including any Change of Control of BXLS).

1.1.31“Claim” means any Third Party claim, demand, suit and/or cause of action.

1.1.32“Clinical Investigator” means the principal investigator at each Site.

4

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

1.1.33“Clinical Study Plan” means the Protocols or Protocol synopsesfor the Product Trials, and all material Trial Activities and related Timelines.  The initial Clinical Study Plan is attached hereto as Exhibit B.

1.1.34“Clinical Trials” means a human clinical trial intended to support the regulatory approval or commercialization of a given pharmaceutical or biologic product.

1.1.35“Clinical Update Summary”means a summary of all material information and developments with respect to (a) the progress of each Product Trial, including providing copies of any regulatory submissions or other material communications made to, and material correspondence received from, the FDA, or corresponding governmental authority in a EU5 country with respect to such Product Trials; (b) a summary of the material data and findings from any such Product Trial, when such data is available and ready for release and (c) the final minutes from any material meeting with any Regulatory Authority to the extent related to the Product Trials or any other Clinical Trial for the Product in any Core Indication and (d) the final CSRs from each Product Trial.  

1.1.36“Closing” has the meaning set forth in Section 4.1.

1.1.37“Closing Date” has the meaning set forth in Section 4.1.

1.1.38“CMC” means chemistry, manufacturing and controls.

1.1.39“CMC Information” means the CMC information intended or required for the submission of a CTA.

1.1.40“CoC Advance Payment” has the meaning ascribed to such term in Section 6.6.

1.1.41“Collateral Account” has the meaning set forth in Section 7.6(b).

1.1.42“Combination Product” means a product containing the Product together with one or more active ingredients other than Bardoxolone, in a co-formulated fixed dose combination sold for a single price for the entire combination.

1.1.43“Commercial Launch” means, with respect to the Product and a country in the Territory, the first commercial sale to a Third Party of such Product in such country after the receipt of regulatory approval and all commercially necessary pricing and reimbursement approvals allowing the sale of the Product in such country.

1.1.44“Commercialization” or “Commercialize” means the commercial manufacture, marketing, promotion, sale and/or distribution of the Product. For clarity, Commercialization excludes all activities associated with Development and seeking Approval for the Product.

1.1.45“Commercialization Costs” means the costs and expenses actually incurred by Reata or an Affiliate of Reata in the Commercialization of the Product.

5

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

1.1.46“Commercialization Plans” means the plans for Commercialization of the Product for ALPS and ADPKD attached hereto as Exhibit C.

1.1.47“Commercialization Update Summary” means a summary of all material information and developments with respect to the Commercialization (including commercial manufacturing plans) for the Product for the Core Indications, which summary may be comprised of materials provided to Reata’s Board or senior management and shall include updated budgets and forecasts (as approved by the Board or otherwise approved by senior management) for such Product.

1.1.48“Commercially Reasonable Efforts” means with respect to the performance of activities under this Agreement by Reata: reasonable, diligent, good-faith efforts to accomplish such activities by Reata, which are consistent with general industry standards for pharmaceutical companies that are developing and commercializing products with similar market potential to the Product with greater than $[***] in annual sales. “Commercially Reasonable Efforts” requires, with respect to a particular task or activity in making, using, selling, offering for sale, importing, exporting, developing (including seeking regulatory approvals or applicable pricing or reimbursement approvals) or otherwise Commercializing the Product, that Reata: (i) promptly assign responsibility for such task or activity to specific suitable employee(s) who are held accountable for progress and monitor such progress on an on-going basis; (ii) set and consistently seek to achieve specific and meaningful objectives for carrying out such task or activity; and (iii) make and implement decisions and allocate financial and other resources in a manner intended to advance progress with respect to such objectives in accordance with established timelines; provided, however, that to the extent that the performance of Reata’s obligations hereunder is adversely affected by the other Party’s breach in performing its obligations hereunder, the impact on Reata of such performance failure will be taken into account in determining whether Reata has used its Commercially Reasonable Efforts to perform any such affected obligations. Notwithstanding the foregoing, Commercially Reasonable Efforts shall not require any action that is likely to cause a fatal, life-threatening, or other adverse safety event, or that would, based upon then-available data, preclude obtaining or maintaining Approval for the Product, or, if Approval of the Product has already been obtained, preclude continued marketing of the Product.

1.1.49“Conditions Precedent” means, as of a specified time, (i) the Approval has occurred and (ii) BXLS has not achieved the IRR Target.

1.1.50“Confidential Information” means, with respect to a given Party, all information and materials provided and/or disclosed (including in written form, electronic form or otherwise) by, or on behalf of, such Party or its Representatives to the other Party, its Affiliates, agents or representatives in connection with this Agreement, including, technical, scientific, regulatory and other information, results, knowledge, techniques, data, analyses, inventions, invention disclosures, plans, processes, methods, know-how, ideas, concepts, test data (including pharmacological, toxicological and clinical test data), analytical and quality control data, formulae, specifications, marketing, pricing, distribution, cost, sales, and manufacturing data and descriptions, as well as the terms and conditions of this Agreement which terms and conditions shall be deemed to the Confidential Information of both Parties.

6

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

1.1.51“Contingent Obligation” is, for any Person, any direct or indirect liability, contingent or not, of that Person for any indebtedness of another Person, in each case, directly or indirectly guaranteed, endorsed or co-made by that Person, or for which that Person is directly or indirectly liable; provided that “Contingent Obligation” does not include endorsements in the ordinary course of business. The amount of a Contingent Obligation is the stated or determined amount of the primary obligation for which the Contingent Obligation is made or, if not determinable, the maximum reasonably anticipated liability for it determined by the Person in good faith; but the amount may not exceed the maximum of the obligations under any guarantee or other support arrangement.

1.1.52“Control” or “Controlled” means (a) for Intellectual Property, a Party’s ability to grant applicable licenses, sublicenses and/or other rights thereunder, and (b) for materials and documents, a Party’s ability to provide, or provide access to, such materials and/or documents, in each case (a)-(b), without violating any contractual obligations to a Third Party. For clarity, if a Party only can grant a license or sublicense and/or provide rights and/or access of limited scope, for a specific purpose or under certain conditions due to an encumbrance, “Control” or “Controlled” will be construed to so limit such license, sublicense, provision of rights and/or access.  

1.1.53“Copyrights” means, collectively, all works of authorship, mask works and any and all other registered and unregistered copyrights and copyrightable works, and all applications, registrations, extensions, and renewals thereof.

1.1.54“Core Indications” means each of the following Indications: (i) ALPS, (ii) ADPKD, [***].

1.1.55“CRO” means contract research organization.

1.1.56“CSR” means clinical study report, or other equivalent document or series of materials, constituting a summary report of the clinical and medical data resulting from the Product Trials and prepared for incorporation into submissions seeking Approval for the Product, and includes all statistical analyses per Reata’s statistical analysis plan. Supplements to the CSR, including safety updates, may be prepared at a later stage, following Reata’s instructions.

1.1.57“CTA” means a Clinical Trial Application submitted to a Regulatory Authority, including an investigational new drug application submitted to FDA, the submission of which is necessary to initiate or conduct clinical testing of a pharmaceutical product in humans in the Territory.

1.1.58“Cumulative Minimum Payment Target” means, as of the end of each specified Calendar Year set forth in the table below, the sum of the amounts set forth in the table below for each Calendar Year commencing with 2025 and through such specified Calendar Year; provided that the Cumulative Minimum Payment Target shall be deemed to be $0 at the end of such Calendar Year unless both of the Conditions Precedent have then been met as of the end of such Calendar Year.

7

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

2025	2026	2027	2028	2029
$[***]	$[***]	$[***]	$[***]	$[***]

2030	2031	2032	2033
$[***]	$[***]	$[***]	$[***]

1.1.59“Cumulative Payments” means, at any time of determination, the aggregate Product Payments made by Reata pursuant to this Agreement through and including such time.

1.1.60“Cumulative Payment Shortfall” means, as at any time of determination with respect to any Calendar Year, the excess of (x) the Cumulative Minimum Payment Target for such Calendar Year, over (y) the sum of Cumulative Payments.

1.1.61“Data Room” means that certain electronic data room established by Reata and to which BXLS and/or its advisors were granted access.  

1.1.62“Deposit Account” means a deposit account as such term is defined in the UCC.

1.1.63“Development” or “Develop” means internal and external research, development and regulatory activities related to pharmaceutical or biologic products, including (a) the conduct of Clinical Trials, (b) the preparation, submission, review and development of data or information for the purpose of submission to a Regulatory Authority to obtain authorization to conduct Clinical Trials and to obtain, support or maintain regulatory approval of a pharmaceutical or biologic product, (c) interacting with Regulatory Authorities in connection with the foregoing and (d) manufacturing scale-up, qualification and validation, quality assurance/quality control, clinical studies and product manufacturing in support of the foregoing.

1.1.64“Development Costs” means the costs and expenses actually incurred by Reata or an Affiliate of Reata in the Development of the Product in the Core Indications.

1.1.65“Development Program” means the program of clinical Development to be undertaken by Reata to develop the Product and seek Approval for the Product for the Core Indications, in accordance with the terms of this Agreement, including the conduct of the Product Trials as set forth in additional detail in the Clinical Study Plan.  For clarity, the Development Program shall conclude upon the Approval of the Product in each of ALPS and ADPKD in the US and in any EU5 country.

1.1.66“Disclosing Party” has the meaning ascribed to such term in Section 10.1.

1.1.67“Dispute” has the meaning ascribed to such term in Section 15.10.

8

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

1.1.68“Effective Date” has the meaning ascribed to such term in the Preamble.

1.1.69“EMA” means the European Medicines Agency; provided that, if Reata, in its sole discretion, elects to seek Approval from a local Regulatory Authority in any of the EU5, references in this Agreement to “EMA” shall be deemed to include references to such local Regulatory Authority.

1.1.70“EU5” means France, Germany, Italy, Spain and the United Kingdom.

1.1.71“Excluded Accounts” means Deposit Accounts exclusively used for payroll, payroll taxes and/or withheld income taxes, and other employee wage and benefit payments to or for the benefit of Reata employees, escrow accounts and trust accounts, in each case entered into in the ordinary course of business and consistent with prudent business practice conduct where Reata holds the funds exclusively for the benefit of one or more unaffiliated third parties, accounts pledged to secure performance (including to secure letters of credit and bank guarantees) to the extent constituting Permitted Liens, and other accounts with funds on deposit not to exceed $[***] in the aggregate at any time.

1.1.72“Excluded Assets” means (i) any license or contract (and any property the subject matter thereof), in each case if the granting of a Lien in such license or contract (or on such property) is prohibited by or would constitute a default under the agreement governing such license or contract (but only to the extent such prohibition is enforceable under Applicable Law, including, after giving effect to Sections 9-406, 9-408 or 9-409 (or any other section) of Division 9 of the IRC); provided that upon the termination, lapsing or expiration of any such prohibition, such license or contract (and the property subject thereof), as applicable, shall automatically be subject to the security interest granted in favor of Collateral Agent hereunder and become part of the “BXLS Collateral”, (ii) real property owned by Reata or any of its Subsidiaries and any leasehold interest in real property, (iii) motor vehicles and other assets subject to certificates of title, (iv) any governmental licenses or state or local franchises, charters and authorizations, to the extent a security interest in any such license, franchise, charter or authorization is prohibited or restricted thereby (after giving effect to the applicable anti-assignment provisions of the UCC or other Applicable Law), (v) Excluded Accounts, (vi) any intent-to-use trademark application prior to the filing of a “Statement of Use” or “Amendment to Allege Use” with respect thereto, to the extent, if any, that, and solely during the period, if any, in which, the grant of a security interest therein would impair the validity or enforceability of such intent-to-use trademark application under Applicable Law, (vii) equity interests in joint ventures or Persons that are not wholly-owned Subsidiaries of Reata to the extent the grant of a security interest is not permitted by such entity’s organizational documents or joint venture documents, (viii) any assets (including intangibles) not located in the US to the extent the grant of a security interest therein is restricted or prohibited by Applicable Law or contract (after giving effect to applicable anti-assignment provisions of the UCC or other Applicable Law), (ix) any Accounts and Payment Intangibles arising under, and proceeds  of the Kyowa Kirin License, and (x) any other assets where the cost of obtaining or perfecting a security interest in such assets exceeds the practical benefit to BXLS afforded thereby as reasonably determined by BXLS in consultation with Reata.

9

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

1.1.73“Executive Officers” means the executive officers of each of Reata and BXLS identified on Exhibit D.

1.1.74“FDA” means the US Food and Drug Administration and any successor agency thereto.

1.1.75“Force Majeure Event” any earthquakes, hurricanes, tsunamis, tornadoes, floods, mudslides, wildfires, outbreaks of contagious disease, epidemics, pandemics (including COVID-19) or other natural disasters, weather conditions, sabotage, terrorism, military action or war (whether or not declared) or other force majeure events in the US or any other country or region in the world.

1.1.76“Fundamental Breach by Reata” shall mean (a) a material failure by Reata to use Commercially Reasonable Efforts to Develop and obtain Approval of the Product as required by Section 2.1.1(a) (provided that such shall not be deemed to be a Fundamental Breach by Reata in the event that such failure is due to Program Failure, unless such Program Failure is due to gross negligence on the part of Reata) or (b) Reata or its Affiliates shall materially violate the Anti-Corruption Laws which shall cause a Material Adverse Event.

1.1.77“GAAP” means generally accepted accounting principles in the US, as consistently applied by the applicable Party; provided, however, that for the purpose of the definition of Indebtedness, no effect shall be given to Accounting Standards Codification 842, Leases (or any other Accounting Standards Codification having similar result or effect) (and related interpretations) to the extent any lease (or similar arrangement) would be required to be treated as a capital lease thereunder where such lease (or arrangement) would have been treated as an operating lease under GAAP as in effect immediately prior to the effectiveness of such Accounting Standards Codification.

1.1.78“Good Clinical Practices” or “GCP” means all applicable good clinical practice standards for the design, conduct, performance, monitoring, auditing, recording, analyses and reporting of Clinical Trials, including, as applicable, (a) the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (“ICH”) Harmonised Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95) and any other guidelines for good clinical practice for Clinical Trials on medicinal products in the EU; (b) the Declaration of Helsinki (2004) as last amended at the 52nd World Medical Association in October 2000 and any further amendments or clarifications thereto; and (c) the equivalent Applicable Laws in any relevant country, each as may be amended and applicable from time to time and in each case, that provide for, among other things, assurance that the clinical data and reported results are credible and accurate and protect the rights, integrity and confidentiality of trial Subjects.

1.1.79“Good Laboratory Practice” or “GLP” means the quality system concerned with the organizational process and the conditions under which laboratory studies are planned, performed, monitored, recorded and reported, in a given country or group of countries including: (a) in relation to the EU, Directive 2004/10/EC as may be amended or replaced from time to time as well as any “Rules Governing Medicinal Products in the European Community”

10

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

Vol III, ISBN 92.825 9619-2 (ex OECD principles of GLP) as amended and applicable from time to time; (b) in relation to the USA, 21 CFR Section 58 (Good Laboratory Practice for Nonclinical Laboratory Studies) as amended and applicable from time to time; and (c) in relation to any other country, the equivalent Applicable Laws in that country as amended and applicable from time to time.

1.1.80“Good Manufacturing Practices” or “GMP” means all applicable good manufacturing practices including, as applicable, (a) the applicable part of quality assurance to ensure that products are consistently produced and controlled in accordance with the quality standards appropriate for their intended use, as defined in European Commission Directive 2003/94/EC laying down the principals and guidelines of good manufacturing practice; (b) the principles detailed in the US Current Good Manufacturing Practices, 21 CFR Sections 210, 211, 601 and 610; (c) the Rules Governing Medicinal Product in the European Community, Volume IV Good Manufacturing Practice for Medicinal Product; (d) the principles detailed in the ICH Q7A guidelines; and (e) the equivalent Applicable Laws in any relevant country, each as may be amended and applicable from time to time.

1.1.81“Government Official” is broadly defined as and includes: (a) any elected or appointed government official (e.g., a member of a ministry of health); (b) any employee or person acting for or on behalf of a government official, agency, or enterprise performing a governmental function; (c) any non-US political party officer, employee, or person acting for or on behalf of a non-US political party or candidate for public office; (d) any employee or person acting for or on behalf of a public international organization; (e) all government employees and employees of state-owned enterprises; or (f) any person otherwise categorized as a government official under local law; where “government” is meant to include all levels and subdivisions of non-US governments (i.e., local, regional, or national and administrative, legislative, or executive).

1.1.82“Governmental Authority” means any supranational, federal, national, state or local court, agency, authority, department, regulatory body or other governmental instrumentality.

1.1.83“ICH” has the meaning ascribed to such term in Section 1.1.74.

1.1.84“Indebtedness” means (a) indebtedness for borrowed money or the deferred price of property or services (excluding any trade accounts incurred in the ordinary course of business), such as reimbursement and other obligations for surety bonds and letters of credit; (b) obligations evidenced by notes, bonds, debentures or similar instruments, (c) capital lease obligations as determined in accordance with GAAP and (d) Contingent Obligations; provided that (i) unsecured obligations to make revenue interest payments or in respect of royalties, in each case that are not guaranteed in amount are not Indebtedness and (ii) payment obligations of Reata under Section 5 of that certain Amended and Restated License Agreement between Reata and AbbVie Ltd., dated October 9, 2019, are not Indebtedness.

1.1.85“Indemnification Claim Notice” has the meaning ascribed to such term in Section 12.2.1.

11

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

1.1.86“Indemnified Party” has the meaning ascribed to such term in Section 12.2.1.

1.1.87“Indemnifying Party” has the meaning ascribed to such term in Section 12.2.1.

1.1.88“Independent Expert” has the meaning ascribed to such term in Section 5.2.2.2.

1.1.89“Indication” means a given human disease or condition that is a discrete clinically recognized form.

1.1.90“Initial Approval” means the first full or accelerated approval of a new drug application in the United States by the FDA, the approval of a marketing authorization application in any of the EU5 by the EMA, or similar approval by the applicable Regulatory Authority in any other country in the world other than in the Kyowa Kirin Territory, of the Product for any Indication.

1.1.91“Intellectual Property” means all intellectual property and industrial property rights of any kind or nature throughout the world, including all US and foreign, (a) Patents; (b) Trademarks; (c) Copyrights; (d) rights in computer programs (whether in source code, object code, or other form), algorithms, databases, compilations and data, technology supporting the foregoing, and all documentation, including user manuals and training materials, related to any of the foregoing; (e) trade secrets and all other confidential information, know-how, inventions, proprietary processes, formulae, models, and methodologies; (f) rights of publicity, privacy, and rights to personal information; (g) all rights in the foregoing and in other similar intangible assets; and (h) all applications and registrations for the foregoing.

1.1.92“IP Security Agreement” has the meaning ascribed to such term in Section 7.6.1.1.

1.1.93“IRB” means institutional review board, or its equivalent.

1.1.94“IRC” means the Internal Revenue Code of 1986, as amended, and the Treasury Regulations adopted thereunder.

1.1.95“IRR Target” means, as of any specified time, BXLS has achieved a Realized IRR of at least [***]%.  For the avoidance of doubt, once the IRR Target has been met as of any specified time, the IRR Target shall be deemed met at all subsequent times.

1.1.96“Kyowa Kirin” means Kyowa Kirin Co., Ltd.

1.1.97“Kyowa Kirin License” means that certain Exclusive License and Supply Agreement, dated as of December 24, 2009, as amended, modified or otherwise supplemented from time to time, by and between Reata and Kyowa Kirin, together with any replacements thereof (whether with Kyowa Kirin or any other entity) for the Kyowa Kirin Territory.

12

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

1.1.98“Kyowa Kirin’s Territory” means Japan, China (including Hong Kong and Macao), South Korea, Taiwan, Thailand, Singapore, Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar and Cambodia.

1.1.99“Licensing Transaction” means a license or sublicense to a Third Party of any of the Reata Restricted Intellectual Property in the US or EU5 to Develop or Commercialize the Product in the US or EU5.

1.1.100“Lien” means a mortgage, deed of trust, levy, charge, pledge, security interest or other encumbrance of any kind in the nature of a security interest, whether voluntarily incurred or arising by operation of law or otherwise against any property; provided that, for the avoidance of doubt, neither non-exclusive licenses nor customary anti-assignment provisions shall be deemed to be a “Lien”.

1.1.101“Losses” means liabilities, losses, costs, damages, fees and/or expenses (including reasonable legal expenses and attorneys’ fees) payable to a Third Party.

1.1.102“Margin Stock” means “margin stock” as such term is defined in Regulation U of the Board of Governors of the Federal Reserve System as amended, or any successor regulation.

1.1.103“Market Capitalization” means, as of any time of determination, the total number of outstanding shares of Reata’s Class A common stock and Class B common stock multiplied by the closing price per share of the Class A common stock, in each case as of the most recent trading day ending immediately prior to such time.

1.1.104“Material Adverse Event” means an event that has a material adverse effect on (i) the business, operations, or financial condition of Reata; (ii) the prospect of payment of the Product Payments by Reata, or (iii) the development of the Product for ALPS and ADPKD or prospects for Approval of Product for ALPS and ADPKD; provided, however, that none of the following would constitute, and none of the effects of the following would be considered in determining whether there has occurred, a Material Adverse Event: (a) changes in laws or regulations or in the interpretations or methods of enforcement thereof; (b) changes in the pharmaceutical or biotechnology industries in general; or (c) a Force Majeure Event.

1.1.105“Material Anti-Corruption Law Violation” means a violation by a Party or its Affiliate of an Anti-Corruption Law relating to the subject matter of this Agreement that would, if it were publicly known, have a material adverse effect on the other Party or its Affiliate because of its relationship with such Party.

1.1.106“NDA” means a new drug application or similar application submitted to FDA for the purpose of obtaining Approval to market and sell a pharmaceutical product in the US.

1.1.107“Net Sales” means with respect to the Product, the gross amount billed in arm’s-length transactions with respect to the sale, distribution or other transfer of the Product

13

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

by Reata, any Affiliate of Reata, or any licensee or sublicensee of Reata or an Affiliate of Reata (the “Selling Party”) recorded according to the given Selling Party’s revenue recognition policies and in accordance with GAAP less deductions for: (A) any refunds, credits or allowances actually given or credited to any Third Party due to rejections, defects or returns, (B) any discounts or rebates actually given or credited to such Third Parties, (C) non-income taxes (including VAT), freight, duty or transportation insurance, in each case, solely to the extent specifically invoiced or incurred and (D) any other similar and customary specifically identifiable deductions that have been credited or deducted from the gross amount billed and that are consistent with accepted revenue recognition policies and GAAP, and which may not be duplicative of any other deductions.  Net Sales would not include Net Sales in Kyowa Kirin’s Territory.  

The transfer of Product by Reata or one of its Affiliates or (sub)licensees to another Affiliate or (sub)licensee shall not be considered a Net Sale, unless any such (sub)licensee is the end user of the Product.

For the avoidance of doubt, the following shall not result in Net Sales: (i) the disposal of Product for or use of Product in Clinical Trials or under compassionate use, patient assistance, named patient or test marketing programs or non-registrational studies, or other similar programs or studies or testing, (ii) the donation by a Reata, its Affiliates, or (sub)licensees to non-profit institutions or government agencies for a non-commercial purpose, and (iii) the use of a Product by a Party, its Affiliates, or (sub)licensees for Development purposes.  

If a Product is sold as a Combination Product, then Net Sales of the Product will be determined on a country-by-country basis by multiplying the actual Net Sales of the Combination Product in the applicable period, by the fraction A/(A+B), where A is the average per unit sale price of the applicable Product when sold separately as a standalone product in finished form in the country in which the Combination Product is sold and B is the average aggregate per unit sale price of the other active ingredients contained in the Combination Product when sold separately as standalone products in finished form in the country in which the Combination Product is sold, in each case during the applicable reporting period or, if sales of stand-alone Product did not occur in such period, then in the most recent reporting period in which arm’s-length fair market sales of such Product occurred.  If such average sale price cannot be determined for the stand-alone Products or the other products, Net Sales for the purposes of determining royalty payments shall be mutually agreed upon by the Parties based on the relative value contributed by each component.

Notwithstanding the foregoing, in the event that the Selling Party is any party other than Reata or its Affiliates, then Net Sales (including Combination Product allocations in connection with such Net Sales) will be calculated based on the corresponding definition of net sales in the applicable license agreement permitting such sales, provided that such definition is commercially reasonable, but subject to challenge by BXLS pursuant to Section 6.8.

1.1.108“Party” or “Parties” has the meaning ascribed to such term in the Preamble.

14

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

1.1.109“Patent” will mean patents, patent applications, patent disclosures, and all related continuations, continuations-in-part, divisionals, reissues, re-examinations, substitutions, and extensions thereof.

1.1.110“Payment Intangible” is any “payment intangible” as defined in the UCC and includes, without limitation, all payment intangibles of Reata.

1.1.111“Permitted Indebtedness” means:

1.1.111.1Reata Obligations;

1.1.111.2Indebtedness existing on the Effective Date and disclosed to BXLS prior to the Effective Date;

1.1.111.3Permitted Priority Debt;

1.1.111.4Senior Refinancing Debt;

1.1.111.5Indebtedness incurred as a result of endorsing negotiable instruments received in the ordinary course of business;

1.1.111.6Indebtedness consisting of capital leases and purchase money financing obligations, in each case incurred by Reata or any of its Subsidiaries to finance the acquisition, repair, improvement or construction of fixed or capital assets of such person, provided that the aggregate outstanding principal amount of all such Indebtedness does not exceed $[***];

1.1.111.7Indebtedness owed to any Person providing workers’ compensation, health, disability or other employee benefits or property, casualty or liability insurance, pursuant to reimbursement or indemnification obligations to such Person, in each case incurred in the ordinary course of business;

1.1.111.8Indebtedness relating to insurance premium financing arrangements.

1.1.111.9Reimbursement obligations in respect of letters of credit and banker’s acceptances (other than letters of credit securing Indebtedness for borrower money or obligations in respect of any royalty or revenue interest sale or financing) in an aggregate amount not to exceed $[***] at any time;

1.1.111.10Intercompany obligations between Reata and its subsidiaries;

1.1.111.11Indebtedness arising out of that certain Lease Agreement dated as of October 15, 2019, between Reata and TC Legacy Phase I Venture, LLC, a Delaware limited liability company, including, for the avoidance of doubt, treatment of such Lease Agreement as a capital lease;

15

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

1.1.111.12other Indebtedness; provided that the aggregate amount of Indebtedness incurred pursuant to this clause shall not to exceed [***]% of the Market Capitalization of Reata measured as of the date of incurrence thereof, or at the option of Reata, as of the date of the entry into a binding commitment for the incurrence or issuance thereof (including in the case of Indebtedness to be incurred in connection with any acquisition, the date of the definitive agreement relating to such acquisition); and

1.1.111.13extensions, refinancings, modifications, amendments and restatements of any items of Permitted Indebtedness, provided that the principal amount thereof does not exceed the principal amount (or accreted value, if applicable) of the Indebtedness so extended, refinanced, modified, amended or restated (plus unpaid accrued interest and premium (including tender premium) thereon, any original issue discount on, and underwriting discounts, fees, commissions and expenses incurred in connection with, such extension, refinancing, modification, amendment or restatement).

1.1.112“Permitted Licensing Transaction” means (i) any license or sublicense by Reata or any of Subsidiary to any Third Party that is not a Licensing Transaction, and (ii) any Licensing Transaction in the US or any country in the EU5 with any of the pharmaceutical companies listed on Exhibit E or any other pharmaceutical company whose annual net sales are within the top [***] ([***]) pharmaceutical companies worldwide as of the year prior to date of such Licensing Transaction.

1.1.113“Permitted Liens” means:

1.1.113.1Liens existing on the Effective Date and disclosed to BXLS prior to the Effective Date;

1.1.113.2Liens for taxes, fees, assessments or other government charges or levies, either (i) not due and payable or (ii) being contested in good faith and for which Reata or the applicable Subsidiary maintains adequate reserves on its books and records, provided that no notice of any such Lien has been filed or recorded under the IRC;

1.1.113.3Liens securing capital leases and purchase money financings constituting Permitted Indebtedness, provided that (i) such Liens exist prior to the acquisition of, or attach substantially simultaneous with, or within ninety (90) days after, the acquisition, lease, repair, improvement or construction of such property financed or leased by such Indebtedness and (ii) such Liens do not extend to any property of Reata other than the property (and proceeds thereof) acquired, leased or built, or the improvements or repairs, financed by such Indebtedness;

1.1.113.4leases, subleases, non-exclusive licenses and sublicenses granted in the ordinary course of business that do not materially interfere with the business of Reata and its Subsidiaries;

1.1.113.5Interests of lessors and licensors under leases and licenses to Reata or any Subsidiary of real property and personal property;

16

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

1.1.113.6Liens of carriers, warehousemen, suppliers, or other Persons that are possessory in nature arising in the ordinary course of business so long as such Liens attach only to inventory, securing liabilities, and which are not delinquent or remain payable without penalty or which are being contested in good faith and by appropriate proceedings which proceedings have the effect of preventing the forfeiture or sale of the property subject thereto;

1.1.113.7Liens to secure payment of workers’ compensation, employment insurance, old-age pensions, social security and other like obligations incurred in the ordinary course of business (other than Liens imposed by ERISA);

1.1.113.8Liens arising from attachments or judgments, orders, or decrees occurring after the Effective Date in an amount not to exceed, individually or in the aggregate, [***] Dollars ($[***]), under circumstances not constituting or arising from a Fundamental Breach by Reata;

1.1.113.9Liens on, and deposits of, cash and cash equivalents securing bids, contracts, letters of credit constituting Permitted Indebtedness, banker’s acceptances and other similar obligations;

1.1.113.10Liens in favor of custom and revenue authorities arising in the ordinary course of business as a matter of law to secure the payment of custom duties in connection with the importation of goods provided such Liens are restricted to the goods being imported and documents relating thereto;

1.1.113.11Liens on assets of Reata or any Subsidiary, including the Bardoxolone IP Collateral but excluding the BXLS Collateral Account Assets, to secure Permitted Priority Debt and/or Senior Refinancing Debt, provided that the holder of any such Lien shall have executed a customary intercreditor agreement complying with Section 7.4;

1.1.113.12Licenses and sublicenses granted in favor of Reata or any subsidiary;

1.1.113.13(a) Liens on property or equity interests of another Person existing at the time such other Person becomes a Subsidiary or is merged with or into or consolidated with Reata or any Subsidiary; provided that such Liens (i) are not incurred in contemplation thereof and (ii) do not extend to any other property owned by Reata (other than assets and property affixed or appurtenant thereto); (b) Liens on property (including equity interests) existing at the time of acquisition of such property by Reata or any Subsidiary; provided that such Liens were in existence prior to such acquisition and not incurred in contemplation of such acquisition; and (c) Liens granted in replacement of or substitute for, or to secure any refinancing (or successive refinancings), as a whole or in part, of any Indebtedness or other obligation secured by, a Lien referred to in the foregoing clauses (a) or (b); provided that the new Lien is limited to all or part of the same property and assets that secured or, under the written agreements pursuant to which the original Lien arose, could secure the original Lien (plus improvements and accessions to, such property or proceeds or distributions thereof);

17

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

1.1.113.14Liens on securities that are the subject of repurchase agreements not prohibited hereunder;

1.1.113.15Liens on insurance policies, premiums and proceeds thereof, or other deposits, to secure insurance premium financings and other liabilities to insurance carriers;

1.1.113.16Liens arising out of conditional sale, title retention, consignment or similar arrangements for the sale of goods entered into in the ordinary course of business;

1.1.113.17Liens securing obligations in respect of swap, forward, future or derivative transaction or option or similar agreement, provided that such agreements are entered into (a) to hedge or mitigate risks to which Reata has actual exposure (other than those in respect of capital stock), or (b) to effectively cap, collar or exchange interest rates (from fixed to floating rates, from one floating rate to another floating rate or otherwise) with respect to any interest-bearing liability or investment of Reata, and in any event are not for purposes of speculation;

1.1.113.18Liens in the nature of the right of setoff in favor of counterparties to non-defaulted contractual agreements with Reata or its Subsidiaries in the ordinary course of business;

1.1.113.19(a) customary Liens incurred to secure ACH Indebtedness, business credit card programs, and netting services, overdrafts and related liabilities arising from treasury, depositary and cash management services, and (b) Liens in favor of financial institutions arising in connection with Reata’s or its Subsidiaries’ Deposit Accounts and/or Securities Accounts held at such institutions;

1.1.113.20 Permitted Licensing Transactions;

1.1.113.21Liens incurred in the extension, renewal or refinancing of the indebtedness secured by Permitted Liens;

1.1.113.22Any encumbrance or restriction (including put and call arrangements) with respect to equity interests of any joint venture, minority investment or similar arrangement pursuant to any joint venture, shareholders, investor rights or similar agreement;

1.1.113.23Liens to secure contractual payments (contingent or otherwise) payable by Reata or its Subsidiaries to a seller after the consummation of an acquisition of a product, business, license or other assets, in an amount not to exceed, individually or in the aggregate, [***] Dollars ($[***]).

1.1.113.24(a) Liens on any assets held by a trustee under any indenture or other debt instrument where the proceeds of the securities issued thereunder are held in escrow pursuant to customary escrow arrangements pending the release thereof;

18

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

1.1.113.25Liens on deposits or other amounts held in escrow to secure payments (contingent or otherwise) payable by Reata or any of its Subsidiaries with respect to the settlement, satisfaction, compromise or resolution or judgments, litigation, arbitration or other disputes, in an amount not to exceed, individually or in the aggregate, [***] Dollars ($[***]);

1.1.113.26Liens in the nature of a “back-up security interest” on accounts receivables, payment intangibles, royalties and related assets sold in connection with any royalty or revenue interest sale or financing transaction; provided that such Liens shall not extend to the Bardoxolone IP Proceeds Collateral;  

1.1.113.27Liens in respect of obligations permitted pursuant to Section 1.1.110.11; and

1.1.113.28Other Liens securing liabilities in an aggregate amount not to exceed [***] Dollars ($[***]).

1.1.114“Permitted Priority Debt” means, from and after the Initial Approval, Indebtedness (exclusive of any Senior Refinancing Debt) in an aggregate principal amount not to exceed [***]% of the Market Capitalization of Reata measured as of the date of incurrence thereof or at the option of Reata, as of the date of the entry into a binding commitment for the incurrence or issuance thereof (including in the case of Indebtedness to be incurred in connection with any acquisition, the date of the definitive agreement relating to such acquisition).  For the avoidance of doubt, Senior Refinancing Debt shall not constitute Permitted Priority Debt.

1.1.115“Permitted Third Party” means any Affiliate, CRO, Site, Clinical Investigator and/or vendor to whom Reata has delegated responsibility or engaged in connection with the Product Trials.

1.1.116“Person” means any individual, corporation, general or limited partnership, limited liability company, joint venture, estate, trust, association, organization, labor union, or other entity or Governmental Authority.

1.1.117“Product” means the product described on Exhibit A.

1.1.118“Product Payment” means, individually and collectively, the payments made by Reata to BXLS under the terms of this Agreement (other than expense reimbursements, interest on late payments and indemnification payments made to BXLS pursuant to Section 6.7, Section 6.8, Section 6.11, Article 12 or Section 15.8 and excluding any amounts deposited in the BXLS Collateral Account pursuant to Section 7.1 or otherwise until such amounts are paid to BXLS), whether pursuant to Sections 6.1, 6.2, 6.6, 6.8 or Article 14 or otherwise, and less any over-payments refunded to Reata pursuant to Section 6.2 or Section 6.8.

1.1.119“Product Trials” means each of (a) Reata’s phase 3 Clinical Trial of the Product in patients with ADPKD (FALCON) and (b) Reata’s phase 2/3 Clinical Trial of the Product in individuals with CKD caused by ALPS (CARDINAL), as set forth in the Clinical Study Plan.

19

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

1.1.120“Program Failure” means any of the following events: (a) the applicable Regulatory Authorities in both the US and the EU (i)impose a clinical hold on further development of the Product under the Product Trials, which clinical hold is not lifted or removed within [***] or (ii) recommend termination of the Product Trials without leave to amend or restart and such recommendation is not lifted within[***]; (b) the mutual agreement of the Parties that, based on data from the Product Trials, the Product will not be able to achieve Approval by either the FDA or the EMA, (c) a material adverse development or event with respect to the clinical Development of the Product occurs as a result of which the Development Program is substantially unlikely to achieve Approval and as a result of which Reata, followinggood faith consultation with BXLS, makes a good faith determination to cease continued Development of the Product(which may include for example, (i) that theProduct fails to meet its primary endpoint in all of the Product Trials, or (ii) that following completion of the Product Trials, the FDA requires an additional Phase III Clinical Trial as a condition for Approval in ALPS or ADPKD, as applicable, and where incurring the expense of such additional Phase III Clinical Trial would not be commercially reasonable taking into account the actual commercial potential for the Product as then-understood); provided that in the case of (c), Reata (A) has expended Development Costs to Develop the Product in the Core Indications in an amount equal to or exceeding the BXLS Development Payment (or where the conduct of any required additional Clinical Trial would require Reata to incur Development Costs in an amount exceeding the BXLS Development Payment by $[***] or more) and (B) provides to BXLS a written basis for its determination to cease continued Development of the Product, (d) the Product presents a risk of death, a life-threatening condition, or such serious safety or health risks to patients such that, based on then-available data, Reata cannot ethically and in good faith continue to administer the Product to patients or continue to commercialize the Product (if already Approved), (e) the reasonable good faith decision by Reata after consultation with BXLS, based on the recommendation of the independent data safety monitoring board, to halt the Product Trials for safety or futility reasons, or (f) the decision by the FDA not to approve the NDAs for ALPS and ADPKD, provided that Reata has utilized Commercially Reasonable Efforts to obtain Approval.

1.1.121“Proposed Buyout Payment” is defined in Section 6.3.

1.1.122“Protocol” means, with respect to a Clinical Trial, the protocol setting forth the conduct and procedures for such Clinical Trial, as may be modified from time to time.

1.1.123“Realized IRR” means, at any time, the internal pre-tax rate of return realized by BXLS, calculated using the XIRR function in Microsoft Excel, and taking into consideration the amount and date of the BXLS Development Payment made by BXLS and the amounts and dates of Product Payments made to BXLS (excluding any over-payments refunded to Reata pursuant to Section 6.2 or Section 6.8), and assuming that any amounts payable to BXLS pursuant to Sections 6.1.1 and 6.1.2 as of the end of a particular Calendar Year are paid on March 1 of the next Calendar Year, and provided that if any such amounts payable to BXLS pursuant to Sections 6.1.1 and 6.1.2 as of the end of a particular Calendar Year are not paid on or before March 1 of the next Calendar Year, then such unpaid amounts shall not be assumed to have been paid at the end of such Calendar Year.

1.1.124“Reata” has the meaning ascribed to such term in the Preamble.

20

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

1.1.125“Reata Background IP” has the meaning ascribed to such term in Section 11.1.1.

1.1.126“Reata Improvement IP” has the meaning ascribed to such term in Section 11.1.2.

1.1.127“Reata Indemnified Parties” has the meaning ascribed to such term in Section 12.1.1.

1.1.128“Reata Intellectual Property” has the meaning ascribed to such term in Section 11.1.2.

1.1.129“Reata Obligations” means all indebtedness, liabilities and other obligations of Reata to BXLS under or in connection with this Agreement and any other documents executed in connection herewith, including all amounts payable to BXLS pursuant to Article 6 hereof, all interest accrued thereon, all fees and all other amounts payable by Reata to BXLS thereunder or in connection therewith, whether now existing or hereafter arising, and whether due or to become due, absolute or contingent, liquidated or unliquidated, determined or undetermined, and including interest that accrues after the commencement by or against Reata of any bankruptcy or insolvency proceeding naming such individual or entity as the debtor in such proceeding, but excluding obligations under the Stock Purchase Agreement.

1.1.130“Reata Restricted Intellectual Property” means Reata Intellectual Property that is necessary for the Approval, manufacture, use, marketing, sale or import of the Product.

1.1.131“Receiving Party” has the meaning ascribed to such term in Section 10.1.

1.1.132“Recipient Party” has the meaning ascribed to such term in Section 6.10.

1.1.133“Regulatory Authority” means, in a particular country or regulatory jurisdiction in the Territory, any applicable Governmental Authority involved in granting approval to initiate or conduct clinical testing in humans, for Approval, including (a) FDA and (b) EMA and for each of (a) and (b), including any successor thereto.

1.1.134“Representatives” means, with respect to a Party, such Party’s Affiliates and its and their respective officers, directors, employees, agents, representatives, consultants and, as applicable, its Permitted Third Parties engaged in connection with the subject matter of this Agreement.

1.1.135“Research Results” means all data, results, information, analyses, discoveries, inventions and know-how arising, or resulting from, the Clinical Trials relating to the Product, the CMC activities relating to the Product and/or the exercise by, or on behalf of, Reata of its rights and obligations hereunder.

21

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

1.1.136“Royalty Percentage” means the percentage of Net Sales payable as Product Payments pursuant to Section 6.1.

1.1.137“Royalty Stepdown” means, as applicable, the stepdown of the Royalty Percentage from [***]% to [***]% pursuant to Section 6.1.1.

1.1.138“SEC” has the meaning ascribed to such term in Section 3.5

1.1.139“Securities Account” means a securities account as such term is defined in the UCC.

1.1.140“Senior Loan Agreement” means that certain Amended and Restated Loan and Security Agreement dated as of June 14, 2018 among Oxford Finance LLC, Silicon Valley Bank and Reata, as amended by the First Amendment to Amended and Restated Loan and Security Agreement dated as of October 9, 2010.

1.1.141“Senior Refinancing Debt” means Indebtedness incurred to refinance in its entirety (other than contingent indemnity obligations), or in replacement of, and in any event in an amount not to exceed, (i) the Indebtedness (including unpaid accrued interest, penalties and fees thereon) under the Senior Loan Agreement (or any successive refinancing or replacement thereof), plus (ii) premium (including tender premium), and any committed or undrawn amounts associated therewith and any original issue discount on, and underwriting discounts, fees, commissions and expenses incurred in connection with, such refinancing or replacement Indebtedness in an amount not to exceed $[***] in the aggregate, whether incurred concurrently or subsequent to any repayment of such Indebtedness; provided that the outstanding principal amount of such Indebtedness in the case of clauses (i) and (ii) shall not exceed $[***] in the aggregate.  For the avoidance of doubt, Permitted Priority Debt shall not constitute Senior Refinancing Debt.

1.1.142“Serious Safety Issue” means any SUSAR or series of SUSARs directly related to or caused by the administration of the Product in any Clinical Trial where such SUSAR or series of SUSARs substantially diminishes the probability of receiving Approval for the Product, or results in a Regulatory Authority imposing a clinical hold on further development of the Product which clinical hold is not lifted or removed within [***].

1.1.143“Site” means each clinical trial site for a Product Trial.

1.1.144“Stock Purchase Agreement” means the Common Stock Purchase Agreement by and between Reata and BXLS, attached hereto as Exhibit F.

1.1.145“Subject” means a human subject participating in a Product Trial.

1.1.146“Subsidiary” means an entity, whether a corporation, partnership, limited liability company, joint venture or otherwise, in which Reata or a Subsidiary of Reata owns or controls 50% or more of the outstanding voting securities.

1.1.147“SUSAR” means a suspected unexpected serious adverse reaction, without regard to causality, that is life-threatening (i.e., causes an immediate risk of death) or that

22

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

results in any of the following outcomes: death; in-patient hospitalization or prolongation of existing hospitalization; persistent or significant disability or incapacity (i.e., substantial disruption of the ability to conduct normal life functions); or a congenital anomaly or birth defect. For clarity, a planned medical or surgical procedure is not, in itself, a SUSAR.

1.1.148“Term” has the meaning ascribed to such term in Section 14.1.

1.1.149“Territory” means the US and the EU5.

1.1.150“Third Party” means any Person other than Reata, BXLS and their Affiliates.

1.1.151“Third Party Infringement” means any actual or threatened infringement, misappropriation, or other violation by a Third Party of any Intellectual Property owned or Controlled by Reata, including the Reata Intellectual Property, arising from the making, using, offering to sell, selling, or importing of a product that is or would be competitive with the Product.

1.1.152“Third Party Licenses” means such agreements between Reata or a Reata Affiliate with a Third Party that grant rights or licenses to Reata or its Affiliates pertaining to the Development, manufacture, use, sale, distribution, or other Commercialization or exploitation of one or more Products for any or all Indications.

1.1.153“Timeline” means, as applicable, the target date (or date range) for completion for a given Trial Activity set forth in the Clinical Study Plan.

1.1.154“Trademarks” means, collectively, all registered and unregistered marks, trade dress rights, logos, taglines, slogans, Internet domain names, web addresses, and other indicia of origin, together with the goodwill associated with any of the foregoing, and all applications, registrations, extensions and renewals thereof, selected for use on the Product.

1.1.155“Trial Activity” shall mean each substantial Development activity for the Product set forth in the Clinical Study Plan.  

1.1.156“UCC” means the Uniform Commercial Code, as the same may, from time to time, be enacted and in effect in the State of Delaware; provided, that, to the extent that the UCC is used to define any term herein and such term is defined differently in different Articles or Divisions of the UCC, the definition of such term contained in Article or Division 9 shall govern; and provided further, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of, or remedies with respect to, BXLS’s security interest on any BXLS Collateral is governed by the Uniform Commercial Code in effect in a jurisdiction other than the State of Delaware, the term “UCC” shall mean the Uniform Commercial Code as enacted and in effect in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority or remedies and for purposes of definitions relating to such provisions.

23

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

1.1.157“US” or “USA” means the US of America, its territories and possessions, including Puerto Rico.

1.1.158“Withholding Party” has the meaning ascribed to such term in Section 6.10.

1.2Construction.  For purposes of this Agreement: (1) words in the singular will be held to include the plural and vice versa as the context requires; (2) the words “including” and “include” will mean “including, without limitation,” unless otherwise specified; (3) the terms “hereof,” “herein,” “herewith,” and “hereunder,” and words of similar import will, unless otherwise stated, be construed to refer to this Agreement as a whole and not to any particular provision of this Agreement; (4) all references to “Section” and “Exhibit,” unless otherwise specified, are intended to refer to a Section or Exhibit of or to this Agreement; (5) the term “or” will be interpreted in the inclusive sense commonly associated with the term “and/or”, (6) words of the masculine, feminine or neuter gender shall mean and include the correlative words of other genders; (7) unless otherwise specified, references to an agreement or other document include references to such agreement or document as from time to time amended, restated, reformed, supplemented or otherwise modified in accordance with the terms hereof, and include any annexes, exhibits and schedules attached thereto; (8) reference to any Applicable Law shall include such Applicable Law as from time to time in effect, including any amendment, modification, codification, replacement or reenactment thereof or any substitution therefor; (9) references to any Person shall be construed to include such Person’s successors and permitted assigns (subject to any restrictions on assignment, transfer or delegation set forth herein), and any references to a Person in a particular capacity excludes such Person in other capacities; (10) in the computation of a period of time from a specified date to a later specified date, the word “from” means “from and including” and each of the words “to” and “until” means “to but excluding;” and (11) where any payment is to be made, any funds are to be applied or any calculation is to be made under this Agreement on a day that is not a Business Day, unless this Agreement otherwise provides, such payment shall be made, such funds shall be applied and such calculation shall be made on the succeeding Business Day, and payments shall be adjusted accordingly.

Article 2

THE DEVELOPMENT PROGRAM

2.1The Development Program.

2.1.1Development and Approval Diligence.  Reata will use Commercially Reasonable Efforts: (a) to Develop and obtain Approval for the Product in ALPS and ADPKD in (i) the United States and (ii) the EU5; and (b) to complete the Trial Activities set forth in the Clinical Study Plan in accordance with the Timelines set forth therein and (c) following the receipt of Approvals for the Product in ALPS and ADPKD in (i) the United States or (ii) the EU5 to Develop and obtain Approval for the Product in the Core Indications in the United States, EU5, and in other major markets as soon as commercially reasonable.

24

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

2.1.2Compliance with Laws.  Reata shall perform its obligations hereunder in compliance with all Applicable Laws in all material respects.  Reata shall use all reasonable efforts to include obligations in its agreements with any Permitted Third Party or other material service providers or vendors engaged to Develop or Commercialize the Product to comply in all material respects with all Applicable Laws to the extent relevant to the activities to be performed by such Third Party, and shall enforce any material known non-compliance by any such Third Party to the extent such non-compliance would be reasonably likely to result in a Material Adverse Event.

2.2Changes to the Development Program.  The Development Program may be updated from time-to-time as reasonably determined by Reata to be necessary or desirable subject to Section 5.2. BXLS shall be entitled to comment on the conduct of the Development Program through the AC and Reata will give reasonable consideration to BXLS’s suggestions relating to the Development of the Product, including suggestions for changes to the Development Program. Reata will provide the AC with summaries of material changes to the Development Program at AC meetings as described in Article 5. Any changes to the Development Program requiring the approval of the AC pursuant to Section 5.2.2 shall be subject to approval by the AC pursuant to such Section.

2.3Performance; Delegation. Reata may perform and discharge any of its obligations hereunder either itself or through one or more Affiliates (subject to Section 15.1) or Third Party(ies) provided that (a) Reata has reasonably determined that each such Third Party can competently perform such obligations in compliance with Applicable Laws, (b) the terms of any agreement with any such Third Party will be consistent with the terms of this Agreement and (c) Reata will remain primarily responsible for all its obligations under this Agreement (including the obligations to comply with Applicable Laws, as set forth in Section 2.1.2, notwithstanding any delegation to an Affiliate or to any Third Party).

Article 3

DEVELOPMENT PROGRAM RESPONSIBILITIES; Reporting Requirements; COMMERCIALIZATION

3.1Product Manufacturing and Supply.  As between the Parties, and subject to the terms of this Agreement, Reata shall be solely responsible for the manufacture and supply of Product required for the conduct the Product Trials in accordance with all Applicable Laws.  Reata will promptly inform the AC in the event that any material issue arises in relation to such supply that would result in a supply shortfall that would reasonably be expected to cause a material delay in the Timeline.  

3.2IRBs and Ethics Committees and Registration.  As between the Parties, and subject to the terms of this Agreement, Reata will be solely responsible for the conduct of any Clinical Trials, including the Product Trials, including all activities reasonably required in the conduct of the same, and specifically including (a) obtaining or maintaining any approvals from any applicable IRBs, and Regulatory Authorities required for the conduct of the Product Trials, (b) responding to all queries from any IRBs and other ethics committees related to the Product Trials

25

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

and (c) registering, maintaining and updating any registries pertaining to the Product Trials to the extent required by any Applicable Laws, including www.clinicaltrials.gov.

3.3Clinical Update Summary; Additional Requests.  Prior to the completion of the Development Program and unless a Change of Control Event has occurred, Reata shall provide BXLS at meetings of the AC (or in advance of such meetings as part of the information that may be distributed to AC members prior to such meetings or, if no such meeting is held in a Calendar Quarter, directly to BXLS) at least once during each Calendar Quarter the Clinical Update Summary.  In addition, during the Development Program, Reata will provide BXLS with copies or summaries of material documents, data and information Controlled by Reata which are reasonably requested by BXLS and reasonably useful or necessary for BXLS to remain informed of and up to date regarding the progress of the Development Program or to understand the information provided in any Clinical Update Summary or otherwise through the AC.  For clarity, Reata will remain the sole owner of, and will retain all right, title and interest in, to and under all such information any materials provided to BXLS, which shall be Reata’s Confidential Information.  The Parties understand and agree that if Reata is unable to obtain any of the foregoing information from any counterparty to any Third Party License, that Reata will not be obligated to provide such information unless and until Reata is in possession and Control of such information.  In such event Reata will use Commercially Reasonable Efforts to obtain such possession and Control, which would be required to be included by Reata in the next to occur Clinical Update Summary.  Reata will use Commercially Reasonable Efforts to include in any Third Party License obligations requiring the relevant counter-party to provide updates on any Clinical Trial of the Product to allow Reata to provide such information to BXLS as contemplated hereunder.

3.4Additional Development and Regulatory Reporting.

3.4.1SUSARS.  Reata will promptly inform BXLS of any Serious Safety Issue following its awareness of the same.

3.4.2Recalls.  Reata will promptly inform BXLS of the initiation by Reata or any Regulatory Authority of a recall, suspension, or withdrawal of a Product after commencement of a Product Trial.

3.4.3MAEs.  Reata will provide BXLS with notice of the occurrence of any Material Adverse Event as soon as reasonably possible after becoming aware of the same.

3.5Reata Company Information.  Unless and until a Change of Control Event has occurred, Reata will provide BXLS (i) to the extent not filed with the Securities and Exchange Commission (the “SEC”) within [***] of the end of each Calendar Quarter (other than the fourth quarter of any Calendar Year), copies of its quarterly financial statements, (ii) to the extent not filed with the SEC within [***] of the end of each Calendar Year, copies of its audited annual financial statements, (iii) within [***] after approval, by Reata’s Board of Directors, annual budgets and annual financial projections (and any approved revisions of the foregoing) and (iv) promptly after request, any information reasonably related to the financial condition, operation or future prospects of Reata reasonably requested by BXLS.

26

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

3.6Commercialization.

3.6.1Responsibility. Subject to the terms of this Agreement, as between the Parties, Reata will have the sole right to conduct, or have conducted, all Commercialization activities relating to the Product its own cost.

3.6.2Commercialization Diligence.  Reata shall use Commercially Reasonable Efforts to (a) Commercialize the Product in each country in the Territory where the Product is Approved, and (b) maximize Net Sales of the Product in each major market.  The Parties understand and agree that Commercially Reasonable Efforts with respect to a particular country or Indication will change over time, reflecting changes in the status of each Product in each Indication, as applicable, and the applicable country(ies) involved.

3.6.3Commercialization Update Reports.  Following Approval of the Product and unless a Change of Control Event has occurred, Reata shall provide BXLS at meetings of the AC (or in advance of such meetings as part of the information that may be distributed to AC members prior to such meetings or, if no such meeting is held in a Calendar Quarter, directly to BXLS) at least once during each Calendar Quarter, with the Commercialization Update Summary.  The Parties understand and agree that if Reata is unable to obtain any of the foregoing information from any counterparty to any Third Party License, that Reata will not be obligated to provide such information unless and until Reata is in possession and control of such information, In such event Reata will use Commercially Reasonable Efforts to obtain such possession and Control, which would be required to be included by Reata in the next to occur Commercialization Update Summary.  Reata will use Commercially Reasonable Efforts to include in any Third Party License obligations requiring the relevant counter-party to provide updates on any material Commercialization activities for the Product to allow Reata to provide such information to BXLS as contemplated hereunder.

Article 4

BXLS payment for DEVELOPMENT and commercialization

4.1Development Funding.  Subject to the terms and conditions hereof, BXLS will pay to Reata $300,000,000 (the “BXLS Development Payment”) on a date within ten (10) Business Days from the Effective Date (the “Closing”, and the date of such Closing, the “Closing Date”) with such funding to be used by Reata to fund Development Costs and Commercialization Costs.

4.2Closing Conditions.  

4.2.1Mutual Conditions.  The obligation of each Party to consummate the transactions contemplated hereby shall be subject to the satisfaction on or prior to the Closing Date of each of the following conditions (any or all of which may be waived by a particular Party on behalf of itself in writing, in whole or in part, to the extent permitted by Applicable Law):

4.2.1.1no Applicable Law shall have been enacted or promulgated, and no Action shall have been taken, by any Governmental Authority of competent jurisdiction

27

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

which temporarily, preliminarily or permanently restrains, precludes, enjoins or otherwise prohibits the consummation of the transactions contemplated by this Agreement or makes the transactions contemplated by this Agreement illegal; and

4.2.1.2there shall not be pending any suit, action or proceeding by any Governmental Authority seeking to restrain, preclude, enjoin or prohibit the transactions contemplated by this Agreement.

4.2.2BXLS's Conditions.  The obligation of BXLS to make the BXLS Development Payment on the Closing Date shall be subject to the satisfaction on or prior to the Closing Date of each of the following conditions (any or all of which may be waived by BXLS in writing, in whole or in part, to the extent permitted by Applicable Law):

4.2.2.1The representations and warranties of Reata contained in this Agreement that are qualified by materiality or Material Adverse Event shall be true and correct when made and as of the Closing and all other representations and warranties shall be true and correct in all material respects when made and as of the Closing, in each case as though made at and as of the Closing  (except that representations made as of a specific date shall be required to be true and correct as of such date only);

4.2.2.2The obligations under the Senior Loan Agreement (other than contingent indemnification obligations for which no claim has been asserted) shall have been (or concurrently with the making of the BXLS Development Payment on the Closing Date shall be) repaid or satisfied and discharged, and in connection therewith all guarantees and liens shall have been released, as evidenced by documentation (including a customary payoff letter) in form and substance reasonably acceptable to BXLS; and

4.2.2.3BXLS shall have received all documents reasonably requested by BXLS and required to be delivered or filed under Sections 7.1, 7.2, 7.3 and 7.6 in order to establish a valid and perfected security interest in the BXLS Collateral in accordance with the terms of this Agreement (provided no actions to perfect the security interests in the BXLS Collateral and no actions to grant or perfect any such security interests in respect of any foreign BXLS Collateral shall be required for the Closing other than the filing of a financing statement in the state of Delaware).

4.2.3Reata's Conditions.  The obligation of Reata to consummate the transactions contemplated hereby shall be subject to the satisfaction on or prior to the Closing of the following conditions (which may be waived by Reata in writing, in whole or in part, to the extent permitted by applicable Law):

4.2.3.1the representations and warranties of BXLS contained in this Agreement that are qualified by materiality shall be true and correct when made and as of the Closing and all other representations and warranties shall be true and correct in all material respects when made and as of the Closing, in each case as though made at and as of the Closing  (except that representations made as of a specific date shall be required to be true and correct as of such date only); and

28

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

4.2.3.2BXLS shall have paid, or shall concurrently pay, the BXLS Development Payment; and

4.2.3.3The Equity Closing shall have occurred.

4.3Effect of Closing. The provisions set forth in Article 2, Article 3, Article 5, Article 6, Article 7 (excluding Section 7.7), Article 8, Article 9, and Sections 11.2, 11.4 and 12.3 of this Agreement shall become effective on the Closing Date.  For the avoidance of doubt, such provisions shall have no effect prior to the Closing  Date or if the Closing does not occur for any reason.  

Article 5

GOVERNANCE

5.1Alliance Committee.

5.1.1Representatives.  Within [***], the Parties will establish an alliance committee to oversee the Development and Commercialization of the Product in an advisory capacity (the “AC”). Each Party initially will appoint [***] representatives to serve as representatives to the AC (the “AC Representatives”), with each AC Representative having knowledge and expertise regarding developing products similar to the Product and sufficient decision-making authority within the applicable Party to make decisions on behalf of such Party within the scope of the AC’s decision‑making authority and, if any such representative is not an employee of the appointing Party, such representative shall execute a confidentiality agreement in form and substance acceptable to the other Party (and, for the avoidance of doubt, the appointing Party shall remain responsible to the other Party for any noncompliance by such representative with such confidentiality obligations). Each Party may replace its AC Representatives at any time upon written notice to the other Party.

5.1.2Chairperson.  The AC chairperson (“AC Chairperson”) shall be designated from the Parties’ AC Representatives and shall serve for a term of [***]. BXLS shall appoint the first AC Chairperson and subsequent appointments will rotate on an annual basis between Reata and BXLS. The AC Chairperson will be responsible for drafting and circulating its Party’s draft agenda and ensuring minutes are prepared by its respective Party.

5.1.3Meetings.  From the Closing Date, through the date of the Approval in both the US and the EU5, the AC will meet at least once per Calendar Quarter (and for clarity, such meetings are intended to be conducted via teleconference) unless the Parties mutually agree otherwise.

5.1.4Participants; Voting. The AC may invite individuals who are not AC Representatives to participate in AC meetings; provided that (a) [***] of both Parties consent to such non-member’s participation; and (b) such non-member has executed a confidentiality

29

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

agreement in form and substance acceptable to the non-inviting Party (and, for the avoidance of doubt, the inviting Party shall remain responsible to the non-inviting Party for any noncompliance by such individual with such confidentiality obligations). For clarity, such non-members will have no voting rights at the AC.

5.1.5Alliance Managers.  Each Party shall appoint an individual to act as an alliance manager for such Party (each, an “Alliance Manager”) by providing the name and contact information for the Alliance Manager to the AC. Each Party may change its Alliance Manager from time to time in its sole discretion upon written notice to the other Party. The Alliance Managers shall be the primary point of contact for the Parties regarding the activities contemplated by the Agreement, and the Parties shall use reasonable efforts to ensure that any requests for information and data made outside of the AC are made through the Alliance Mangers. The Alliance Managers shall attend all meetings of the AC. For clarity, the Alliance Managers may also be members of the AC.

5.1.6Costs of AC.  Each Party will bear its own expenses relating to the meetings and activities of the AC.

5.2AC Responsibilities and Decision-Making.

5.2.1Responsibilities (Review and Discuss).  Other than to the extent specifically set forth in Sections 5.2.2 and 5.2.3, the AC is not a decision-making body, but rather an advisory and informational body. The AC’s core responsibilities will include reviewing and discussing (but not approving) the following:

5.2.1.1the conduct of the Development Program, including (i) overall strategic direction, (ii) developing strategies to maximize the value of the Product for the treatment of the Core Indications, and (iii) reviewing and commenting on the Clinical Study Plan and Commercialization Plans;

5.2.1.2material changes in the Development Program that do not require approval pursuant to Sections 5.2.2 or 5.2.3 below, including material changes that are required by, or made to respond to comments from, a Regulatory Authority;

5.2.1.3Clinical Update Summary and Commercialization Update Summary;

5.2.1.4Prior to and following completion of the Development Program, updates regarding material Development plans or events for the Product in any Core Indication other than ALPS or ADPKD.

5.2.1.5Reata’s forecast of the estimated timeline (on at least a quarterly basis) for Commercial Launch with respect to the Product for the Core Indications; or

5.2.1.6any other matters the Parties mutually agree will be, or are expressly provided in this Agreement to be, reviewed and discussed by the AC.

30

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

5.2.2Responsibilities (Review and Approve).  The AC shall be tasked with discussing and approving (in each case, such approval not to be unreasonably withheld, conditioned or delayed):(i)the Timeline Remediation Plan as set forth in Section 5.2.2.1 below, provided that such approval rights set forth in Section 5.2.2.1 shall lapse on [***], and (ii) material changes to the Development Plan as and to the extent set forth in Section 5.2.3; provided, that such approval rights set forth in Section 5.2.3 shall lapse upon[***], or as otherwise set forth in Section 5.2.3, as applicable.

5.2.2.1Timeline Remediation Plan.  If Reata fails to, or reasonably knows that it will not, complete a Trial Activity within the specified Timeline for such Trial Activity, Reata will promptly notify the AC, and, unless the AC’s approval rights have lapsed pursuant to Section 5.2.2, then: if Reata has failed to, or knows that it will not, complete (a) any Trial Activity within [***] of the expected Timeline for such Trial Activity, or (b) the final Trial Activity set forth in the Clinical Development Plan within [***] of the Timeline for such final Trial Activity, then, in either case of (a)-(b), Reata will provide the AC with a written remediation plan detailing the means by which, and a target date by which, Reata expects to be able to complete the relevant Trial Activities (each, a “Timeline Remediation Plan”). Following receipt thereof, the AC Representatives will discuss and consider in good faith such Timeline Remediation Plan, and if the AC approves such Timeline Remediation Plan (such approval not to be unreasonably withheld, conditioned or delayed), the AC will provide Reata with written notice thereof. Reata will use Commercially Reasonable Efforts to carry out the activities set forth in the Timeline Remediation Plan, and Reata will be required to update the AC of its progress with respect thereto.  If the AC does not approve the Timeline Remediation Plan, then BXLS’s representatives on the AC shall (i) provide a written justification to Reata for such refusal and (ii) propose an alternate timeline remediation plan setting forth the means by which, and a target date by which, it expects Reata to be able to complete the relevant Trial Activities (the “Alternate Remediation Proposal”). The Parties shall negotiate in good faith for a period of [***], and if the Parties cannot agree on a final Timeline Remediation Plan, then either Party may refer the matter for final resolution pursuant to Section 5.2.2.2.  

5.2.2.2Expedited Resolution by Independent Expert.  If the AC does not approve a Timeline Remediation Plan or the Alternate Remediation Proposal, and the Parties are unable to reach mutual agreement within the period specified in the last sentence of Section 5.2.2.1, then, upon the written request of either Party, the determination of whether to approve the initially proposed Timeline Remediation Plan or the proposed Alternate Remediation Proposal shall be referred to an independent Third Party expert in the field of drug development and commercialization who is (i) acceptable to both Parties or (ii) if the Parties fail to agree on an independent Third Party expert in accordance with the preceding clause (i), an independent Third Party expert in the field of drug development and commercialization selected by the ICC International Centre for ADR in accordance with the Rules for the Appointment of Experts and Neutrals of the International Chamber of Commerce (the “Independent Expert”).  The sole authority of the Independent Expert will be to (A) set a schedule for expedited dispute resolution, (B) request supporting documentation from each Party with respect to their proposed Timeline Remediation Plan or Alternate Remediation Proposal, as applicable, and (C) select, on the basis of which plan is more reasonable (taking into account the Parties respective rights and obligations under this Agreement and their rights in and to the Product and the Net Sales thereof (including

31

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

the right to receive the Product Payments)) either the (1) the Timeline Remediation Plan or (2) the Alternate Remediation Proposal in its entirety (i.e. the Independent Expert shall not be able to select any middle ground proposal).  Unless otherwise agreed by the Parties, the Independent Expert’s determination shall be final and binding upon the Parties and Reata will be obligated to perform the tasks set forth in the selected plan, and use Commercially Reasonable Efforts to complete such tasks in accordance with the timelines set forth therein.  Unless otherwise agreed by the Parties, the Independent Expert shall be required to make his or her determination within [***] after his or her selection as the Independent Expert.  The Party who’s plan is not selected shall pay the costs of the Independent Expert.

5.2.3BXLS Approval. Until such time as Reata shall [***], the approval of the AC Representatives of BXLS (such approval not to be unreasonably withheld or delayed) shall be required (a) in connection with any change in the Development Program that would materially decrease the likelihood of obtaining or materially increase the timeline for obtaining an Approval in the US or the EU5 and that is either (i) a change to the lead Indication of a Product Trial; or (ii) a change to any primary endpoint of the Product Trials as set forth in the Clinical Study Plan, in either case of (i) and (ii) where such change is not required by, or made to respond to comments from, a Regulatory Authority, and (b) the addition of any new Clinical Trial by Reata that is reasonably likely to result in a Serious Safety Issue that would significantly reduce the likelihood of Approval or result in a drug product label that would significantly reduce the commercial potential of the Product, provided that such approval shall not be required for a Clinical Trial seeking Approval for [***] Indications, unless such Clinical Trial would utilize safety exclusion criteria less restrictive from those set forth on Exhibit G-1, with respect to [***], or Exhibit G-2 with respect to [***], and provided that the Protocol for such Clinical Trial has been accepted by the FDA, EMA, or the Pharmaceuticals and Medical Devices Agency (PMDA).  In the event that Reata shall [***], such approval shall not be required with regard to any change to the Development Program that applies specifically with regard to obtaining Approval in such country.

5.2.4Limitation on Authority.  Notwithstanding anything to the contrary set forth in this Agreement, the AC will have no authority to (x) amend, modify or waive compliance with this Agreement, (y) resolve any dispute concerning the validity, interpretation, construction of, or breach of this Agreement or (z) require that either Party take any action (or refrain from taking any action) that would cause it to breach any agreement to which such Party is a party as of the Closing Date or cause such Party to be in violation of Applicable Law.  

5.2.5Decision-Making.  Reata shall retain sole decision-making authority over all matters within the scope of the AC’s oversight other than the matters described in the foregoing Section 5.2.2 and 5.2.3. The unanimous approval of the AC will be required with respect to all matters within its decision-making authority as described in the foregoing Section 5.2.2. The AC Representatives of each Party will collectively have one (1) vote (with the result that each Party (rather than the individual AC Representatives) has one vote). If the AC cannot reach consensus on any matter for which approval is required under Section 5.2.3, then neither party shall have the final decision-making authority, and absent agreement at the AC, the status quo shall persist with respect to such matter, subject to Section 5.2.4.

32

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

5.2.6Disbandment of the AC.  The AC will terminate immediately at Reata’s option upon delivery of written notice by Reata to BXLS, provided that such dissolution notice may only be provided following the occurrence of any of the following:(i) [***], (ii) the date that Cumulative Payments equal [***]% of the BXLS Development Paymentor (iii) any assignment transfer or sale by BXLS of all or substantially all of its rights to receive payments under this Agreement to any party other than an Affiliate of BXLS (including any Change of Control of BXLS). Upon the termination of the AC, the AC will thereafter have no further authority or meetings with respect to the activities hereunder, and Reata shall not have any additional obligations to provide information to the AC, but for clarity, shall continue to provide all Product Payment reports, as required pursuant to Section 6.5.

Article 6

PAYMENTS TO BXLS

6.1Tiered Bardoxolone Payments.  Subject to the remainder of this Section 6.1, Reata will pay to BXLS the following Royalty Percentage of aggregate Calendar Quarter worldwide Net Sales of the Product as follows:

6.1.1Provided that the BXLS Development Payment has been made, following the receipt of Initial Approval, Reata will pay to BXLS [***]% of Net Sales of the Product until (a) if the Product does not receive Approval for ADPKD in the United States on or before [***] (in which case Section 6.1.2 shall apply following such date), or (b) if the Product does receive Approval for ADPKD in the United States on or before [***], the date that Cumulative Payments equal [***]% of the BXLS Development Payment.  Solely in the case that subsection (b) applies, following the date that Cumulative Payments equal [***]% of the BXLS Development Payment, Reata will pay to BXLS a lower royalty of [***]% of Net Sales of the Product (as opposed to [***]% of such Net Sales) in perpetuity for so long as the Product is being sold by or on behalf of Reata or its Affiliates (for the avoidance of doubt, with a BXLS Development Payment of $[***], the Royalty Stepdown will occur when Product Payments reach an aggregate of $[***]).

6.1.2If the Product has received Initial Approval, but does not receive Approval for ADPKD in the United States on or before [***], then commencing on [***], and continuing until December 31, 2033, Reata will pay to BXLS [***]% of Net Sales of the Product (in lieu of any payment pursuant to Section 6.1.1); provided that if, at any point during the period commencing with the Calendar Quarter ending [***] and ending with the Calendar Quarter ending [***], the aggregate Net Sales of the Product during any [***] consecutive Calendar Quarters exceeds $[***], the Royalty Percentage shall be decreased to [***]% of Net Sales (as opposed to [***]% of such Net Sales) commencing on the first day of the next Calendar Quarter (for example, if the threshold has been met as of [***], such decrease shall take effect as of [***]). For the avoidance of doubt, (i) such adjustment shall not be applicable if the Product has been Approved for ADPKD in the United States on or before [***] and (ii) there shall never be an instance where payments are owed under both Section 6.1.1 and Section 6.1.2 with respect to the Net Sales of the Product.  For purposes of determining whether the aggregate Net Sales during any [***] consecutive Calendar Quarters exceeds $[***] and for purposes of determining Net Sales of the Calendar Year [***], Net Sales shall exclude any sales of the Product which result in wholesalers, distributors  or other

33

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

members of Reata’s distribution channel that purchase directly from Reata or its Subsidiaries holding in the aggregate more than a [***]supply of product based on average Net Sales during the preceding [***] Calendar Quarters, provided that any such excess Net Sales amount shall be applied to following Calendar Quarter.

6.1.3Following the receipt of the Approval, if, at the end of each Calendar Year commencing with 2025 and through the end of Calendar Year 2033, Cumulative Payments as of the end of such Calendar Year (which for purposes of this Section 6.1.3 shall include Product Payments that are due but not yet payable pursuant to Section 6.4 but only to the extent such Product Payments are paid within the timeframe specified in Section 6.4), would for any reason result in BXLS receiving less than the Cumulative Minimum Payment Target for such Calendar Year, then, subject to each Condition Precedent, which are to be applied and tested separately with respect to each potential Cumulative Minimum Payment Target each Calendar Year, Reata will pay BXLS an additional amount (which shall in no event be less than zero) equal to (a) the Cumulative Minimum Payment Target as of the end of such Calendar Year, minus (b) Cumulative Payments as of the end of such Calendar Year (such amounts to be calculated, for the avoidance of doubt, after giving effect to any payments made pursuant to Sections 6.1.1 or 6.1.2 and any payments due but not yet payable under Section 6.6 in respect of such Calendar Year).  For the avoidance of doubt, the requirements of this Section 6.1.3 shall not apply prior to the Approval.

6.2Product Payment True-Up.  Upon written request by BXLS made within [***] after the end of any Calendar Year after Initial Approval Reata will perform a “true-up” reconciliation within [***] after the end of such Calendar Year (and provide BXLS with a written report of such reconciliation) of the deductions outlined in the definition of Net Sales. The reconciliation will be based on the actual cash paid or credits issued in such Calendar Year relative to the accrued amounts (if any) of such deductions used to calculate Net Sales for such Calendar Year.  If such reconciliation report shows either an underpayment or overpayment of Product Payments the Party owing payment to the other Party will pay the amount of such difference to the other Party within [***] of the date of delivery of such report.

6.3Product Payment Assignment. BXLS will not have the right to sell or assign its rights under this Agreement or the Product Payments to a Third Party at any time prior to the earlier of (i) [***] months after the Approval and (ii) [***]. At any time after the earlier of (i) [***] months after the Approval and (ii) [***], BXLS will have the have the right to sell or assign the Product Payments to a Third Party, by providing Reata written notice of its intention to do so.  Reata will have the right to notify BXLS of the price it is willing to pay to purchase the Product Payment (the “Proposed Buyout Payment”) within [***] after receiving such notice from BXLS.  If BXLS accepts the Proposed Buyout Payment, Reata shall purchase the Product Payments from BXLS in exchange for the Proposed Buyout Payment.  If BXLS does not so accept such offer within [***] of receipt of such notice, BXLS will be free (but shall not be required) to sell or assign the Product Payments to a Third Party within [***] ([***]) days from the expiration of the foregoing [***] period at a price higher than the Proposed Buyout Payment.

6.4Payments; Prepayments. From and after the Initial Approval, Reata shall make the payments required pursuant to Sections 6.1.1 and 6.1.2 on a quarterly basis no later than [***] after the end of each Calendar Quarter and the payments required pursuant to Section 6.1.3 on an

34

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

annual basis no later than [***] after the end of the applicable Calendar Year; provided that in Reata’s sole election, it may make any such payments on a more frequent basis.  Reata shall not be entitled to make prepayments in respect of future Product Payments not yet due.

6.5Product Payment Reports and Records Retention.  Reata shall deliver to BXLS, together with the applicable Product Payment (as set forth in Section 6.4 above), a written report setting forth in reasonable detail, the calculation of the Product Payment payable and identifying (i) each Selling Party, (ii) the foreign currency exchange rates used, and (iii) a break-down of all permitted deductions from gross sales used to determine Net Sales and the Product Payment due to BXLS.  For [***] (unless Reata’s internal company procedures for its Affiliate require a shorter period) after each sale, transfer or other disposition of the Product, Reata will keep (and will obligate its Affiliates, and any Selling Party to keep) complete and accurate records in sufficient detail to confirm the accuracy and completeness of the Net Sales of the Products made by such Selling Party. Reata will retain such records for [***] after the earlier of expiration or early termination of this Agreement.

6.6Change of Control of Reata. In the event of a Change of Control of Reata prior to January 1, 2026, Reata will pay to BXLS a fully creditable amount equal to (i) [***] % of the BXLS Development Payment if the Change of Control occurs prior to [***] after the Effective Date, or (ii) [***]% of the BXLS Development Payment if the Change of Control occurs [***] after the Effective Date or later (either such payment a “CoC Advance Payment”), in each case within sixty (60) days of the date of Change in Control, which CoC Advance Payment, in either case, will be fully creditable toward any future Product Payments. Reata (including for the avoidance of doubt its successor in such Change of Control): (a) shall be obligated to continue to exercise Commercially Reasonable Effort to develop the Product and seek Approval as set forth herein following the date of such Change in Control, and (b) shall remain obligated to pay any Product Payments that become due and payable pursuant to Article 6 at such time as such Product Payments become due and payable (if ever) pursuant to Article 6, provided that such Product Payments shall be reduced by the amount previously paid to BXLS and credited toward such Product Payments as set forth in this Section 6.6.  For clarity, there shall be no amounts payable under this Section 6.6 in the event of a Change of Control of Reata following January 1, 2026.

6.7Late Payments. All payments due and payable to a Party under this Agreement will earn interest from the date due until paid at a per annum rate equal to the lesser of (a) the maximum rate permissible under Applicable Law and (b) [***]% per annum. Interest will be calculated on the basis of a 360-day year. The payment of such interest will not limit the Parties from exercising any other rights at their disposal as a consequence of any late payments.

6.8Financial Audits.  Following Commercial Launch for the Product, upon at least fourteen (14) Business Days written notice and during normal business hours, no more frequently than once per calendar year, BXLS may cause an inspection and/or audit by an independent public accounting firm reasonably acceptable to Reata to be made of Reata’s books of account for the three (3) calendar years prior to the audit for the purpose of determining the correctness of Product Payments made under this Agreement.  Upon BXLS’s reasonable request not more than once in any calendar year while any Third Party License remains in effect, Reata shall exercise any rights it may have under any Third Party License to cause an inspection and/or audit by an independent

35

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

public accounting firm to be made of the books of account of any counterparty thereto for the purpose of determining the correctness of Product Payments made under this Agreement and promptly provide BXLS with the results of such inspection and/or audit.  and Reata shall include in any such Third Party License provisions allowing Reata (or an independent public accounting firm) reasonable andcustomary rights to inspect and audit the relevant books of account of such counterparty consistent in scope with the rights granted to BXLS hereunder with respect to Reata’s books and records.  All of the expenses of any inspection or audit requested by BXLS hereunder (including the fees and expenses of such independent public accounting firm designated for such purpose) shall be borne by (i) the BXLS, if the independent public accounting firm determines that Product Payments previously paid were incorrect by an amount less than or equal to [***]% of the Product Payments actually paid or (ii) Reata, if the independent public accounting firm determines that Product Payments previously paid were incorrect by an amount greater than [***]% of the Product Payments actually paid.  The terms on which any such independent public accounting firm is engaged shall provide that such independent public accounting firm may not disclose the confidential information of Reata or any such counterparty to any Third Party License to BXLS, except to the extent such disclosure is either necessary to determine the correctness of Product Payments or such confidential information otherwise would be included in a Product Payment report provided pursuant to Section 6.5.  All information obtained by BXLS as a result of any such inspection or audit shall be Confidential Information of Reata and the independent public accounting firm shall be considered a Representative of BXLS for purposes of Article 10.  Absent manifest error, the financial results of the audit of the independent public accounting firm will be final and non-appealable.  Any payment owed by one Party to another as a result of the audit shall be made within [***] of receipt of the audit report.  Without limiting the foregoing, Reata shall, on the request of BXLS, provide BXLS with a copy of the Net Sales provision under any Third Party License and supporting financial data provided to Reata that is being used to determine the Product Payments payable to BXLS, and if BXLS so desires it may challenge whether such provision is commercially reasonable in accordance with the dispute resolution process set forth in Section 15.10.

6.9Methods of Payment and Currency.  

6.9.1Unless otherwise expressly agreed in writing by the Parties, all payments owed to BXLS or Reata hereunder shall be made by deposit of US Dollars to such United States bank account as BXLS or Reata, as applicable, may from time to time designate by written notice to the other Party. The Parties may vary the method of payment set forth herein at any time by written agreement, and any change shall be consistent with Applicable Law at the place of payment or remittance.

6.9.2With respect to Net Sales not denominated in US Dollars, Net Sales in foreign currency will be converted into US Dollars by using the then-current and reasonable standard exchange rate methodology applied to Reata’s external reporting.  

6.10Taxes.  Each Party represents and warrants that it is a “United States person” within the meaning of Section 7701(a)(30) of the IRS (a “U.S. Person”). Based on the foregoing representation, the Parties hereby acknowledge and agree that no withholding or similar taxes are required to be deducted or withheld from any payment made under this Agreement, unless (a) such

36

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

withholding or similar tax becomes payable due to the assignment of this Agreement or any payment obligation hereunder (to the extent permitted) by either Party to an Affiliate or Third Party, the re-domiciling of either Party outside the US or any other circumstance that results in such Party no longer being a U.S. Person, (b) there is a change in Applicable Laws at any time during the Term such that withholding or other additional taxes may be imposed or levied on account of the payment of any amounts under this Agreement or (c) a Party receiving payments under this Agreement (the “Recipient Party”) fails to provide the other Party (the “Withholding Party”) or its agent with an executed IRS Form W-9 certifying that the Recipient Party is a U.S. Person and is exempt from U.S. federal backup withholding tax. If a Withholding Party is required to withhold any taxes on any amounts payable to the Recipient Party hereunder, the Withholding Party shall be entitled to deduct and withhold from the consideration otherwise payable pursuant to this Agreement such amounts as are required to be deducted and withheld under Applicable Laws with respect to the making of such payment; provided, that if the requirement to deduct or withhold is due to the Withholding Party (or its Affiliate) having taken any of the actions described in clause (a) of this Section 6.10, then the amount payable to the Recipient Party shall be increased as necessary so that after such deduction or withholding has been made (including such deductions and withholdings applicable to additional sums payable under this Section 6.10), the Recipient Party shall have received an amount equal to the sum it would have received had no such deduction or withholding been made.To the extent that amounts are so withheld, such withheld amounts shall be treated for all purposes of this Agreement as having been paid to the Person in respect of whom such deduction and withholding was made. The Parties agree to cooperate in good faith and use their respective reasonable efforts to reduce or eliminate, to the extent permitted under Applicable Laws,any withholding or similar taxes on account of or in respect of any payments hereunder (including through the provisions of tax forms as described in Section 6.11).

6.11Tax Cooperation.  The Parties will cooperate and produce on a timely basis any tax forms or reports, including any IRS Forms W-8BEN, W-8BEN-E or W-9, as applicable, reasonably requested by the other Party in connection with any payment made under this Agreement. Each Party will provide to the other Party any other tax forms that may be reasonably necessary in order for such Party not to withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty. Each Party will provide, upon request, to the other Party any tax forms at least thirty (30) days prior to the due date for any such payments; provided that such request for such forms was made in a timely manner. Each Party will provide the other with reasonable assistance to enable the recovery, as permitted by law, of withholding taxes, VAT, or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or VAT. Each Party will provide commercially reasonable cooperation to the other Party, at the other Party’s expense, in connection with any official or unofficial tax audit or contest relating to tax payments made with respect to amounts paid or payable to such other Party under this Agreement.

Article 7

SECURITY INTEREST

7.1BXLS Collateral Account.

37

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

7.1.1On or prior to the Initial Approval, Reata shall designate one of its Deposit Accounts (which, at Reata’s option, may be a newly opened or existing Deposit Account)as the BXLS Collateral Account and take reasonable action to provide BXLS with an exclusive senior secured first-priority Lien on such account in accordance with Section 7.2 of this Agreement, including by entering into a deposit account control agreement granting BXLS “control” over such account within the meaning provided by the UCC. From and after the occurrence of the Initial Approval, Reata shall cause to be deposited intothe BXLS Collateral Accounton a monthly basis no later than [***] after the end of each month an amount equal to the applicable Royalty Percentage of collections received by Reata in respect of Net Sales during the prior month; provided that in Reata’s sole discretion, deposits may be made on a more frequent basis.  

7.1.2In addition, commencing with the later of (i) the Calendar Quarter ending [***], and (ii) the receipt of Approval, and continuing with each Calendar Quarter thereafter until the IRR Target has been met, no later than the date Program Payments are due in respect of such Calendar Quarter pursuant to Section 6.4, Reata shall cause to be deposited into the BXLS Collateral Account for each such Calendar Quarter an additional amount equal to the product of the quarterly percentage applicable to such Calendar Quarter as set forth in the table below and the excess of (x) the Cumulative Minimum Payment Target for such Calendar Year, over (y) the sum of Cumulative Payments and amounts on deposit in the BXLS Collateral Account at such time:

Calendar Quarter	Quarterly Percentage
First Quarter	[***]%
Second Quarter	[***]%
Third Quarter	[***]%
Fourth Quarter	[***]%

7.1.3Reata shall not be permitted to disburse funds from the BXLS Collateral Account without the prior written consent of BXLS, except Reata may from time to time and without notice to or consent from BXLS (A) make Product Payments to BXLS from the BXLS Collateral Account, (B) disburse funds misdirected into the BXLS Collateral Account and (C) if the amount of funds on deposit in the BXLS Collateral Account at any time exceeds the greater of the Cumulative Minimum Payment Target or the Product Payment projected to be payable by Reata as reasonably determined by mutual agreement by Reata and BXLS, in each case for the then-ongoing Calendar Year, disburse any funds exceeding such amount.  

7.1.4The provisions of this Section 7.1 shall cease to apply upon the termination of the BXLS Security Period.

7.1.5Notwithstanding the requirements of this Section 7.1, to the extent any prepayments or other payments made under the terms of this Agreement are credited toward the Product Payments, such amounts shall also be credited toward deposits made into the BXLS

38

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

Collateral Account and no deposits into the BXLS Collateral Account shall be required in respect of Section 7.1 or otherwise until such credit is exhausted.

7.2Grant of Security Interest. As security for the payment and performance of the Reata Obligations, Reata hereby grants to BXLS a security interest in all of Reata’s right, title and interest in, to and under (i) effective solely during the BXLS Security Period, the BXLS Collateral Account Assets, (ii) effective solely during the BXLS Security Period, the Bardoxolone IP Collateral, and (iii) effective solely during the BXLS Security Period and prior to Approval, all of its personal property, wherever located and whether now existing or owned or hereafter acquired or arising, including all accounts (including health care receivables), books and records, cash, chattel paper (whether tangible or electronic), commercial tort claims, contract rights, Deposit Accounts, documents, equipment (including all fixtures), franchise agreements, general intangibles (including all Intellectual Property, and including all license rights to such Intellectual Property and all rights to receive proceeds from and all proceeds of such Intellectual Property), instruments (including any promissory notes), inventory, investment property, leases, letter-of-credit rights (whether or not the letter of credit is evidenced by a writing), license agreements, money, other goods, securities, all books and records relating to the foregoing, and any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, proceeds, supporting obligations and insurance proceeds of any or all of the foregoing (collectively, together with the BXLS Collateral Account Assets and the Bardoxolone IP Collateral, the “BXLS Collateral”); provided that the BXLS Collateral shall not include any Excluded Assets.  For the avoidance of doubt, the security interests granted pursuant to this Section 7.2 shall not be effective and shall not attach prior to the Closing.

7.3Authorization to File Financing Statements.  Without limitation of any of BXLS’s rights under Section 7.1, including with respect to its rights to perfect its security interest in the BXLS Collateral Account Assets, Reata hereby authorizes BXLS to, during the BXLS Security Period, without notice to Reata, file with all appropriate jurisdictions such financing statements, amendments to financing statements, continuation financing statements, termination statements, security agreements relating to the BXLS Collateral constituting Intellectual Property, fixture filings (if applicable), notices and other documents and instruments as may be necessary in BXLS’s reasonable judgment to perfect, continue perfected, maintain the priority of and/or provide notice of BXLS’s security interest in the BXLS Collateral during the BXLS Security Period. Such financing statements may indicate the BXLS Collateral as “all assets of Debtor” or words of similar effect, or as being of an equal or lesser scope, or with greater detail, all in BXLS’s discretion.  Reata shall execute and deliver such filings and documents to BXLS during the BXLS Security Period, in each case as BXLS may reasonably request and in form reasonably satisfactory to BXLS, as may be necessary in BXLS’s reasonable judgment to perfect, continue perfected, maintain the priority of and/or provide notice of BXLS’s security interest in the BXLS Collateral during the BXLS Security Period.

7.4Subordination to Senior Debt.  

In connection with the entry by Reata into any Permitted Priority Debt from and after the Initial Approval or any Senior Refinancing Debt, the Parties shall enter into an intercreditor

39

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

agreement with any new lender(s) on terms and conditions reasonably acceptable to BLXS and Reata, providing for the subordination of the Reata Obligations to such Permitted Priority Debt or Senior Refinancing Debt; provided, however, that such intercreditor agreement shall provide that any Liens securing such Permitted Priority Debt or Senior Refinancing Debt, as applicable, shall (a) for the avoidance of doubt not include the BXLS Collateral Account Assets, and (b) be junior in priority to BXLS’s Liens on the Bardoxolone IP Proceeds Collateral; provided further, that for the purposes of establishing the aggregate amount of any Reata Obligations in any intercreditor agreement pursuant to Section 7.4, the aggregate amount of Reata Obligations at any time shall not exceed amount equal to [***]% of the BXLS Development Payment, less Cumulative Payments as of such time.

7.5Negative Covenants.  

7.5.1Incurrence of Certain Indebtedness.  During the BXLS Security Period, Reata shall not, without BXLS’s prior written consent, create, incur, assume, or be liable for any Indebtedness, or permit any Subsidiary to do so, other than Permitted Indebtedness.

7.5.2Encumbrances.  During the BXLS Security Period, Reata shall not, without BXLS’s prior written consent:

7.5.2.1prior to the expiration of the provisions set forth in Section 7.1,  permit any BXLS Collateral Account Assets not to be subject to the first priority security interest granted pursuant to this Article 7; and

7.5.2.2permit any BXLS Collateral on which a Lien has been granted pursuant to Section 7.2 and not released pursuant to Section 7.7 (other than due to any act or omission by BXLS in maintaining the perfection of such Lien) not to be subject to the first priority security interest granted pursuant to this Article 7, subject to Permitted Liens and the terms of any subordination agreement contemplated to be executed by Section 7.4; and

7.5.2.3create, incur, allow, or suffer any Lien on any of Reata’s rights or any Subsidiary’s rights in any Bardoxolone IP Collateral, other than Permitted Liens and subject to the terms of any subordination agreement contemplated to be executed by Section 7.4, as applicable.

7.5.3Licensing Transactions.  During the BXLS Security Period, Reata shall not, without BXLS’s prior written consent (such consent not to be unreasonably withheld or delayed), enter into a Licensing Transaction unless such Licensing Transaction is a Permitted Licensing Transaction, in which case such prohibition shall not apply and no such consent of BXLS shall be required. For the avoidance of doubt, nothing in this Agreement shall prohibit Reata from entering into commercialization, development, collaboration or other partnering or licensing arrangements outside of the Territory with respect to products and intellectual property of Reata.

7.5.4Royalty Sales. During the BXLS Security Period, Reata shall not sell, transfer or assign, directly or indirectly, in whole or in part, any rights to receive payments of

40

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

royalties or license fees with respect to the Product or any of its rights in Bardoxolone IP (including any Accounts with respect to such royalties or license fees) other than to a wholly-owned direct or indirect Subsidiary, unless such transferee or assignee shall have executed a subordination agreement in favor of BXLS in the form contemplated by and containing terms described in Section 7.4; provided that the foregoing shall not restrict the creation of any Permitted Lien, the incurrence of Permitted Debt, the entry into any Permitted Licensing Transaction, or the sale of any royalties or other proceeds of any license with Kyowa Kirin or any replacement thereof in Kyowa Kirin’s Territory or under any other Third Party License.

7.6Affirmative Covenants.  Reata shall do all of the following:

7.6.1Execution of Additional Security Agreements and Other Further Assurances.

7.6.1.1Without limitation of any of BXLS’s rights under Section 7.1 including with respect to its rights to perfect its security interest in the BXLS Collateral Account Assets, during the BXLS Security Period, Reata shall, upon request of BXLS from time to time thereafter, execute such security agreements, stock pledge agreements, deposit account control agreements, and take such further action, as reasonably required to perfect or continue BXLS’s security interest in the BXLS Collateral, as applicable, or to otherwise effect the purposes of this Article 7, including by taking the following actions:

(a) Reata shall execute and deliver to BXLS, promptly upon commencement of the BXLS Security Period, such security agreements and pledge agreements as BXLS may reasonably request, in each case in form and substance reasonably acceptable to BXLS and Reata, and shall take such other action as may be necessary or as BXLS may reasonably request to effect and perfect BXLS’s security interest in the BXLS Collateral granted pursuant to Section 7.2. Such agreements shall include customary Patent and Trademark security agreements (each an “IP Security Agreement”), which BXLS may record with the US Patent and Trademark Office. In addition, Reata shall (i) within [***] of the last day of the Calendar Quarter during which the BXLS Security Period commences and each Calendar Quarter ending thereafter during such period, notify BXLS in writing of the creation or acquisition of any Intellectual Property owned by Reata that is registered or becomes registered or the subject of an application for registration with the US Patent and Trademark Office, in each case during such Calendar Quarter then ended, and (ii) deliver to BXLS any further IP Security Agreement (or amendment to an existing IP Security Agreement) for recordation with the US Patent and Trademark Office, and shall take such other action as may be necessary or as BXLS may reasonably request to perfect BXLS’s security interest in such Intellectual Property.

(b) No later than [***] after commencement of the BXLS Security Period, Reata shall use commercially reasonable efforts to deliver to BXLS fully executed deposit account control agreements or securities account control agreements, as applicable, in favor of BXLS in form and substance reasonably satisfactory to BXLS with respect to all Deposit Accounts and Securities Accounts (collectively with any Deposit Account other than the BXLS Collateral Account, each a “Collateral Account”) maintained within the United States by Reata.  Reata represents and warrants to BXLS that, as of the Effective Date, it maintains no Collateral Accounts other than the

41

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

Collateral Accounts described on Schedule 7.6.1.1(b) hereto.  In addition to and without limiting the foregoing, during the BXLS Security Period, Reata shall provide BXLS with [***] prior written notice before establishing any additional Collateral Account at or with any bank or financial institution within the United States.  For each such additional Collateral Account that Reata at any time maintains during the BXLS Security Period, Reata shall use commercially reasonable efforts to cause the applicable bank or financial institution at or with which any Collateral Account is maintained to execute and deliver a deposit account control agreement, securities account control agreement or other appropriate instrument with respect to such account to perfect BXLS’s Lien in such account in accordance with the terms hereunder within [***] after the opening of each such account, which agreement may not be terminated without the prior written consent of BXLS during the BXLS Security Period.  The provisions of this Section 7.6.1.1(b) shall not apply to Excluded Accounts and for the avoidance of doubt shall terminate upon Approval.

(c) If, prior to the expiration of the BXLS Security Period, Reata sells, contributes or otherwise transfers its right, title and interest in, to and under, any Bardoxolone IP to any Subsidiary, during the BXLS Security Period, Reata shall, upon request of BXLS from time to time thereafter, execute such security agreements, charges and pledges and take such further action, as reasonably required to perfect or continue BXLS’s security interest in such Bardoxolone IP, including actions required under the applicable jurisdiction of such Subsidiary; provided that the foregoing shall not apply to any non-exclusive license of Bardoxolone IP.  Notwithstanding anything to the contrary herein, (i) no filings in any jurisdiction outside the United States, France, Germany, and the United Kingdom shall be required with regards to any Bardoxolone IP registered in jurisdictions outside the United States and (ii) no actions in any jurisdiction outside the United States shall be required where the cost of obtaining or perfecting a security interest in such assets exceeds the practical benefit to BXLS afforded thereby as reasonably determined by BXLS (in consultation with Reata).

7.6.2Government Compliance.

7.6.2.1Maintain its and all its Subsidiaries’ legal existence and good standing in their respective jurisdictions of formation and maintain qualification in each jurisdiction in which the failure to so qualify would reasonably be expected to have a material adverse effect on Reata’s consolidated business or operations taken as a whole, provided that any Subsidiary may liquidate or dissolve so long as such liquidation or dissolution would not reasonably be expected to have a material adverse effect on Reata’s consolidated business or operations taken as a whole, and provided that in connection with such liquidation or dissolution all assets and property of any such Subsidiary shall be transferred to Reata or another Subsidiary. Reata shall comply, and have each subsidiary comply, in all material respects, with all laws, ordinances and regulations to which it is subject noncompliance with which would reasonably be expected to have a material adverse effect on Reata’s consolidated business or operations taken as a whole.

7.6.2.2Obtain all of the Governmental Approvals, if any, necessary for the grant of a security interest to BXLS in the BXLS Collateral Account and BXLS Collateral, in each case at (but not before) such time as such grant of a security interest is required by this Agreement.  

42

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

7.6.3Regulatory Compliance. Reata shall not become an “investment company” or a company “controlled” by an “investment company” under the Investment Company Act of 1940, as amended. Reata shall not become engaged as one of its important activities in extending credit for Margin Stock. Neither Reata nor any of its Subsidiaries’ properties or assets shall be used by Reata or any Subsidiary in disposing, producing, storing, treating, or transporting any hazardous substance other than legally. Reata and each of its Subsidiaries shall obtain all consents, approvals and authorizations of, make all declarations or filings with, and give all notices to, all Governmental Authorities that are necessary to continue their respective businesses as currently conducted, unless such failure would not reasonably be expected to cause a Material Adverse Event.

7.6.4Protection and Enforcement of Intellectual Property Rights.  Reata shall use Commercially Reasonable Efforts in the exercise of its business judgment to prosecute, protect, defend and maintain the validity and enforceability of Reata’s Intellectual Property related to the Product and, if appropriate to enforce such Intellectual Property against any Third Party Infringement.

7.7Release of Security Interests.  

7.7.1To the extent any Lien has been granted pursuant to Section 7.2 on any BXLS Collateral, effective immediately upon:

7.7.1.1Approval, BXLS’s Lien on all BXLS Collateral (other than the Bardoxolone IP Collateral and the BXLS Collateral Account Assets) shall be automatically and without further action released and terminated;

7.7.1.2the end of the BXLS Security Period, BXLS’s Lien on all BXLS Collateral shall be automatically and without further action released and terminated;

7.7.1.3the termination of the provisions set forth in Section 7.1, BXLS’s Lien on the BXLS Collateral Account Assets shall be automatically and without further action released and terminated; and

7.7.1.4any sale or other transfer (other than any lease or license) by Reata of any BXLS Collateral (other than the transfer of Bardoxolone IP or any BXLS Collateral Account Assets and other than in connection with the sale of all or substantially all the assets of Reata), the security interests in such item of Collateral shall be automatically and without further action released and terminated;

and, in each such case, BXLS shall take such reasonable actions as Reata requests to evidence such release and termination.

7.7.2In addition, upon the request of any holder (or prospective holder) of obligations secured by a Permitted Lien (other than any Lien on Bardoxolone IP) specified in Section 1.1.113.3, Section 1.1.113.11 (subject to Section 7.4), Section 1.1.113.13 and Section 1.1.113.26 or, in the case of a license or sub-license, the applicable licensee or sub-licensee (or

43

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

prospective licensee or sub-licensee), BLXS shall, at the reasonable request of Reata, (A) subordinate any Lien on any BXLS Collateral (other than any lien on Bardoxolone IP or any BXLS Collateral Account Assets) to the holder of any such Permitted Lien, and (B) enter into subordination, non-disturbance and similar agreements in connection with the licensing of intellectual property and other general intangibles permitted under this Agreement to the extent reasonably requested by a licensee or sub-licensee thereof.

Article 8

EQUITY INVESTMENT

8.1Equity Investment.  Upon the payment of $50,000,000 from BXLS to Reata, the (“BXLS Equity Investment”), Reata will issue to BXLS the number of shares (with any fractional share will be rounded up or down to the nearest whole number of shares) of Reata’s Class A common stock valued at $50,000,000 at a price per share equal to the volume weighted average price of the shares over the thirty (30) calendar days prior to the Effective Date.  The closing of such BXLS Equity Investment (the “Equity Closing”) will occur on the Closing Date and will be pursuant to the terms and conditions of the Stock Purchase Agreement.  

Article 9

PRODUCT TRIAL RECORDS

9.1Except as otherwise provided herein, Reata will maintain materially complete and accurate records related to the Product Trials until the later of (a) [***] following the completion of the Development Program or (b) the time period required by Applicable Law.

Article 10

CONFIDENTIAL INFORMATION

10.1Confidentiality.  Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, each Party (each, a “Receiving Party”) agrees that, during the Term and for the [***] following the expiration or termination of this Agreement (except that the obligations will survive thereafter with respect to any Confidential Information that constitutes a trade secret under Applicable Law), it will keep confidential and will not publish or otherwise disclose and will not use for any purpose other than as provided for in this Agreement (which includes the exercise of any rights or the performance of any obligations hereunder) any Confidential Information furnished to it by or on behalf of the other Party (each, a “Disclosing Party”) or its Affiliates in connection with this Agreement. The foregoing obligations will not apply to any portion of such information or materials that the Receiving Party can demonstrate:

10.1.1was publicly disclosed by the Disclosing Party before or after such Confidential Information becomes known to the Receiving Party;

44

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

10.1.2was already known to the Receiving Party or any of its Affiliates, other than under an obligation of confidentiality or non-use, prior to when it was received from or on behalf of the Disclosing Party;

10.1.3is subsequently disclosed to the Receiving Party or any of its Affiliates by a Third Party lawfully in possession thereof without obligation to keep such Confidential Information confidential and without further restriction on use or dissemination;

10.1.4has been published by a Third Party or otherwise enters the public domain through no fault of the Receiving Party or any of its Affiliates in breach of this Agreement; or

10.1.5has been independently developed by the Receiving Party or any of its Affiliates, without the aid, application or use of any Confidential Information of the other Party.

10.2Authorized and Required Disclosures.

10.2.1Required Disclosures.  Each Party may disclose Confidential Information belonging to the other Party to the extent such disclosure is reasonably necessary for complying with Applicable Laws, including regulations promulgated by securities exchanges, provided that, to the extent not prohibited by Applicable Laws, the Party required to disclose such information promptly notifies the Disclosing Party prior to making any such disclosure and cooperates with the Disclosing Party’s efforts to seek confidential treatment or to otherwise limit disclosure.

10.2.2Authorized Disclosures.  Each Receiving Party may disclose the other Party’s Confidential Information:

10.2.2.1to its Representatives, in each case as reasonably required in connection with the performance of this Agreement, provided that (a) each Person receiving Confidential Information must be bound by obligations of confidentiality and non-use at least as stringent as an equivalent in scope to those set forth in this Article 10 prior to any such disclosure (or with respect to professional service providers, that are bound by customary and reasonable obligations of confidentiality and non-use (including under any ethical or professional standards)) prior to any such disclosure; and (b) the Party making such disclosure to such Person shall be liable to the other Party for any breach of such obligations by such disclosee (provided that a Party’s Representative(s) shall only be bound by the obligations set forth in this Article 10 to the extent that such Representative(s) actually receives such Confidential Information);

10.2.2.2prosecuting or defending litigation;

10.2.2.3for regulatory, Tax or customs purposes;

10.2.2.4for audit purposes, provided that each recipient of Confidential Information must be bound by customary and reasonable obligations of confidentiality and non-use prior to any such disclosure;

45

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

10.2.2.5to any bona fide potential or actual investor (including limited partners), collaboration partner, licensee, sublicensee, investment banker, acquirer, provider of debt or royalty financing, or other potential or actual financial partner without the consent of the other Party, provided, that such disclosure shall be made only to the extent customarily required to consummate or monitor such investment, financing transaction partnership, collaboration or acquisition and provided that each recipient of Confidential Information must be bound by customary obligations of confidentiality and non-use prior to any such disclosure in relation to the relevant transaction; and

10.2.2.6in connection with any permitted assignment of this Agreement.

In any event, each Party agrees to take all reasonable action to avoid unauthorized use or disclosure of Confidential Information of the other Party hereunder.  Notwithstanding anything in the foregoing to the contrary, Exhibit B constitutes Reata’s Confidential Information and not BXLS’s Confidential Information, and Reata may disclose Exhibit B to Third Parties as determined by Reata in its sole discretion.  

10.3Return of Confidential Information.  Except as otherwise provided herein, upon expiration or earlier termination of this Agreement, all Confidential Information (including any copies thereof) in written or other tangible form will, at the Disclosing Party’s direction, be returned to the Disclosing Party or destroyed by the Receiving Party, and any Person(s) to whom the Receiving Party disclosed (with such destruction being confirmed in writing by an authorized officer of the Receiving Party), except (i) to the extent such Confidential Information is necessary to exercise any license and/or rights hereunder that survive such expiration or earlier termination; and (ii) one (1) copy of each document may be retained by the Receiving Party solely to the extent necessary to permit it to comply with any ongoing rights and responsibilities with respect to such Confidential Information.

10.4Confidential Status of the Agreement.  Subject to the provisions of this Section 10.4 and Section 10.5 below, the terms of this Agreement are deemed to be Confidential Information and will be subject to the confidentiality requirements of this Article 10, with each Party being deemed a Receiving Party for such purposes. The Parties each acknowledge that it will be necessary for Reata to file this Agreement with the SEC and to make other required public disclosures regarding the terms of this Agreement or the Development of the Product, and accordingly Reata shall provide BXLS and its legal counsel a reasonable opportunity to review and comment on such filing as well as on the first required public disclosure about the Agreements and to reasonably take into accounts such comments, provided that, for clarity, Reata is permitted to disclose any information that is legally required to be disclosed as advised by its legal counsel.

10.5Publicity.  The Parties recognize that following the Effective Date the Parties (either individually or jointly) shall issue mutually agreed press release(s) announcing the execution of this Agreement, and thereafter each Party may from time to time desire to issue additional press releases and make other public statements or disclosures regarding the subject matter of this Agreement, and hereby agree that such additional press releases, public statements and disclosures regarding the terms of this Agreement will be permitted only with the other Party’s written consent

46

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

(which shall not be unreasonably withheld, conditioned or delayed), except that no consent shall be required if a Party is legally obligated to disclose the information contained in such press release. Any publication, news release or other public announcement relating to the terms of this Agreement will first be reviewed and approved in writing by both Parties. For avoidance of doubt, this Section 10.5 shall not restrict Reata from releasing public statements or disclosures regarding Reata’s Development and Commercialization activities with respect to the Product.

10.6BXLS Name.  Unless otherwise expressly permitted herein, Reata will obtain the written consent of BXLS (which consent will not unreasonably be withheld, conditioned or delayed) prior to referring to BXLS or Blackstone in any correspondence with any Regulatory Authority or Governmental Authority, in any filings with the SEC, or in any press release except as may be required by Applicable Law.  

10.7Equitable Relief.  Given the nature of the Confidential Information and the competitive harm that could result to a Party upon unauthorized disclosure, use, or transfer of its Confidential Information to any Third Party, the Parties agree that monetary damages may not be a sufficient remedy for any breach of this Article 10.  In addition to all other remedies, a Party will be entitled to seek specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this Article 10.

Article 11

INTELLECTUAL PROPERTY

11.1Ownership and Rights.

11.1.1Background IP.  Reata will retain all of its right, title and interest in, to and under all data, results, information, analyses, discoveries, inventions and know-how that are owned or Controlled by Reata as of the Effective Date or are acquired, made or invented by or on behalf of Reata independent of this Agreement (“Reata Background IP”) and no such right, title or interest therein, thereto or thereunder is granted to BXLS hereunder.  BXLS will retain all of its right, title and interest in, to and under all data, results, information, analyses, discoveries, inventions and know-how that are owned or Controlled by BXLS as of the Effective Date or are acquired, made or invented by or on behalf of BXLS independent of this Agreement (“BXLS Background IP”) and no such right, title or interest therein, thereto or thereunder is granted to Reata hereunder.

11.1.2Arising IP. The Parties do not contemplate or anticipate the development or generation of any intellectual property by the Parties in connection with their activities under this Agreement.  Without limiting the foregoing, and except as expressly set forth in this Section 11.1.2, (a) each Party shall solely own any idea, discovery, method, technique, know-how, or other intellectual property developed or generated solely by or on behalf of such Party in the course of such Party’s performance under this Agreement, and (b) the Parties shall jointly own any idea, discovery, method, technique, know-how, or other intellectual property developed or generated jointly by both Parties in the course of performing activities under this Agreement and each Party shall have full rights to license, assign and exploit such jointly owned

47

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

intellectual property anywhere in the world, without any requirement of gaining the consent of, or accounting to, the other Party. Notwithstanding the foregoing, Reata will solely own all right, title and interest in and to any idea, discovery, method, technique, know-how, or other intellectual property developed or generated in connection with either Party’s activities under this Agreement (irrespective of inventorship) that is related in any way to (i) the Product (including the use, manufacture or administration thereof and specifically including (A) all Research Results; (B) all discoveries and inventions discovered, developed or invented by, or on behalf of, Reata, and any of their Affiliates, in connection with the Product Trials), (ii) the Reata Background IP, or (iii) the Bardoxolone IP ((i)-(iii), collectively the “Reata Improvement IP” and together with the Reata Background IP, the “Reata Intellectual Property”).  For clarity, the Reata Improvement IP shall not include any BXLS Improvement IP.

11.1.3Covenant in Support of Assignment.  BXLS agrees to assign and hereby assigns to Reata all of BXLS’ right, title and interest in and to any Reata Improvement IP and any Intellectual Property therein or thereto.  All Reata Improvement IP generated by BXLS shall, to the extent permitted by law, be deemed “works made for hire.”  BXLS will take (and cause its Affiliates and their respective employees, agents, and contractors to take) such further actions reasonably requested by Reata to evidence such assignment, at Reata’s cost.

11.1.4No Other Rights.  Neither the delivery of any information nor of any materials to BXLS hereunder will be construed to grant BXLS any rights or license to use any Reata Intellectual Property. BXLS may not use, publish or otherwise disclose any Reata Intellectual Property (including any Reata Improvement IP) without Reata’s prior written consent.

11.2Patent Prosecution.  As between BXLS and Reata, Reata will prepare, file, prosecute and maintain all Patents within the Reata Intellectual Property, including all Patents that cover the Reata Intellectual Property, at its own expense (provided that Reata will use Commercially Reasonable Efforts to prosecute and maintain such Patents).

11.3Intellectual Property Infringement Notices.

11.3.1Infringement of Third Party Rights.  If either Party learns of (i) Third Party allegations that it or the other Party or any of its or the other Party’s Affiliates, or with respect to Reata any Permitted Third Parties, have infringed, misappropriated or otherwise violated, or are infringing, misappropriating or otherwise violating, any Intellectual Property of a Third Party in connection with either the Product Trials or performing its obligations or duties hereunder, or (ii) any Third Party Infringement, then, in either case such Party will promptly notify the other Party, provided that, as between the Parties, Reata will have sole control and responsibility of, and discretion with respect to, such allegation and any related actions and/or litigation, subject its express obligations set forth in Section 7.6.4.

11.4Personally Identifiable Information.

11.4.1Subject Personally Identifiable Information.  Reata expressly agrees that, in conducting the Product Trials and its other obligations hereunder, Reata will comply and will use Commercially Reasonable Efforts to require each applicable Permitted Third Party agree

48

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

to comply with Applicable Laws relating to privacy or data protection applicable to Reata or the Product Trials, as set forth in Section 2.1.2 and Section 2.3.Without limiting the foregoing, Reata will maintain commercially reasonable technical and organizational security measures with respect to any use or transmission of any personal health information or other protected personally identifiable information.

Article 12

INDEMNIFICATION AND INSURANCE

12.1Indemnification by Each Party.

12.1.1By BXLS.  BXLS will indemnify and hold Reata; its Affiliates and its and their respective officers, directors, employees and agents (the “Reata Indemnified Parties”), harmless from any and all Losses arising or resulting from any Claims by a Third Party against any Reata Indemnified Parties to the extent arising from (a) BXLS’s gross negligence or willful misconduct in performing its obligations under this Agreement; and/or (b) BXLS’s material breach of this Agreement; provided that the foregoing shall not subject BXLS to liability for lost revenue, profits or other consequential damages of Reata or its Affiliates, and further provided that BXLS shall not have any responsibility for a Claim to the extent that any of the foregoing (a) through (b) were caused by any Reata Indemnified Party or Permitted Third Parties’ gross negligence, willful misconduct, or material breach of this Agreement.

12.1.2By Reata.  Reata will indemnify and hold BXLS, its Affiliates, BXLS’s investors and its and their respective members, officers, directors, employees and agents (the “BXLS Indemnified Parties”), harmless from any and all Losses arising or resulting from any Claims by a Third Party against any BXLS Indemnified Parties to the extent arising from (a) a Product; (b) injuries sustained by Subjects in connection with the Product Trials, including Claims arising prior to the Effective Date, based upon physical injury or death of a Subject in connection with the Product Trials (including a personal injury or death of a Subject that is caused by the Subject’s participation in the Product Trials whether or not directly attributable to the Product), or from the Commercialization of the Product; (c) Reata’s gross negligence or willful misconduct in performing its obligations under this Agreement including in the conduct of the Product Trials or preparation and submission of the information for Approval; or (d) Reata’s breach of this Agreement, provided that the foregoing shall not subject Reata to liability for lost revenue, profits, or other consequential damages of BXLS or its Affiliates; (e) any Permitted Third Party’s material breach of the Protocol, (f) actual or alleged infringement of any Third Party’s Intellectual Property by the Product or by Reata in performing activities hereunder; (g) any breach by Reata of Section 11.4; and further provided that Reata shall not have any responsibility for a Claim to the extent that any of the foregoing (a) through (g) were caused by any BXLS Indemnified Party’s gross negligence, willful misconduct, or material breach of this Agreement.

12.2Indemnification Procedure.

12.2.1Notice of Claim.  A Party believing that it is entitled to indemnification under Section 12.1.1 or 12.1.2 (an “Indemnified Party”) will give prompt written notice (each,

49

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

an “Indemnification Claim Notice”) to the other Party (the “Indemnifying Party”) of commencement of any Claim for which indemnification may be sought, or if earlier, upon the assertion of any such Claim by a Third Party (it being understood and agreed, however, that the failure by an Indemnified Party to give notice of a Claim of a Third Party as provided in this Section 12.2.1 will not relieve the Indemnifying Party of its indemnification obligation under this Agreement except and only to the extent that such Indemnifying Party is actually prejudiced as a result of such failure to give notice). The Indemnified Party will furnish promptly to the Indemnifying Party copies of all papers and official documents received in respect of any Losses.

12.2.2Control of Defense.  At its option, the Indemnifying Party may assume the defense of any Claim by giving written notice to the Indemnified Party within [***] after the Indemnifying Party’s receipt of an Indemnification Claim Notice. The assumption of the defense of a Claim by the Indemnifying Party will not be construed as an acknowledgment that the Indemnifying Party is liable to indemnify the Indemnified Party in respect of the Claim, nor will it constitute a waiver by the Indemnifying Party of any defenses it may assert against the Indemnified Party’s claim for indemnification. Upon assuming the defense of a Claim, the Indemnifying Party may appoint as lead counsel in the defense of the Claim any legal counsel selected by the Indemnifying Party and approved by the Indemnified Party, such approval not to be unreasonably withheld. Without limiting the Indemnified Party’s other obligations under Section 12.2, in the event the Indemnifying Party assumes the defense of a Claim, the Indemnified Party will promptly deliver to the Indemnifying Party all original notices and documents (including court papers) received by the Indemnified Party in connection with the Claim. Should the Indemnifying Party assume the defense of a Claim, the Indemnifying Party will not be liable to the Indemnified Party for any legal expenses subsequently incurred by such Indemnified Party in connection with the analysis, defense or settlement of such Claim.

12.2.3Right to Participate in Defense.  Without limiting Section 12.2.2, the Indemnified Party will be entitled to (a) participate in, but not control, the defense of such Claim and to engage counsel of its choice for such purpose; provided, however, that such engagement will be at the Indemnified Party’s own expense unless the engagement thereof has been specifically authorized by the Indemnifying Party in writing, and (b) control its defense of such Claim and to engage counsel of its choice for such purpose, at the expense of the Indemnifying Party, if the Indemnifying Party has failed to assume the defense and engage counsel in accordance with Section 12.2.2.

12.2.4Settlement.  With respect to any Losses related solely to payment of money damages in connection with a Claim that (a) includes a complete and unconditional release of the Indemnified Party, (b) will not result in the Indemnified Party admitting liability, becoming subject to injunctive or other equitable relief that will otherwise adversely affect the business of the Indemnified Party in any manner, and (c) as to which the Indemnifying Party will have acknowledged in writing the obligation to indemnify the Indemnified Party hereunder, the Indemnifying Party will have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such terms as the Indemnifying Party, in its sole discretion, will deem appropriate. With respect to all other Losses in connection with Claims, where the Indemnifying Party has assumed the defense of the Claim in accordance with Section 12.2.2, the Indemnifying Party will have authority to consent to the entry of any judgment,

50

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

enter into any settlement or otherwise dispose of such Loss provided it obtains the prior written consent of the Indemnified Party (which consent will not be unreasonably withheld, conditioned or delayed). The Indemnifying Party will not be liable for any settlement or other disposition of a Loss by the Indemnified Party that is reached without the written consent of the Indemnifying Party. Regardless of whether the Indemnifying Party chooses to defend or prosecute any Claim, the Indemnified Party will not admit any liability with respect to, or settle, compromise or discharge, any Claim without the prior written consent of the Indemnifying Party, not to be unreasonably withheld or delayed.

12.2.5Cooperation.  Regardless of whether the Indemnifying Party chooses to defend or prosecute any Claim, the Indemnified Party will reasonably cooperate in the defense or prosecution thereof and will furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith. Such cooperation will include access during normal business hours afforded to the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Claim, and making employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder, and the Indemnifying Party will reimburse the Indemnified Party for all its reasonable out-of-pocket expenses in connection therewith.

12.3Insurance.

12.3.1Generally.  Commencing as of the Closing Date and thereafter during the Term, and subject to Section 12.3.2 below, Reata will carry and maintain, at its own expense, insurance coverage of the kind and with liability limits that, at a minimum, satisfy the requirements of Section 12.3.2, to protect itself and BXLS against any claims or liabilities that may arise from the conduct of the Product Trials and all other rights and obligations hereunder with insurers with a minimum “A-” A.M. Best rating (except for Lloyds of London, which is not rated). Any deductibles for such insurance policies will be assumed by Reata. Such insurance policies will be primary and non-contributing with respect to any other similar insurance policies available to BXLS or its Affiliates. Prior to the Closing Date, and annually, at each anniversary of the Closing Date (unless, during such year, expiration of the applicable policy occurs first, in which case, on such expiration date), at BXLS’s written request Reata will provide BXLS with documentation of such insurance coverage via original certificates of insurance, if applicable. Reata will provide BXLS a minimum of [***] prior written notice to BXLS if it is unable to obtain appropriate insurance coverage or if its coverage is canceled, unable to be renewed or materially changed. For clarity, failure to maintain adequate insurance coverage does not relieve or reduce Reata’s liability under this Agreement. Reata will ensure that no subcontractor, including any Permitted Third Party, will continue to perform the work unless such subcontractor is insured as deemed appropriate by the Party engaging the Permitted Third Party.

12.3.2Minimum Requirements.  Commencing as of the start of the Product Trials and thereafter, during the Term (or longer if otherwise stated below), at a minimum, Reata, will maintain the following types of insurance coverage at a minimum level that is the greater of (a) the highest minimum level required by Applicable Law in the countries in which the Product

51

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

Trials and other obligations hereunder are being performed or (b) the following (to the extent different):

12.3.2.1Commercial General Liability:  [***] dollars ($[***]) per occurrence; [***] dollars ($[***]) Product and Completed Operations aggregate, including Premises & Operations, Personal Injury, Product and Completed Operations; [***] ($[***]) combined single limit on all owned, non-owned and hired vehicles of Reata.

12.3.2.2Umbrella Excess Liability:  [***] dollars ($[***]) per occurrence.

12.3.2.3Clinical Trial Liability:  [***] dollars ($[***]) per occurrence. Coverage must be maintained for at least [***] after the later of termination of this Agreement or release of the last Subject from the Product Trials.

12.3.3Additional Insured.  Reata will include BXLS and its Affiliates as additional insured parties on Reata’s Clinical Trials Liability insurance, as set forth in Section 12.3.2.3, for the duration of the Product Trials and for five (5) years after the later of termination of this Agreement or release of the last Subject from the Product Trials.

12.3.4Product Liability Insurance. Reata will be responsible for maintaining product liability insurance related to the Commercialization of the Product at its expense.

Article 13

REPRESENTATIONS AND WARRANTIES

13.1Representations, Warranties and Covenants of Both Parties.

13.1.1Each Party hereby represents and warrants that it has the requisite corporate power and authority to enter into this Agreement and that this Agreement constitutes a legal and valid obligation binding upon such Party, enforceable in accordance with its terms.

13.1.2Each Party hereby represents and warrants that it is not a party to any agreement that would prevent it from fulfilling its obligations under this Agreement or that otherwise conflicts with the provisions of this Agreement.

13.1.3Each Party hereby represents and warrants that it has not and will not and will require that Permitted Third Parties of such Party will not directly or indirectly offer or pay, or authorize such offer or payment, of any money or anything of value to improperly or corruptly seek to influence any Government Official or any other person in order to gain an improper business advantage. During the Term, each Party will maintain in effect and enforce policies and procedures designed to ensure compliance by such Party, its subsidiaries and their respective directors, officers, employees and agents with Anti-Corruption Laws.

52

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

13.2Additional Reata Representations, Warranties and Covenants.

13.2.1No Contravention. The execution, delivery and performance by Reata of this Agreement have been duly authorized by all necessary corporate or other organizational action, and do not and will not (a) contravene the terms of any of Reata’s organizational documents; (b) conflict with or result in any breach or contravention of, or the creation of (or the requirement to create) any lien or encumbrance under, or require any payment to be made under (i) any contractual obligation to which Reata is a party or affecting Reata, or the properties of Reata or any Subsidiary, or (ii) any order, injunction, writ or decree of any governmental authority or any arbitral award to which Reata or its property is subject; or (c) violate any Applicable Law, except in the case of this Section 13.2.1 with respect to any conflict, breach, violation, or payment, to the extent that such conflict, breach, violation, or payment would not reasonably be expected to have a material adverse effect on Reata’s ability to satisfy its obligations under this Agreement.

13.2.2Anti-Corruption. Each Party agrees, on behalf of itself and its Representatives, that in connection with the exercise of its rights or its performance hereunder:

13.2.2.1Such party, its Affiliates and its and their respective Representatives will comply with the Anti-Corruption Laws and will not take any action that will, or would reasonably be expected to, cause the other Party or its Affiliates to be in violation of any Anti-Corruption Laws; and

13.2.2.2Such Party will promptly provide the other Party with written notice of the following events: (a) upon becoming aware of any breach or violation by such Party, its Affiliates or any of its or their respective Representatives of any representation, warranty or undertaking set forth in Section 13.2.2, or (b) upon receiving a formal notification that it is the target of a formal investigation by a Governmental Authority for a Material Anti-Corruption Law Violation or upon receipt of information from any of its Representatives connected with this Agreement that any of them is the target of a formal investigation by a governmental authority for a Material Anti-Corruption Law Violation.

13.2.3Licensure, Registration and Accreditation.  

13.2.3.1Reata hereby represents and warrants that, as of the Effective Date, it is licensed, registered, or otherwise qualified under all Applicable Laws in all material respects to do business in each jurisdiction where such licenses, registrations or other qualifications are required and where failure to so qualify would cause a Material Adverse Event. Reata further represents and warrants that, to its knowledge as of the Effective Date, there has not been any breach or default by Reata under the Third Party Licenses, and that it shall not knowingly take any action that would permit the termination by any counter party to a Third Party License for the material breach thereof. Reata further covenants that it shall, and it shall obligate any Permitted Third Parties to, have at the required times, such certifications, permits, and authorizations as are required to conduct the Product Trials and perform any and all of their obligations in connection with the Product Trials.

53

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

13.2.3.2Reata hereby represents and warrants that, prior to the Effective Date, (a)it and its Affiliates have conducted all preclinical and clinical activities related to the Development of the Product in material compliance with Applicable Laws, and (b)to Reata’s knowledge, all Third Parties utilized by Reata to perform any portion of the preclinical and clinical activities have conducted such portion of such preclinical activities in material compliance with Applicable Laws.

13.2.3.3Reata certifies that, as of the Effective Date, neither it, nor its Affiliates, nor to its knowledge any Permitted Third Parties engaged by it to perform activities in relation to the Product are debarred under subsections 306(a) or (b) of the US Federal Food, Drug, and Cosmetic Act (US Generic Drug Enforcement Act of 1992; 21 USC 335a (a) or (b)), and that it has not knowingly used, and will not knowingly use in any capacity the services of any Person or Permitted Third Party debarred under this law to conduct the Product Trials. Reata further certifies that, as of the Effective Date, neither it, nor any of its Affiliates are excluded from any US health care program, including to Medicare and Medicaid. Reata will notify the AC immediately if either of these certifications needs to be amended in light of new information.

13.2.4No Other Agreements.  There are no other agreements to which Reata is a party that are related to, or pursuant to which Reata has obtained or granted rights regarding, the Product and that would conflict with or restrict the rights granted to BXLS hereunder.

13.2.5Clinical Trial Permits; Certifications; Authorizations. Reata further covenants that, as of the Effective Date, (a) it has, and that it has obligated any Permitted Third Parties to have, at the required times, such INDs or other filings with all Regulatory Authorities as are required to conduct the Product Trials, and (b) all INDs and other required filings for the conduct of the Product Trials in existence as of the Effective Date are valid and in full force and effect and, to its knowledge, no default has occurred with respect to any material obligations thereunder.  As of the Effective Date, Reata has not received any notice that the FDA, other Regulatory Authority, institutional review board or independent ethics committee, has initiated, or threatened to initiate, any action to suspend or terminate any IND for any Product Trial or otherwise require the indefinite termination or suspension of any planned Clinical Trial for the Product.

13.2.6Disclosure of Regulatory Notices and Communications.  Reata hereby represents and warrants that, as of the Effective Date, all material regulatory communications and, if any, notices of inspection, inspection reports, warning letters and deficiency letters related to the Product made available by Reata in the Data Room, and to Reata’s knowledge, all such materials were true and complete copies of such documents. To the knowledge of Reata, such documents comprise all material written regulatory communications related to Product Trials design or the chemistry, manufacturing or controls of the Product from the FDA or the EMA in the possession of Reata as of the Effective Date.  

13.2.7CRO Inquiry.  Reata hereby represents and warrants that, up to and as at the Effective Date Reata has not received any written notice of the occurrence of any Serious Safety Issue in the Product Trials.  

54

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

13.2.8Reata Data Provided as of the Effective Date.  Reata hereby represents and warrants that, up to and as of the Effective Date, (i)the CMC Information set forth in the Data Room is accurate in all material respects, (ii) the descriptions of, Protocols for, and data and other results of, the Clinical Trials of the Product for the Core Indications conducted by or on behalf of Reata set forth in the Data Room are accurate and complete in all material respects and there are no material omissions from such documents, data and other results that render such documents, data or other results materially misleading and (iii)the summaries of primary data regarding the Product set forth in the Data Room are accurate and complete in all material respects, and there are no omissions from such summaries as so presented that render such summaries materially misleading.

13.2.9Compliance.  Reata represents and warrants that, prior to the Effective Date, (a) it has conducted all preclinical and clinical activities related to the development of the Product in material compliance with Applicable Laws, including GLP and GCP, and (b) to Reata’s knowledge, all Third Parties utilized by Reata to perform any portion of the preclinical and clinical activities have conducted such portion of such preclinical activities in material compliance with Applicable Laws.  

13.2.10Intellectual Property.  Reata hereby represents and warrants as of the date hereof as follows:

13.2.10.1Reata is the sole and exclusive owner or licensee of the Bardoxolone IP, free and clear of all Liens other than Permitted Liens.

13.2.10.2Reata has not received any written notice, contesting the registrability, scope, ownership, use, enforceability or validity of any of the Bardoxolone IP, excluding any notice received from Governmental Authorities in the normal course of Patent prosecution.

13.2.10.3To Reata’s knowledge, the Bardoxolone IP is not being infringed, misappropriated or otherwise violated by any Person in connection with the development or commercialization of any product that is, or is reasonably likely to be competitive with a Product.  

13.2.10.4To Reata’s knowledge the Development and Commercialization of the Product will not violate or infringe the Intellectual Property of any Third Party. Reata has not received any written notice of any claim by any Person or asserting that the development, manufacture, importation, sale, offer for sale or use of the Product infringes, misappropriates or otherwise violates or will infringe, misappropriate or otherwise violate such Person’s Patents or other intellectual property rights.

13.3Outstanding Indebtedness.  Reata hereby represents and warrants that, as at the Effective Date, Reata and its Subsidiaries have no indebtedness for borrowed money other than indebtedness under the Senior Loan Agreement.

55

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

13.4Disclosure. Reata has delivered or made available to BXLS true and complete copies of each agreement, data, contract or other document or information that has been requested by BXLS. All written information furnished by or on behalf of Seller or any of its Affiliates to Purchaser in connection with this Agreement or any transaction contemplated hereby are true and correct in all material respects on the date as of which such information is dated and does not contain any untrue statements of a material fact or omit any material fact necessary in order to make such information not misleading in light of the circumstances under which they were made. No representation or warranty of Reata contained in this Agreement contains any untrue statements of a material fact or omits any material fact necessary in order to make the statements contained herein not misleading in light of the circumstances under which they were made, including any information regarding any impact on the Development, Commercialization or supply chain of the Product resulting from the coronavirus identified as COVID-19.

13.5DISCLAIMER OF REPRESENTATIONS AND WARRANTIES.

13.5.1Each Party hereby agrees and understands that because the studies and Clinical Trials for the Product and the Product itself are experimental in nature, the outcome of the activities under this Agreement is inherently uncertain and unpredictable. Each Party hereby agrees and understands that the other Party makes no representation, guarantee or warranty, express or implied, regarding the outcome of any Clinical Trial for the Product, the ability to obtain Approval or the patentability, legal protectability or usefulness of any Reata Intellectual Property.

13.5.2EXCEPT AS OTHERWISE SET FORTH IN THIS ARTICLE 13, NEITHER PARTY MAKES, AND EACH PARTY EXPRESSLY DISCLAIMS, ANY REPRESENTATION OR WARRANTY OF ANY KIND WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT, EITHER ORAL OR WRITTEN, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, INCLUDING ANY REPRESENTATION OR WARRANTY REGARDING THE USE, RESULTS, SUCCESS OR APPROVAL, MARKET FOR OR EFFICACY OF THE PRODUCT.

Article 14

TERM AND TERMINATION

14.1Term.  The term of this Agreement (the “Term”) will commence on the Effective Date and will expire upon the earliest of (i) termination of this Agreement in accordance with Section 14.2 and (ii) the expiration of Reata’s obligations to make Product Payments hereunder.

14.2Termination.

14.2.1Termination for Breach.

14.2.1.1BXLS may terminate this Agreement in the event of a Fundamental Breach by Reata; provided that BXLS shall provide written notice to Reata of the alleged Fundamental Breach by Reata, specifying in reasonable detail the particulars of the alleged

56

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

Fundamental Breach by Reata, and such alleged Fundamental Breach by Reata has not been cured within [***] after the date of the relevant notice.

14.2.1.2Either Party may terminate this Agreement in the event of a material breach of this Agreement by the other Party other than a Fundamental Breach by Reata; provided that the breaching Party has received written notice from the non-breaching Party of such breach, specifying in reasonable detail the particulars of the alleged breach and such breach has not been cured within [***] after the date of the relevant notice. The non-breaching Party will have the right to pursue remedies it may have at law or equity, including the right to seek damages from the breaching Party.

14.2.2Termination for Failure to Receive Approval.  

14.2.2.1Prior to receipt of the Initial Approval, this Agreement will, upon written notice from either Party to the other Party, terminate with no further action from either Party in the event of Program Failure. For the avoidance of doubt, if Approval is received from either the FDA or the EMA, then this Agreement shall not be terminated pursuant to this Section 14.2.2.1.

14.2.2.2This Agreement will, upon written notice from either Party to the other Party, terminate with no further action from either Party upon the mutual agreement of Reata and BXLS that the Research Results do not support seeking Approval and that an application for Approval shall not be submitted to either the FDA or the EMA on such basis.  For avoidance of doubt, if an application for Approval is submitted to one, but not both, of FDA or the EMA, then this Agreement shall not be terminated pursuant to this Section 14.2.2.2.

14.2.3Termination for Bankruptcy.  BXLS may terminate this Agreement upon written notice to Reata (i) if Reata makes an assignment for the benefit of creditors, or commences a case or proceeding under any bankruptcy, reorganization, insolvency, or similar laws, or (ii) has a trustee or receiver or similar officer of any court appointed for Reata, or for substantial part of the property of Reata, or bankruptcy, reorganization, insolvency, or liquidation proceedings are instituted by or against Reata, in each case of (i) or (ii), without such proceedings being dismissed, for a period of at least [***].

14.2.4Termination for Safety Concerns.  This Agreement shall automatically terminate if (a) the independent data safety monitoring committee for the Product Trials recommends termination of any of the Product Trials for reasons pertaining to the health or safety of the Subjects or for futility, or (b) a Program Failure as set forth in clause (a), (d) or (e) of the definition of Program Failure occurs.

14.2.5Termination for Failure to Close. This Agreement may be terminated by Reata if the Closing or the Equity Closing shall not have occurred (other than by reason of the conditions set forth in Section 4.2.2 of this Agreement or 6.01 (b) of the Stock Purchase Agreement not having been satisfied or waived), in each case within ten (10) Business Days of the Effective Date.

57

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

14.2.6Termination by Mutual Agreement.  Notwithstanding anything herein to the contrary, this Agreement may be terminated at any time at or prior to the Closing Date by mutual agreement of the Parties.

14.3Effects of Termination.

14.3.1Termination for Breach.

14.3.1.1In the event that BXLS terminates this Agreement pursuant to Section 14.2.1.1 above prior to Approval, then Reata will pay BXLS, within [***] of the date of termination, a fully creditable amount equal to [***]% of the BXLS Development Payment, less Product Payments previously paid pursuant hereto.  Additionally, if Reata elects to continue development and obtains Approval following such termination, Reata will remain obligated to pay any Product Payments that become due and payable pursuant to pursuant to Article 6 at such time as such payments become due and payable (if ever), provided that any amounts paid by Reata to BXLS pursuant to this Section 14.3.1.1 shall be fully credited toward the future Product Payments.

14.3.1.2In the event that either Party terminates this Agreement pursuant to Section 14.2.1.2 above, then, if Reata elects to continue development and obtains Approval following such termination, Reata shall (subject to the immediately following sentence) remain obligated to pay to BXLS any Product Payments that become due and payable pursuant to pursuant to Section 6.1.1 and Section 6.1.2 (but not, for the avoidance of doubt, Section 6.1.3) at such time that such payments become due and payable (if ever) pursuant to such Sections.

14.3.2Termination for Failure to Achieve Approval.  In the event that this Agreement is terminated pursuant to Section 14.2.2 above, then, if Reata elects to continue development and obtains Approval following such termination, Reata shall remain obligated to make any Product Payments that become due and payable pursuant to Section 6.1.1 and Section 6.1.2 (but not, for the avoidance of doubt, Section 6.1.3) at such time that such payments become due and payable (if ever) pursuant to such Sections.

14.3.3Termination for Bankruptcy.  In the event BXLS terminates this Agreement pursuant to Section 14.2.3 above, then Reata will pay BXLS within [***] after the date of termination an amount equal to [***]% of BXLS Development Payment, less Product Payments previously paid pursuant hereto. Additionally, Reata will remain obligated to pay any Product Payments that become due and payable pursuant to Section 6.1.1 and Section 6.1.2 (but not, for the avoidance of doubt, Section 6.1.3) at such time that such payments become due and payable (if ever) pursuant to such Sections, provided that any amounts paid by Reata to BXLS pursuant to this Section 14.3.3 shall be fully credited toward the future Product Payments.

14.3.4Termination for Safety Concerns.  In the event that this Agreement terminates pursuant to Section 14.2.4 above prior to receipt of the Approval and such termination (i) arises as a result of gross negligence on the part of Reata, or (ii) is due to the applicable independent data monitoring committee recommending termination of the Product Trials or Reata and BXLS mutually agreeing to terminate the Product Trials, in either case due to a Serious Safety Issue that was previously known by Reata as being material as of the Effective Date and such

58

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

Serious Safety Issue was not included in the Data Room or otherwise disclosed in writing to BXLS by Reata prior to the Effective Date, then (A)Reata will pay BXLS a fully creditable amount equal to [***]% of BXLS Development Payment, less Cumulative Payments as of such time, within [***] of the date of termination, and (B)if Reata elects to continue Development and obtains Approval following such termination, Reata will remain obligated to pay any Product Payments that become due and payable pursuant to Article 6at such time as such Product Payments become due and payable (if ever) pursuant to Article 6, providedany amounts paid by Reata to BXLS pursuant to this Section 14.3.4shall be fully credited toward the future Product Payments.

14.3.5Accrued Rights and Obligations. Expiration or termination of this Agreement for any reason will not release either Party from any obligation or liability which, at the time of such expiration or termination, has already accrued to the other Party or which is attributable to a period prior to such expiration or termination.  Notwithstanding anything to the contrary in this Agreement (including without limitation any provisions in Article 7 or the definition of “BXLS Security Period”), any security interests in favor of BXLS on any BXLS Collateral that have not yet then terminated shall survive any termination with respect to any unpaid obligations under Section 6.1, Section 6.2, Section 6.6, Section 6.7 or this Section 14.3, in each case, that have accrued and are then payable.

14.3.6Not Exclusive Remedy. Notwithstanding anything herein to the contrary, termination of this Agreement by a Party will be without prejudice to other remedies such Party may have at law or equity.  

14.3.7Surviving Obligations.  Expiration or earlier termination of this Agreement will not relieve either Party of any obligation accruing prior to or upon such expiration or earlier termination, including that neither Party will be relieved of any payment obligation that may have accrued prior to such expiration or earlier termination. Further, other than in the case of a termination pursuant to Section 14.2.5, the following provisions of this Agreement, together with any other provisions that expressly specify that they survive, will survive expiration or earlier termination of this Agreement: Sections 6.1.1, 6.1.2, 6.1.3 (solely to                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 the extent specified in Section 14.3.1 or Section 14.3.4), 6.2, 6.3 (but only the first two sentences thereof) 6.4, 6.5, 6.7, 6.8, 6.9, 6.10 and 6.11 (in each case solely to the extent the obligation to make Product Payments survives pursuant to this Article 14), Sections 7.2, 7.3, and 7.6 (in each case solely to the extent a security interest in favor of BXLS on any BXLS Collateral survives pursuant to Section 14.3.5), Section 7.7, Sections 12.1 and 12.2, Article 1, Article 10, Article 11, Article 14 and Article 15.

14.3.8Termination for Failure to Close or by Mutual Agreement. In the event that this Agreement is terminated pursuant to Section 14.2.5 or 14.2.6 above, then, Reata shall not be obligated to make any payments to BXLS pursuant to Section 6 or otherwise, all security interest shall be terminated and released; provided that the following provisions of this Agreement, will survive expiration or earlier termination of this Agreement pursuant to Section 14.2.5, Section 7.7, Article 1, Article 10, Article 11, Article 14 and Article 15 (other than Section 15.6).

59

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

Article 15MISCELLANEOUS

15.1Relationship with Affiliates.  Each Party will be responsible for any breach by its Affiliates of such Party’s obligations in connection with this Agreement, and each such Party will remain responsible for any responsibilities that it has delegated to an Affiliate or Permitted Third Party as though such Party had performed (or failed to perform) such responsibilities itself.

15.2Prior Agreements.  The Parties agree on behalf of themselves and their respective Affiliates that any prior Confidentiality Agreement, by and between Reata and BXLS (the “Prior CDA”) is hereby terminated and superseded by this Agreement and that all Information disclosed under or pursuant to the Prior CDAs will constitute Confidential Information disclosed pursuant to this Agreement and will be subject to the terms of Article 10, with the confidentiality and non-use provisions of Article 10 applying retroactively to such Confidential Information from the date of disclosure.

15.3Notices.  Any notice or other communication required or permitted to be given by either Party under this Agreement will be in writing and will be effective when delivered if delivered by fax, e-mail, hand, reputable courier service, or five (5) days after mailing if mailed by registered or certified mail, postage prepaid and return receipt requested, addressed to the other Party at the following addresses or such other address as may be designated by notice pursuant to this Section:

15.3.1If to Reata:

Reata Pharmaceuticals, Inc.
5320 Legacy Drive
Plano, TX 75024
Attention: Chief Operating Officer
email:  manmeet.soni@reatapharma.com

with copies to:

Reata Pharmaceuticals, Inc.
5320 Legacy Drive
Plano, TX 75024
Attention:  Chief Legal Officer
email:  mike.wortley@reatapharma.com

Cooley LLP
101 California Street, 5th Floor
San Francisco, MA 94111-5800
Attention: Mischi a Marca
email: gmamarca@cooley.com

60

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

15.3.2If to BXLS:

BXLS V – River  L.P.
c/o Blackstone Life Sciences
101 Main Street
Suite 1210
Cambridge, MA 02142
Attention: [***]
email: [***]

with copies to:

Blackstone Life Sciences – Legal Department
101 Main Street
Suite 1210
Cambridge, MA 02142
Attention: [***]
email: [***]

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, CA 94304-1018
Attention:  Michael O’Donnell
email: MichaelODonnell@MoFo.com

15.4Force Majeure.  Neither Party will be liable for any breach or delay in performance of any obligation under this Agreement to the extent caused by a Force Majeure Event. The Party invoking this Section 15.4 must provide prompt written notice and full particulars of such event to the other Party and will use diligent and commercially reasonable efforts to mitigate the effects of any such force majeure event on such Party’s compliance with and performance under this Agreement.

15.5Use of Names.  Neither Party will use the other Party’s nor any of its Affiliates’ (including the limited partners of BXLS or Blackstone) names or trademarks (including, with respect to Blackstone, any reference to “Blackstone” or “The Blackstone Group”) in any promotional materials, advertising, marketing, endorsement, promotional or sales literature, publicity, public announcement or disclosure in any document employed to obtain funds or financing without the prior written consent of the other Party except as otherwise expressly permitted in this Agreement. Notwithstanding the foregoing, BXLS and Blackstone may use the name, logos, and other insignia of Reata in any “tombstone” or other advertisements, in its publications, marketing or promotional materials to existing and prospective investors and otherwise on the website or in other marketing materials of BXLS and/or Blackstone, as applicable, without Reata’s prior approval.

15.6Assignment.  Without the prior written consent of the other Party hereto, neither Party will sell, transfer, assign, pledge or otherwise dispose of, whether voluntarily, involuntarily,

61

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

by operation of law or otherwise, this Agreement or any of its rights or duties hereunder; provided, however, that either Party may assign, sublicense or transfer this Agreement and all of its rights and obligations hereunder, in their entirety, to any of its Affiliates or to a successor in connection with the sale or other transfer of all or substantially all of its assets to which this Agreement relates or in the event of its merger, consolidation, Change of Control (other than as set forth in clause (b) of its definition) or other similar transaction. Notwithstanding the foregoing, any assignment of the rights or obligations under this Agreement by Reata (i) to an Affiliate shall require Reata to guarantee the performance of such Affiliate’s financial and performance obligations hereunder or (ii) in connection with a sale of assets, merger, consolidation, or Change of Control (other than other than as set forth in clause (b) of its definition) of Reata without the consent of BXLS, such consent not to be unreasonably withheld, delayed or conditioned, shall require (x) the ultimate Affiliate controlling the other party in such transaction to guarantee Reata’s financial and performance obligations under this Agreement and (y) Reata to remain liable for such financial and performance obligations notwithstanding such sale of assets, merger, consolidation, or Change in Control. Furthermore, notwithstanding any of the foregoing, on or after the Closing Date BXLS may (a) assign its right to receive Product Payments to (i) the limited partners of BXLS, provided that such limited partners agree that a majority in interest shall be entitled to take all actions and make any consents on behalf of BXLS hereunder and provided that such limited partners notify Reata of a single account to which Reata can make all payments that may become due hereunder and assume sole responsibility for distributing all such payments, or to a liquidating trust or similar entity that is established to receive and distribute Product Payments for the benefit of the limited partners of BXLS, that is required to carry out such responsibilities as a single entity, and provided that such limited partners or liquidating trust takes such rights to receive and distribute Product Payments subject to all of Reata’s rights and defenses hereunder (and in any case under this clause (i) Reata shall have the unconditional right to follow any instruction it receives or rely on any actions, consents and communications received from or taken by such limited partners or liquidating trust or similar entity without any duty to verify or otherwise determine the validity thereof) or (ii) an other Third Party to which BXLS assigns this Agreement in its entirety as set forth above, or assigns its right to receive Product Payments, in each case as provided in, and subject to, Section 6.3provided that, following any assignment by BXLS to a Third Party pursuant to the foregoing clause (ii) the AC shall terminate, such assignee shall not have any further rights under Article 5 and such assignee shall not have any further rights to approve or consent (and Reata shall not have any further obligation to seek BXLS’s approval or consent) as to any matter relating to Reata’s Development and Commercialization of the Product and, provided that such assignment complied with the terms of Section 6.3, Section 6.5 shall not apply to such Third Party, and (b) assign its right to receive up to [***] of the Product Payments to an Affiliate provided that BXLS shall retain the sole right to take all actions and make any consents on behalf of BXLS hereunder and that all Product Payments made to such Affiliate shall be deemed to be made to BXLS for all purposes of this Agreement. This Agreement is binding upon and will inure to the benefit of each of the Parties, its successors and permitted assigns.

15.7Further Assurances.  The Parties will execute such further reasonable documents and perform such further reasonable acts as may be necessary to comply with or more fully effectuate the terms of this Agreement.

62

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

15.8Fees and Expenses.  Reata will be responsible for paying the reasonable legal and administrative expenses of BXLS on the Closing Date and reimbursing BXLS for the same, including reasonable fees and expenses incurred by BXLS in connection with the preparation and negotiation of transaction documents for the diligence investigation, and legal counsel to BXLS. In addition, Reata shall pay all expenses associated with, and have all rights to, the commercial/revenue assessment conducted by an outside consultancy (e.g.,[***]) engaged by BXLS prior to the date hereof. Notwithstanding the foregoing,Reata’s obligation to reimburse and pay any reasonable legal fees, administrative expenses and other amounts pursuant to this Section 15.8 shall not exceed an aggregate amount of $[***].

15.9Governing Law.  The construction and validity of this Agreement and the provisions hereof, and the rights and obligations of the Parties hereunder, will be governed by the internal laws of the State of New York, and, to the extent applicable to Patents and Trademarks, the applicable federal laws of the USA, in each instance without regard to conflict of laws principles.

15.10Dispute Resolution. The Parties recognize that disputes as to certain matters arising out of and relating to this Agreement may arise from time to time. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes in an expedient manner by mutual cooperation and without resort to litigation. Accordingly, the Parties agree that any dispute, controversy or claim arising under, out of, relating to or in connection with this Agreement, including any subsequent amendments, or the formation, applicability, validity, enforceability, construction, performance, breach or termination hereof (and including the scope and applicability of this Section 15.10 to any such dispute, controversy or claim) (each a “Dispute”) shall be resolved by the Parties as follows:

15.10.1Prior to commencing an arbitration, a Party shall first refer such Dispute to the Executive Officers for attempted resolution by good faith negotiations during a period of [***] running from the date the notice of Dispute is received. Any final decision mutually agreed to by the Executive Officers in writing shall be conclusive and binding on the Parties. With respect to any Dispute that is not resolved after the [***] period expires, then such Dispute shall be submitted to the American Arbitration Association (“AAA”) for final and binding arbitration pursuant as set forth in Section 15.10.2 in accordance with its Commercial Arbitration Rules then in force. Notwithstanding the foregoing, disputes relating to the ownership of any intellectual property by the Parties in connection with their activities under this Agreement, if any, including disputes relating to the validity or enforceability thereof, shall be resolved by a US federal court of appropriate jurisdiction and not through arbitration.  Any question about whether a dispute is arbitrable shall be decided by the arbitrators. Notwithstanding anything in this Agreement to the contrary, either Party shall be entitled to seek preliminary injunctive relief in any court of competent jurisdiction immediately if necessary to prevent irreparable harm to that Party.  

15.10.2Arbitration Process.

15.10.2.1Either Party shall have the right to initiate arbitration at any time after the expiration of [***] after receipt of the notice of Dispute as set forth in Section 15.10.1 by filing a written demand for arbitration. Any disputes concerning whether a dispute is arbitrable,

63

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

or whether any conditions precedent to commencing arbitration have been fulfilled or the thirty-day period has expired, shall be finally settled by the arbitral panel. Notwithstanding the foregoing, any dispute between the Parties as to whether entering into a Licensing Transaction would have a Material Impact shall be resolved as set forth in Section 15.10.

15.10.2.2The seat, or legal place of arbitration, shall be New York City, New York, and the language of the proceedings shall be English. The arbitration shall be before three (3) arbitrators.  Within [***] after the commencement of the arbitration, each Party shall select one arbitrator and the two (2) Party-selected arbitrators shall select the third, who shall serve as the panel’s chair or president, within [***] after the second arbitrator’s appointment. Any arbitrator(s) not timely selected shall by selected by the American Arbitration Association. All three (3) arbitrators shall be professionals with substantial experience in development and Commercialization of biopharmaceutical products. An arbitrator shall be deemed to meet these qualifications unless a Party objects within [***] after the arbitrator is selected.  The Parties acknowledge that this Agreement evidence a transaction involving interstate commerce.  Notwithstanding the provision in Section 15.9 with respect to the applicable substantive law, any arbitration conducted under this Agreement shall be governed by the Federal Arbitration Act, 9 U.S.C. §§ 1-16.  

15.10.2.3Consistent with the expedited nature of arbitration, each Party will, upon the written request of the other Party, [***] of the preliminary hearing or such other date as established at the preliminary hearing, provide the other with copies of documents on which the producing Party intends to rely in support of or in opposition to any claim or defense. At the request of a Party, the arbitrators shall have the discretion to order examination by deposition if the arbitrators deem such additional discovery relevant and appropriate. Depositions shall be limited to a maximum of [***] per Party. Each deposition shall be limited to seven hours on the record. The arbitrators shall also have the discretion to allow requests for production of documents, upon a showing of good cause.  No other discovery shall be allowed. Any Dispute regarding discovery, or the relevance or scope thereof, shall be determined by the arbitrators, which determination shall be conclusive. All discovery shall be completed within [***] following the appointment of the arbitrators. All costs and/or fees relating to the retrieval, review and production of electronic discovery shall be paid by the Party requesting such discovery.

15.10.2.4The arbitrators will have no authority to award punitive or other damages not measured by the prevailing Party’s actual damages. Each Party expressly waives and foregoes any right to consequential, punitive, special, exemplary or similar damages or lost profits. The arbitrators shall have no power or authority, under the AAA Commercial Arbitration Rules and procedures or otherwise, to relieve the Parties from their agreement hereunder to arbitrate or otherwise to amend or disregard any provision of this Agreement. The arbitrators shall award to the prevailing party of all of its reasonable arbitration costs and fees.  Costs and fees mean all reasonable pre-award expenses of the arbitration, including the arbitrators’ fees, administrative fees, out-of-pocket expenses, witness fees and attorneys’ fees.

15.10.2.5The arbitrators shall render a reasoned award.  If an arbitral award does not impose an injunction on the losing Party or contain a money damages award in excess of [***] dollars USD ($[***]), then the arbitral award shall be final and binding and the

64

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

Parties undertake to carry out any award without delay.  Judgment on that award may be entered in any court of competent jurisdiction.In the event that the arbitration does result in an arbitral award that imposes an injunction or a monetary award in excess of [***] dollars USD ($[***]), the Parties agree that such award may be appealed pursuant to the AAA’s Optional Appellate Arbitration Rules (“Appellate Rules”) and shall not be considered final until after the time for filing the notice of appeal pursuant to the Appellate Rules has expired.  Appeals must be initiated within [***] of receipt of the award by filing a Notice of Appeal with any AAA office.  Following the appeal process, the decision rendered by the appeal tribunal may be entered in any court of competent jurisdiction.  

15.10.2.6Except as may be required by law, to protect or pursue a legal right, or enforce or challenge an award in bona fide legal proceedings before a state court or other judicial authority, neither a Party nor an arbitrator may disclose the existence, contents, or any rulings or awards of any arbitration hereunder without the prior written consent of both Parties except to the extent necessary for the preparation or presentation of a claim or defense in the arbitration, where such information is already in the public domain other than as a result of a breach of this clause, or by order of the arbitrators upon application of a Party.

15.11Limitation of Liability.  TO THE MAXIMUM EXTENT PERMITTED BY LAW AND NOTWITHSTANDING ANY PROVISION IN THIS AGREEMENT TO THE CONTRARY, NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, RELIANCE OR PUNITIVE DAMAGES OR LOST OR IMPUTED PROFITS OR ROYALTIES OR COST OF PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES, WHETHER LIABILITY IS ASSERTED IN CONTRACT, TORT (INCLUDING NEGLIGENCE AND STRICT PRODUCTS LIABILITY), INDEMNITY OR CONTRIBUTION, AND IRRESPECTIVE OF WHETHER THAT PARTY OR ANY REPRESENTATIVE OF THAT PARTY HAS BEEN ADVISED OF, OR OTHERWISE MIGHT HAVE ANTICIPATED THE POSSIBILITY OF, ANY SUCH LOSS OR DAMAGE. THE PARTIES AGREE THAT THE LIMITATIONS SPECIFIED IN THIS SECTION WILL APPLY EVEN IF ANY LIMITED REMEDY SPECIFIED IN THIS AGREEMENT IS FOUND TO HAVE FAILED OF ITS ESSENTIAL PURPOSE. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, “CONSEQUENTIAL DAMAGES” WILL BE DEEMED TO INCLUDE, AND NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY OR ANY OF SUCH OTHER PARTY’S AFFILIATES, REPRESENTATIVES OR STOCKHOLDERS FOR ANY DAMAGES BASED ON OR MEASURED BY LOSS OF PROJECTED OR SPECULATIVE FUTURE SALES OF THE PRODUCT, ANY PAYMENT DUE UPON ANY UNACHIEVED EVENT UNDER ARTICLE 6, OR ANY OTHER UNEARNED, SPECULATIVE OR OTHERWISE CONTINGENT PAYMENTS PROVIDED FOR IN THIS AGREEMENT. FOR THE AVOIDANCE OF DOUBT, THIS SECTION 15.11 IS NOT MEANT TO LIMIT REATA’S OBLIGATION TO PAY BXLS THE AMOUNTS SET FORTH IN ARTICLE 6 OR SECTION 14.3.

15.12Cumulative Remedies.  Unless expressly set forth in this Agreement, all rights and remedies of the Parties, including all rights to payment, rights of termination, rights to injunctive relief, and other rights provided under this Agreement, will be cumulative and in addition to all other remedies provided for in this Agreement, in law, and in equity.

65

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

15.13Relationship of the Parties.

15.13.1Relationship of the Parties.  Nothing contained herein will be deemed to create a partnership, joint venture, or similar relationship between the Parties, including for any applicable Tax purposes.  Neither Party is the agent, employee, joint venturer, partner, franchisee, or representative of the other Party. Each Party specifically acknowledges that it does not have the authority to, and will not, incur any obligations or responsibilities on behalf of the other Party.  Notwithstanding anything to the contrary in this Agreement, each Party (and its officers, directors, agents, employees, and members) will not hold themselves out as employees, agents, representatives, or franchisees of the other Party or enter into any agreements on such Party’s behalf.

15.13.2Direction.  Neither Party will be subject to the supervisory direction of the other Party in regard to the conduct of the Product Trials.

15.14No Third Party Beneficiaries.  This Agreement and the provisions herein are for the benefit of the Parties only, and are not intended to confer any rights or benefits to any Third Party.

15.15Rights Reserved.  No license or any other right is granted to either Party, by implication or otherwise, except as specifically set forth in this Agreement. All rights not exclusively granted to BXLS are reserved to Reata and its Affiliates. Notwithstanding any other provision of this Agreement to the contrary, and for clarity, no Intellectual Property or other proprietary rights Controlled by Reata or its Affiliates will be assigned or licensed to BXLS in connection with this Agreement.  

15.16Amendments; No Waiver.  Unless otherwise specified herein, no amendment, supplement, or modification of this Agreement will be binding on either Party unless it is in writing and signed by both Parties. No delay or failure on the part of a Party in the exercise of any right under this Agreement or available at law or equity will be construed as a waiver of such right, nor will any single or partial exercise thereof preclude any other exercise thereof. All waivers must be in writing and signed by the Party against whom the waiver is to be effective. Any such waiver will constitute a waiver only with respect to the specific matter described in such writing and will in no way impair the rights of the Party granting such waiver in any other respect or at any other time.

15.17Severability.  If any provision (or portion thereof) of this Agreement is determined by a court or arbitration to be unenforceable as drafted by virtue of the scope, duration, extent, or character of any obligation contained herein, it is the Parties’ intention that such provision (or portion thereof) will be construed in a manner designed to effectuate the purposes of such provision to the maximum extent enforceable under such Applicable Law. The Parties will enter into whatever amendment to this Agreement as may be necessary to effectuate such purposes.

15.18Entire Agreement.  This Agreement, including all Exhibits hereto, contains the entire understanding of the Parties and supersedes, revokes, terminates, and cancels any and all other arrangements, understandings, agreements, term sheets, or representations and warranties, whether oral or written, between the Parties relating to the subject matter of this Agreement.

66

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

15.19Counterparts.  This Agreement will be executed in two(2) counterparts, one(1) for either Party, which, taken together, will constitute one and the same agreement. This Agreement will not be binding on the Parties or otherwise effective unless and until executed by both Parties.

15.20Construction.  This Agreement has been negotiated by the Parties and their respective counsel. This Agreement will not be construed in favor of or against either Party by reason of the authorship of any provisions hereof.

[Signature Page Follows]

67

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

IN WITNESS WHEREOF, the Parties, intending to be legally bound hereby, have caused this Agreement to be executed in duplicate by their duly authorized representatives as of the Effective Date.

REATA PHARMACEUTICALS, INC.

By: /s/ Manmeet S. Soni

Name: Manmeet S. Soni

Title: Chief Financial Officer, Chief Financial Officer and Executive Vice President

Signature Page to the Development Funding Agreement

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

IN WITNESS WHEREOF, the Parties, intending to be legally bound hereby, have caused this Agreement to be executed in duplicate by their duly authorized representatives as of the Effective Date.

BXLS V – River L.P.

By: Blackstone Life Sciences Advisors L.L.C. on behalf of BXLS V – River L.P.

By: /s/ Robert Liptak

Name: Robert Liptak

Title: Authorized Person

Signature Page to the Development Funding Agreement

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

EXHIBIT AND SCHEDULE LIST

Exhibit A:Product Description

Exhibit B:Clinical Study Plan

Exhibit C: Commercialization Plans

Exhibit D:Executive Officers

Exhibit E:“Top [***]” Pharmaceutical Companies

Exhibit F:Form of Stock Purchase Agreement

Exhibit G:Safety Exclusion Criteria

Schedule 7.6.1.1(b):Collateral Accounts

Signature Page to the Development Funding Agreement

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

Exhibit A

Product Description

Omitted pursuant to Item 601(a)(5) of Regulation S-K.

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

Exhibit B

Clinical Study Plan

Omitted pursuant to Item 601(a)(5) of Regulation S-K.

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

Exhibit C

Commercialization Plans

Omitted pursuant to Item 601(a)(5) of Regulation S-K.

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

Exhibit D

Executive Officers

Omitted pursuant to Item 601(a)(5) of Regulation S-K.

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

Exhibit E

“Top [***]” Pharmaceutical Companies

Omitted pursuant to Item 601(a)(5) of Regulation S-K.

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

Exhibit F

Form of Stock Purchase Agreement

Omitted pursuant to Item 601(a)(5) of Regulation S-K.

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

Exhibit G

Safety Exclusion Criteria

Omitted pursuant to Item 601(a)(5) of Regulation S-K.

Specific terms in this Exhibit have been redacted because such terms are both not material and would likely cause competitive harm to the Company if publicly disclosed. These redacted terms have been marked in this Exhibit with three asterisks [***].

Schedule 7.6.1.1(b)

Collateral Accounts

Omitted pursuant to Item 601(a)(5) of Regulation S-K.

EX-10.4

Exhibit 10.4

REATA PHARMACEUTICALS, INC.

FOURTH AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY

Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Reata Pharmaceuticals, Inc. (“Reata”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Fourth Amended and Restated Non-Employee Director Compensation Policy (the “Policy”) for his or her Board service or service on a committee of the Board (“Committee”). This Policy is effective as of June 10, 2020 (the “Effective Date”) and may be amended at any time in the sole discretion of the Board or the Compensation Committee of the Board.

Annual Cash Compensation

The annual cash compensation amount set forth below is payable in equal quarterly installments, payable after each regular quarterly Board meeting, beginning with the Board meeting held on September 18, 2019 (collectively, the “Annual Cash Fees”). All Annual Cash Fees are vested upon payment.

1. Annual Board Service Retainer:

a. All Eligible Directors: $40,000

b. Lead Independent Director Service Retainer (in addition to Annual Board Service Retainer): $20,000

2. Annual Committee Member Service Retainer:

a. Member of the Audit Committee: $10,000

b. Member of the Compensation Committee: $6,375

c. Member of the Nominating and Corporate Governance Committee: $5,000

3. Annual Committee Chair Service Retainer (in addition to Annual Committee Member Service Retainer):

a. Chairman of the Audit Committee: $25,000

b. Chairman of the Compensation Committee: $7,125

c. Chairman of the Nominating and Corporate Governance Committee: $5,000

Beginning with the second regular Board meeting held after the 2020 annual stockholder meeting, the Annual Cash Fees shall be as follows:

      1.   Annual Board Service Retainer:

a. All Eligible Directors: $45,000

b. Lead Independent Director Service Retainer (in addition to Annual Board Service    Retainer): $25,000

Exhibit 10.4

2. Annual Committee Member Service Retainer:

a. Member of the Audit Committee: $10,000

b. Member of the Compensation Committee: $7,500

c. Member of the Nominating and Corporate Governance Committee: $5,000

3. Annual Committee Chair Service Retainer (in addition to Annual Committee Member Service Retainer):

d. Chairman of the Audit Committee: $25,000

e. Chairman of the Compensation Committee: $7,500

f. Chairman of the Nominating and Corporate Governance Committee: $5,000

Equity Compensation

The equity compensation set forth below will be granted under the Reata’s Second Amended and Restated Long Term Incentive Plan (the “Plan”). All stock options granted under this Policy will be nonstatutory stock options to purchase shares of Class A common stock of Reata (“Common Stock”), with (a) an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the underlying Common Stock on the date of grant, which shall be the closing price on the date of grant (or, if not a business day, the first business day thereafter) of a share of Reata’s Class A common stock on the Nasdaq Global Market, and (b) a term of ten years from the date of grant. The other terms and provisions of the stock options, including vesting on termination of service, Disability (as defined in the form stock option agreement), death and Change in Control (as defined in the Plan) will be in conformity with the Plan and the form of stock option agreement and notice of grant previously approved by the Board for members of the Board, as the Plan or any such form may be amended from time to time. The terms and provisions of the stock options as set forth in this paragraph are referred to herein as the “Terms”.

1. Initial Grant: On the date of the Eligible Director’s initial election or appointment to the Board (or, if such date is not a market trading day, the first market trading day thereafter), the Eligible Director will automatically, and without further action by the Board or Compensation Committee of the Board, be granted a stock option to purchase 10,000 shares of Common Stock (the “Initial Grant”). The stock option constituting each Initial Grant will vest in equal annual installments over a three-year period so that the Initial Grant will become fully vested on the third anniversary of the date of grant, subject to the Terms.

2. Annual Grant: On the date of the first regular Board meeting held after each Reata annual stockholder meeting, for each Eligible Director who continues to serve as a non-employee member of the Board (or who is first elected to the Board at such annual stockholder meeting), the Eligible Director will automatically, and without further action by the Board or Compensation Committee of the Board, be granted a stock option to purchase 6,300 shares of Common Stock (the “Annual Grant”). In addition, each Eligible Director who is first elected or appointed to the Board other than at the first

Exhibit 10.4

regular Board meeting held after a Reata annual stockholder meeting will automatically, and without further action by the Board or Compensation Committee of the Board, be granted an Annual Grant on the date of the Eligible Director’s initial election or appointment to the Board, prorated by multiplying 6,300 by a fraction (1) the numerator of which is the number of subsequent regular Board meetings remaining until (and including) the first regular Board meeting held after Reata’s next annual stockholder meeting and (2) the denominator of which is four. Subject to the Terms, the stock options constituting the Annual Grant will vest in the number of equal quarterly installments that is the number of regular quarterly Board meetings scheduled to be held following the date of grant to and including Reata’s regular Board meeting scheduled to be held after Reata’s next annual stockholder meeting following the date of grant. An example of the above proration procedures follows: if an Eligible Director is appointed to the Board on January 5, 2020, then the Eligible Director would receive an Annual Grant of 3,150 shares on January 5, 2020,  which Annual Grant would vest 50% on April 5, 2020, and 50% on July 5, 2020, subject to the Terms;  the new Eligible Director and all other Eligible Directors would receive an Annual Grant of 6,300 shares on the date of the June regular Board meeting (held after the June annual stockholder meeting) following the January date of grant, which would vest in four equal quarterly installments, subject to the Terms.

    Election to Receive Stock Options in Lieu of Cash Compensation

An Eligible Director may elect to receive a grant of stock options pursuant to the Equity Compensation provisions of this Policy in lieu of receiving future cash compensation payments, or any portion thereof, of the Annual Board Service Retainer, the Lead Independent Director Service Retainer, the Annual Committee Member Service Retainer, and/or the Annual Committee Chair Service Retainer (the “Election Grant”). This election to receive an Election Grant may be made by an Eligible Director  on the date of Reata’s first regular Board meeting held after an annual stockholder meeting by submitting an executed election form (the “Election Form”) to Reata’s chief legal counsel in the form and pursuant to procedures established by the Company.  The stock options granted pursuant to an Election Grant will be granted on the day of Reata’s first regular Board meeting held after each annual stockholder meeting, will have a Black-Scholes value equal to the annual amount of the applicable Retainer, and will otherwise be subject to the Terms. In addition, each Eligible Director serving as of the Effective Date, and each Eligible Director who is first elected or appointed to the Board following the Effective Date and not at an annual stockholder meeting, may execute an Election Form on a date other than the date of Reata’s first regular Board meeting held after an annual stockholder meeting, in which case, in addition to receiving a grant of stock options pursuant to an Election Grant on the day of Reata’s first regular Board meeting held after each annual stockholder meeting, such Eligible Director will also be granted on the date of execution of the Election Form a prorated Election Grant with a Black-Scholes value equal to the Black-Scholes value of the applicable Retainer multiplied by a fraction (1) the numerator of which is the number of subsequent regular Board meetings that will be held after the date of grant to, and including, the first regular Board meeting held after Reata’s next annual stockholder meeting, and (2) the denominator of which is 4, and will otherwise be subject to the Terms. The stock options constituting Election Grants will vest in the number of equal quarterly installments that is the number of regular quarterly Board

Exhibit 10.4

meetings scheduled to be held following the date of grant to and including Reata’s regular Board meeting scheduled to be held after Reata’s next annual stockholder meeting following the date of grant, subject to the Terms. Any election to receive an Election Grant will be irrevocable until the third anniversary of such election. Once an Election Form has been executed and delivered to Reata, no additional Election Form is required to be executed, unless (1) an Eligible Director has revoked an election to receive an Election Grant and thereafter determines to again receive an Election Grant or (2) an Eligible Director becomes entitled to receive a Retainer which the Eligible Director was not entitled to receive at the time of the execution of an Election Form. If the amount of any Retainer is changed, no additional Election Form is required to be executed if it included an election as to that type of Retainer.

Fractions

Stock options granted pursuant to an Election Grant shall be for a number of whole shares of Common Stock. Any fractional share of Common Stock shall be rounded down to the nearest whole share of Common Stock. Fractions of shares of Common Stock subject to a stock option shall not vest on a vesting date of an Initial Grant, an Annual Grant, an Interim Annual Grant, or an Election Grant, and the shares of Common Stock that do vest on a vesting date shall be rounded down to the nearest whole share of Common Stock; provided, however, that such fractions of shares of Common Stock shall be added to the number of shares of Common Stock that vest on the final vesting date or that otherwise vest due to the vesting acceleration (with any resulting fraction of a share of Common Stock being rounded down to the nearest whole share of Common Stock).

Waiver

An Eligible Director may, at any time and from time to time, waive receipt of any or all cash or equity compensation payable to such Eligible Director pursuant to the Policy (a “Waiver”). After a Waiver, the Eligible Director may, at any time and from time to time, withdraw the Waiver and begin receiving future cash and equity compensation pursuant to the Policy. Any Waiver or withdrawal of a Waiver shall be made by providing written notice to an officer of Reata.

Equity Value Cap

The number of stock options that would otherwise be granted pursuant to an Initial Grant, an Annual Grant, an Interim Grant, or an Election Grant shall be reduced, including if necessary to zero, in order to comply with Section 5 of the Plan (such number of stock options not granted pursuant to this sentence being referred to as the “Reduced Options”). If two or more types of grants would otherwise be made simultaneously pursuant to the provisions of the Policy and the number of stock options permitted to be granted must be reduced in order to comply with Section 5 of the Plan, then, in order to allocate the Reduced Options to the applicable grant, an Interim Grant, an Annual Grant, and an Election Grant will be reduced, in that order, before an Initial Grant is reduced; and an Annual Grant will be reduced before an Election Grant is reduced.

Prior Policies

Exhibit 10.4

Cash payments and equity grants made pursuant to the terms and provisions of any prior version of this Policy shall be governed by the terms and provisions of such prior version of this Policy.

EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, J. Warren Huff, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Reata Pharmaceuticals, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 10, 2020	By:	/s/ J. Warren Huff
		J. Warren Huff
		Chief Executive Officer
		(Principal Executive Officer)

EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Manmeet S. Soni, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Reata Pharmaceuticals, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 10, 2020	By:	/s/ Manmeet S. Soni
		Manmeet S. Soni
		Chief Operating Officer, Chief Financial Officer, and Executive Vice President
		(Principal Financial Officer)

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Reata Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, J. Warren Huff, as Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: August 10, 2020	By:	/s/ J. Warren Huff
		J. Warren Huff
		Chief Executive Officer
		(Principal Executive Officer)

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Reata Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Manmeet S. Soni, as Chief Operating Officer, Chief Financial Officer and Executive Vice President of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: August 10, 2020	By:	/s/ Manmeet S. Soni
		Manmeet S. Soni
		Chief Operating Officer, Chief Financial Officer, and Executive Vice President
		(Principal Financial Officer)

XML

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 05, 2020
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Trading Symbol	RETA
Entity Registrant Name	Reata Pharmaceuticals, Inc.
Entity Central Index Key	0001358762
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity File Number	001-37785
Entity Tax Identification Number	11-3651945
Entity Address, Address Line One	5320 Legacy Drive
Entity Address, City or Town	Plano
Entity Address, State or Province	TX
Entity Address Postal Zip Code	75024
City Area Code	972
Local Phone Number	865-2219
Document Quarterly Report	true
Document Transition Report	false
Title of 12(b) Security	Class A Common Stock, Par Value $0.001 Per Share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	DE
Common Stock A
Document Information [Line Items]
Entity Common Stock Shares Outstanding		28,559,247
Common Stock B
Document Information [Line Items]
Entity Common Stock Shares Outstanding		5,045,092

XML

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Assets
Cash and cash equivalents	$ 610,419	$ 664,324
Prepaid expenses and other current assets	7,830	4,952
Income tax receivable	22,218	0
Total current assets	640,467	669,276
Property and equipment, net	4,267	2,996
Other assets	7,670	10,148
Total assets	652,404	682,420
Liabilities and stockholders’ equity
Accounts payable	11,263	1,908
Accrued direct research liabilities	16,689	23,774
Other current liabilities	14,545	11,631
Current portion of payable to collaborators	0	150,000
Current portion of deferred revenue	4,688	4,701
Total current liabilities	47,185	192,014
Other long-term liabilities	6,940	6,982
Term loan, net of debt issuance costs	0	155,017
Liability related to sale of future royalties, net	294,234	0
Payable to collaborators, net of current portion	70,055	66,862
Deferred revenue, net of current portion	2,363	4,688
Total noncurrent liabilities	373,592	233,549
Commitments and contingencies
Stockholders’ equity:
Additional paid-in capital	1,058,606	967,317
Accumulated deficit	(827,013)	(710,493)
Total stockholders’ equity	231,627	256,857
Total liabilities and stockholders’ equity	652,404	682,420
Common Stock A
Stockholders’ equity:
Common stock value	29	28
Total stockholders’ equity	29	28
Common Stock B
Stockholders’ equity:
Common stock value	5	5
Total stockholders’ equity	$ 5	$ 5

XML

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Common Stock A
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	28,526,532	27,878,550
Common stock, shares outstanding	28,526,532	27,878,550
Common Stock B
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	5,058,319	5,318,157
Common stock, shares outstanding	5,058,319	5,318,157

XML

Unaudited Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Collaboration revenue
Collaboration revenue	$ 3,073	$ 7,833	$ 4,426	$ 15,603
Expenses
Research and development	36,783	29,554	84,436	55,668
General and administrative	16,600	11,706	37,387	21,744
Depreciation	284	232	562	401
Total expenses	53,667	41,492	122,385	77,813
Other income (expense), net	(16,990)	(701)	(20,804)	(1,301)
Loss before taxes on income	(67,584)	(34,360)	(138,763)	(63,511)
(Benefit from) provision for taxes on income	(3)	20	(22,243)	23
Net loss	$ (67,581)	$ (34,380)	$ (116,520)	$ (63,534)
Net loss per share—basic and diluted	$ (2.03)	$ (1.14)	$ (3.51)	$ (2.12)
Weighted-average number of common shares used in net loss per share basic and diluted	33,265,778	30,069,048	33,243,931	29,950,241
License and milestone
Collaboration revenue
Collaboration revenue	$ 1,169	$ 7,813	$ 2,338	$ 15,539
Other revenue
Collaboration revenue
Collaboration revenue	$ 1,904	$ 20	$ 2,088	$ 64

XML

Unaudited Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock A	Common Stock B	Additional Paid-In Capital	Total Accumulated Deficit
Balance, value at Dec. 31, 2018	$ 15,159	$ 24	$ 6	$ 435,452	$ (420,323)
Balance, shares at Dec. 31, 2018		24,000,683	5,728,175
Net loss	(63,534)				(63,534)
Compensation expense related to stock options	8,710			8,710
Exercise of options, value	6,085			6,085
Exercise of options, shares			369,076
Conversion of common stock Class B to Class A, shares		465,724	(465,724)
Other shareholder transactions	107			107
Balance, value at Jun. 30, 2019	(33,473)	$ 24	$ 6	450,354	(483,857)
Balance, shares at Jun. 30, 2019		24,466,407	5,631,527
Balance, value at Mar. 31, 2019	(4,610)	$ 24	$ 6	444,837	(449,477)
Balance, shares at Mar. 31, 2019		24,403,477	5,639,666
Net loss	(34,380)				(34,380)
Compensation expense related to stock options	4,483			4,483
Exercise of options, value	1,034			1,034
Exercise of options, shares			54,791
Conversion of common stock Class B to Class A, shares		62,930	(62,930)
Balance, value at Jun. 30, 2019	(33,473)	$ 24	$ 6	450,354	(483,857)
Balance, shares at Jun. 30, 2019		24,466,407	5,631,527
Balance, value at Dec. 31, 2019	256,857	$ 28	$ 5	967,317	(710,493)
Balance, shares at Dec. 31, 2019		27,878,550	5,318,157
Net loss	(116,520)				(116,520)
Compensation expense related to stock options	34,104			34,104
Exercise of options, value	$ 1,786			1,786
Exercise of options, shares	47,351		47,351
Conversion of common stock Class B to Class A, shares		307,189	(307,189)
Issuance of Common Stock, value	$ 55,400	$ 1		55,399
Issuance of Common Stock, shares		340,793
Balance, value at Jun. 30, 2020	231,627	$ 29	$ 5	1,058,606	(827,013)
Balance, shares at Jun. 30, 2020		28,526,532	5,058,319
Balance, value at Mar. 31, 2020	228,647	$ 28	$ 5	988,046	(759,432)
Balance, shares at Mar. 31, 2020		28,166,652	5,070,271
Net loss	(67,581)				(67,581)
Compensation expense related to stock options	14,796			14,796
Exercise of options, value	365			365
Exercise of options, shares			7,135
Conversion of common stock Class B to Class A, shares		19,087	(19,087)
Issuance of Common Stock, value	55,400	$ 1		55,399
Issuance of Common Stock, shares		340,793
Balance, value at Jun. 30, 2020	$ 231,627	$ 29	$ 5	$ 1,058,606	$ (827,013)
Balance, shares at Jun. 30, 2020		28,526,532	5,058,319

XML

Unaudited Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Operating activities
Net loss	$ (116,520)	$ (63,534)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	562	401
Amortization of debt issuance costs and implied interest	4,163	678
Non-cash interest expense on liability related to sale of future royalty	664	0
Stock-based compensation expense	34,104	8,710
Loss on extinguishment of debt	11,183	0
Changes in operating assets and liabilities:
Income tax receivable	(22,218)	0
Prepaid expenses and other current assets and other assets	(1,815)	(2,271)
Accounts payable	9,355	312
Accrued direct research, other current, and long-term liabilities	(4,247)	9,802
Payable to collaborators	(150,000)	0
Deferred revenue	(2,338)	(15,539)
Net cash used in operating activities	(237,107)	(61,441)
Investing activities
Purchases of property and equipment	(384)	(2,092)
Net cash used in investing activities	(384)	(2,092)
Financing activities
Proceeds from issuance of common stock, net	55,399	0
Payments on long-term debt	(167,170)	0
Exercise of options	1,786	6,085
Proceeds from sale of future royalties, net	293,571	107
Net cash provided by financing activities	183,586	6,192
Net decrease in cash and cash equivalents	(53,905)	(57,341)
Cash and cash equivalents at beginning of year	664,324	337,790
Cash and cash equivalents at end of period	610,419	280,449
Supplemental disclosures
Cash paid for interest	8,021	4,153
Non-cash activity:
Right-of-use assets obtained in exchange for lease obligations	0	8,981
Purchases of equipment in accounts payable, accrued direct research, other current, and long-term liabilities	$ 1,448	$ 170

XML

Description of Business

6 Months Ended

Jun. 30, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Description of Business

1. Description of Business

The Company’s mission is to identify, develop, and commercialize innovative therapies that change patients’ lives for the better.  The Company focuses on small-molecule therapeutics with novel mechanisms of action for the treatment of severe, life-threatening diseases with few or no approved therapies.  The Company’s lead programs are in rare forms of chronic kidney disease (CKD) and a rare neurological disease.  The Company announced positive topline data from registrational trials for both of its lead product candidates, bardoxolone methyl (bardoxolone) in patients with CKD caused by Alport syndrome, and omaveloxolone in patients with a neurological disorder called Friedreich’s ataxia (FA).  Both bardoxolone and omaveloxolone activate the transcription factor Nrf2 to normalize mitochondrial function, restore redox balance, and resolve inflammation.  Because mitochondrial dysfunction, oxidative stress, and inflammation are features of many diseases, the Company believes bardoxolone and omaveloxolone have many potential clinical applications.  Reata possesses exclusive, worldwide rights to develop, manufacture and commercialize bardoxolone, omaveloxolone, and our next-generation Nrf2 activators, excluding certain Asian markets for bardoxolone in certain indications, which are licensed to Kyowa Kirin Co., Ltd. (KKC).

The Company’s consolidated financial statements include the accounts of all majority-owned subsidiaries.  Accordingly, the Company’s share of net earnings and losses from these subsidiaries is included in the consolidated statements of operations.  Intercompany profits, transactions, and balances have been eliminated in consolidation.

XML

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements.  In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.  Operating results for the six months ended June 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020.  The consolidated balance sheet at December 31, 2019, has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements.  For further information, refer to the annual consolidated financial statements and footnotes thereto of the Company.

Summary of Significant Accounting Policies

The significant accounting policies used in preparation of these condensed consolidated financial statements for the three and six months ended June 30, 2020 are consistent with those discussed in Note 2 to the consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, except as noted below with respect to the Company’s liability related to sale of future royalties and as noted within the “Recent Accounting Pronouncements – Recently Adopted Accounting Pronouncements” section.

Liability Related to Sale of Future Royalties

On June 10, 2020, the Company entered into a Development and Commercialization Funding Agreement with an affiliate of Blackstone Life Sciences, LLC (BXLS) that provides funding for the development and commercialization of bardoxolone for the treatment of CKD caused by Alport syndrome, autosomal dominant polycystic kidney disease (ADPKD), and certain other rare CKD indications in return for future royalties (Development Agreement).  The Company accounted for the Development Agreement as a sale of future revenues resulting in a debt classification, primarily because the Company has significant continuing involvement in generating the future revenue on which the royalties are based. The debt will be amortized under the effective interest rate method and, accordingly, the Company is recognizing non-cash interest expense over the estimated term of the Development Agreement. The liability related to sale of future royalties, and the debt amortization, are based

on the Company’s current estimate of future royalties expected to be paid over the estimated term of the Development Agreement. The Company will periodically assess the expected royalty payments and, if materially different than its previous estimate, will prospectively adjust and recognize the related non-cash interest expense. The transaction costs associated with the liability will be amortized to non-cash interest expense over the estimated term of the Development Agreement. See Note 5, Liability Related to Sale of Future Royalties, of Notes to Consolidated Financial Statements contained in this Quarterly Report on Form 10-Q.

Fair Value Measurements

The Company categorizes its financial instruments measured at fair value into a three-level fair value hierarchy that prioritizes the inputs used in determining the fair value of the asset or liability. The three levels of the fair value hierarchy are as follows:

• Level 1 - Financial instruments that have values based on unadjusted quoted prices for identical assets or liabilities in an active market which the Company has the ability to access at the measurement date

• Level 2 - Financial instruments that have values based on quoted market prices in markets where trading occurs infrequently or that have values based on quoted prices of instruments with similar attributes in active markets.

• Level 3 - Financial instruments that have values based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset.

The Company has determined the fair value of the liability related to the sale of future royalties is based on the Company’s current estimates of future royalties expected to be paid to BXLS, over the life of the arrangement, which are considered Level 3. See Note 5, Liability Related to Sale of Future Royalties, of Notes to Consolidated Financial Statements contained in this Quarterly Report on Form 10-Q.

Recently Adopted Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board (FASB) issued Topic 842, amended by ASU 2018-11, Leases (Topic 842): Targeted Improvements. The new guidance requires a lessee to recognize assets and liabilities for all leases with lease terms of more than 12 months and provide additional disclosures. Topic 842 requires adoption using a modified retrospective transition approach with either 1) transition provisions at the beginning of the earliest comparative period with its cumulative adjustment recognized to retained earnings at the beginning of the earliest period presented or 2) a cumulative-effect adjustment recognized to the opening balance of retained earnings on the adoption.  We adopted this standard on January 1, 2019, using the cumulative-effect adjustment approach. We elected the package of practical expedients in transition for leases that commenced prior to January 1, 2019 whereby these contracts were not reassessed or reclassified from their previous assessment as of December 31, 2018.

In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808) (ASU 2018-18).  This update provides clarification on the interaction between Revenue from Contracts with Customers (Topic 606) and Collaborative Arrangements (Topic 808) including the alignment of unit of account guidance between the two topics.  This update is effective in fiscal years, including interim periods, beginning after December 15, 2019, and early adoption is permitted.  The Company adopted this standard on January 1, 2020 and its adoption did not have a material impact on the Company’s consolidated financial statements and related disclosure.

In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. This update requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to defer and recognize as an asset. This guidance should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. The Company adopted this standard on January 1, 2020 and its adoption did not have material impact to the Company’s consolidated financial statements and related disclosure.

XML

Collaboration Agreements

6 Months Ended

Jun. 30, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Collaboration Agreements

3. Collaboration Agreements

AbbVie

In September 2010, the Company entered into a license agreement with AbbVie Inc. (AbbVie) (the AbbVie License Agreement) for an exclusive license to develop and commercialize bardoxolone in the Licensee Territory (as defined in the AbbVie License Agreement).

In December 2011, the Company entered into a collaboration agreement with AbbVie (the AbbVie Collaboration Agreement) to jointly research, develop, and commercialize the Company’s portfolio of second and later generation oral Nrf2 activators.

On October 9, 2019, the Company and AbbVie entered into an Amended and Restated License Agreement (the Reacquisition Agreement) pursuant to which the Company reacquired the development, manufacturing, and commercialization rights concerning its proprietary Nrf2 activator product platform originally licensed to AbbVie in the AbbVie License Agreement and the AbbVie Collaboration Agreement.  In exchange for such rights, the Company agreed to pay AbbVie $330.0 million, of which $100.0 million was paid as of December 31, 2019, $150.0 million was paid on June 30, 2020, and $80.0 million will be payable on November 30, 2021.  Additionally, the Company will pay AbbVie an escalating, low single-digit royalty on worldwide net sales, on a product-by-product basis, of omaveloxolone and certain next-generation Nrf2 activators. The Company recognized interest expense related to the Reacquisition Agreement of approximately $1.6 million and $0 million, during the three months ended June 30, 2020 and 2019, respectively, and $3.2 million and $0 million, during the six months ended June 30, 2020 and 2019, respectively.  As of June 30, 2020, the Company’s payable to collaborators was $80.0 million, with a present value of $70.1 million.  

The execution of the Reacquisition Agreement ended our performance obligations under the AbbVie Collaboration Agreement and included the write off of the remaining related deferred revenue balance, after which no further revenue was recognized.  Accordingly, there was no revenue recognized in 2020.  The Company recognized revenue related to the AbbVie Collaboration Agreement totaling approximately $6.6 million and $13.2 million during the three and six months ended June 30, 2019, respectively. The deferred revenue balance was $0 million as of June 30, 2020.

KKC

In December 2009, the Company entered into an exclusive license with KKC (the KKC Agreement) to develop and commercialize bardoxolone in the licensed territory.  The Company received a nonrefundable, up-front license fee of $35.0 million in 2009 and regulatory milestones totaling $45.0 million in 2010, 2012, and 2018 and could receive additional regulatory milestones of $52.0 million and commercial milestones of $140.0 million, as well as tiered royalties ranging from the low teens to the low 20 percent range, depending on the country of sale and the amount of annual net sales, on net sales by KKC in the licensed territory.  

The up-front payment and regulatory milestones are accounted for as a single unit of accounting.  Revenue is being recognized ratably through December 2021, which is the estimated minimum period that is needed to complete the deliverables under the terms of the KKC Agreement.  The Company began recognizing revenue related to the up-front payment upon execution of the KKC Agreement. The Company recognized collaboration revenue totaling approximately $1.2 million during each of the three months ended June 30, 2020 and 2019 and $2.3 million during each of the six months ended June 30, 2020 and 2019.  As of June 30, 2020, the Company recorded deferred revenue totaling approximately $7.1 million of which approximately $4.7 million is reflected as the current portion of deferred revenue.

XML

Term Loan

6 Months Ended

Jun. 30, 2020

Debt Disclosure [Abstract]

Term Loan

4. Term Loan

On October 9, 2019, the Company entered into the First Amendment to the Amended and Restated Loan and Security Agreement (the Amended Restated Loan Agreement).  Under the Amended Restated Loan Agreement, the Term A Loan principal amount was $80.0 million, and the Term B Loan availability was increased from $45.0 million to $75.0 million (collectively with the Term A Loan, the Term Loans).  On December 20, 2019, the Company borrowed $75.0 million under the Term B Loan resulting in a principal balance of the Term Loans of $155.0 million.

On June 24, 2020, the Company paid off the total outstanding balance of the Term Loans prior to the maturity date.  The payoff consisted of (i) the outstanding principal balance of $155.0 million, (ii) exit fees of $6.7 million, which has been partially accrued up to the date of repayment, (iii) prepayment fees of $5.4 million, and (iv) accrued and unpaid interest of $1.0 million. At the time of payoff, all liabilities and obligations under the Amended Restated Loan Agreement were terminated. In connection with the payoff of the Term Loans, the Company recorded a loss on extinguishment of debt of $11.2 million in the three and six months ended June 30, 2020.

XML

Liability Related to Sale of Future Royalties

6 Months Ended

Jun. 30, 2020

Liability Related To Sale Of Future Royalties [Abstract]

Liability Related to Sale of Future Royalties

5. Liability Related to Sale of Future Royalties

On June 24, 2020, the Company closed on the Development Agreement with BXLS.  The Development Agreement includes a $300.0 million payment by an affiliate of BXLS in return for various percentage royalty payments on worldwide net sales of bardoxolone, once approved in the United States or certain specified European countries, by Reata and its licensees, other than KKC.  The royalty percentage will initially be in the mid-single digits and, in future years, can vary between higher-mid single digit percentages to low-single digit percentages depending on various milestones, including indication approval dates, cumulative royalty payments, and cumulative net sales.  Pursuant to the Development Agreement, we have granted BXLS a security interest in substantially all of our assets.

In addition, concurrent with the Development Agreement, the Company entered into a common stock purchase agreement (Purchase Agreement) with affiliates of BXLS to sell an aggregate of 340,793 shares of the Company’s Class A common stock at $146.72 per share for a total of $50.0 million.

The Company concluded that there were two units of accounting for the consideration received, comprised of the liability related to the sale of future royalties and the common shares.  The Company allocated the $300.0 million from the Development Agreement and $50.0 million from the Purchase Agreement between the two units of accounting on a relative fair value basis at the time of the transaction. The Company allocated $294.2 million, which includes $0.8 million in transaction costs incurred, in transaction consideration to the liability, and $55.5 million to the common shares.  The Company determined the fair value of the common shares based on the closing stock price on the June 24, 2020, the closing date of the Development Agreement. The effective interest rate under the Development Agreement, including transaction costs, is approximately 13.7%.

The following table shows the activity within the liability related to sale of future royalties for the six months ended June 30, 2020:

	Liability Related to Sale of Future Royalties
	(in thousands)
Transaction date balance	$	294,454
Non-cash interest expense recognized, net of transaction cost amortization		664
Balance at June 30, 2020		295,118
Less: Unamortized transaction cost		(884	)
Carrying value at June 30, 2020	$	294,234

XML

Other Income (Expense), Net

6 Months Ended

Jun. 30, 2020

Other Income And Expenses [Abstract]

Other Income (Expense), Net

6. Other Income (Expense), Net

	Three Months Ended						Six Months Ended
	June 30						June 30
	2020			2019			2020			2019
Other income (expense), net
Investment income	$	501		$	1,705		$	2,555		$	3,502
Interest expense		(5,644	)		(2,413	)		(11,512	)		(4,810	)
Non-cash interest expense on liability    related to sale of future royalty		(664	)		—			(664	)		—
Other income (expense)		—			7			—			7
Loss on extinguishment of debt		(11,183	)		—			(11,183	)		—
Total other income (expense), net	$	(16,990	)	$	(701	)	$	(20,804	)	$	(1,301	)

Investment Income

Interest income consists primarily of interest generated from our cash and cash equivalents.

Interest Expense

Interest expense consists primarily of interest on our borrowing activities under our loan agreements and the imputed interest from amount due to AbbVie under the Reacquisition Agreement.

Non-Cash Interest Expense on Liability Related to Sale of Future Royalties

Non-cash interest expense consists of recognition of interest expense based on the Company’s current estimate of future royalties expensed to be paid over the estimated term of the Development Agreement.

Other Income (Expense)

Other income (expense) consists primarily of gains and losses on foreign currency exchange and sales of assets.

Loss on Extinguishment of Debt

In June 2020, the Company paid off the Term Loans and recorded a loss on the extinguishment of debt of $11.2 million, which consisted primarily of prepayment fees, exit fees and unamortized debt issuance costs.

XML

Leases

6 Months Ended

Jun. 30, 2020

Leases [Abstract]

Leases

7. Leases

The Company’s headquarters are located in Plano, Texas, where it leases approximately 122,000 square feet of office space.  The Company leases additional office and laboratory space of approximately 34,890 square feet located in Irving, Texas. The lease terms for the Irving and Plano offices extend through October 31, 2022 with an option to renew up to six months and through April 30, 2022 with four successive three-month-period renewal options, respectively.  

The Company has an additional lease of a single-tenant, build-to-suit building of approximately 327,400 square feet of office and laboratory space located in Plano, Texas with an initial lease term of 16 years.  The Company entered into the lease agreement on October 15, 2019 (the Lease Agreement), and at the Company’s option, it may renew the lease for two consecutive five-year renewal periods or one ten-year renewal period.  The Company does not have control of the space or the construction prior to completion of construction.  Therefore, no right-of-use or lease liabilities were recorded in connection with the Lease Agreement as of June 30, 2020.  Under the First Amendment to the Lease Agreement executed in May 2020, the landlord will fund the Company’s leasehold improvements up to $31.3 million, of which the Company has recorded a leasehold incentive obligation of approximately $1.7 million as other long-term liabilities as of June 30, 2020.

At June 30, 2020, the weighted average incremental borrowing rate and the weighted average remaining lease term for the operating leases held by the Company were 9.6% and 2.3 years, respectively.  During the three and six months ended June 30, 2020, cash paid for amounts included for the measurement of lease liabilities was $1.0 million and $1.9 million, respectively. During the three and six months ended June 30, 2020 the Company recorded operating lease expense of $1.0 million and $1.9 million, respectively.  The Company has elected to net the amortization of the right-of-use assets and the reduction of the lease liabilities principal in accrued direct research and other current and long-term liabilities in the consolidated statements of cash flows.

Supplemental balance sheet information related to the Company’s operating leases is as follows:

	Balance Sheet Classification	As of June 30, 2020
		(in thousands)
Non-current right-of-use assets	Other assets	$	7,653
Current lease liabilities	Other current liabilities		3,452
Non-current lease liabilities	Other long-term liabilities		5,212

Maturities of lease liabilities by fiscal year for the Company’s operating leases:

	As of June 30, 2020
	(in thousands)
2020 (remaining six months)	$	2,063
2021		4,142
2022		3,500
Total lease payments		9,705
Less: Imputed interest		(1,041	)
Present value of lease liabilities	$	8,664

XML

Income Taxes

6 Months Ended

Jun. 30, 2020

Income Tax Disclosure [Abstract]

Income Taxes

8. Income Taxes

On March 27, 2020, the United States enacted the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act).  The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and to provide assistance to individuals, families, and businesses affected by COVID-19.  Accordingly, under its provisions, for the six months ended June 30, 2020, the Company recognized a tax benefit and receivable of $22.1 million associated with the ability to carryback an applicable prior year’s net operating losses to a preceding year to generate a refund.

For the three months ended June 30, 2020, the Company’s effective tax rate was a benefit of 0.0% compared to 0.0% for the three months ended June 30, 2019.  The Company’s effective tax rate for the three months ended June 30, 2020 varies with the statutory rate primarily due to valuation allowances on deferred taxes.  For the six months ended June 30, 2020, the Company’s effective tax rate was a benefit of 16.0% compared to 0.0% for the six months ended June 30, 2019.  The Company’s effective tax rate for the six months ended June 30, 2020 varies with the statutory rate primarily due to the favorable impact associated with the CARES Act and changes in the valuation allowance related to certain deferred tax assets generated or utilized in the applicable period.  The Company’s deferred tax assets have been fully offset by a valuation allowance at June 30, 2020, and the Company expects to maintain this valuation allowance until there is sufficient evidence that future earnings can be achieved, which is uncertain at this time.  

XML

Stock-Based Compensation

6 Months Ended

Jun. 30, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation

9. Stock-Based Compensation

The following table summarizes stock-based compensation expense reflected in the consolidated statements of operations:

	Three Months Ended June 30				Six Months Ended June 30
	2020		2019		2020		2019
	(in thousands)
Research and development	$	7,527	$	1,659	$	19,044	$	3,350
General and administrative		7,269		2,824		15,060		5,360
	$	14,796	$	4,483	$	34,104	$	8,710

Restricted Stock Units (RSUs)

The following table summarizes RSUs as of June 30, 2020, under the Second Amended and Restated Long Term Incentive Plan (LTIP Plan) agreement and standalone option agreements:

	Number of RSUs		Weighted-Average Grant Date Fair Value
Outstanding at January 1, 2020		50,000	$	72.70
Granted		24,751	$	184.00
Vested		—	$	—
Forfeited		—	$	—
Outstanding at June 30, 2020		74,751	$	109.55

As of June 30, 2020, the performance targets for the performance-based RSUs have not been met. Accordingly, the fair value related to these performance-based RSUs of approximately $4.2 million has not been recognized. During the quarter ended June 30, 2020, the Company recognized $0.3 million in compensation expense related to time-based RSUs.

Stock Options  

The following table summarizes stock option activity as of June 30, 2020, and changes during the six months ended June 30, 2020, under the LTIP and standalone option agreements:

	Number of Options			Weighted-Average Exercise Price
Outstanding at January 1, 2020		4,038,949		$	41.24
Granted		973,999		$	203.19
Exercised		(47,351	)	$	37.51
Forfeited		(171,917	)	$	94.68
Outstanding at June 30, 2020		4,793,680		$	72.27
Exercisable at June 30, 2020		2,240,699		$	33.31

Stock-based compensation expense for the three and six months ended June 30, 2020, included accelerated recognition of expense due to modifications of outstanding stock options as a result of the death of an executive and employees who entered into consulting agreements at the termination of employment, which were considered to be non-substantive services. Accordingly, the Company recognized $2.9 million and $10.0 million for the three and six months ended June 30, 2020, respectively.

As of June 30, 2020, the Company has approximately 303,000 shares of performance-based stock options for which the performance targets have not been met.  Accordingly, the fair value related to these performance-based stock options of approximately $34.1 million has not been recognized.

The total intrinsic value of all outstanding options and exercisable options at June 30, 2020 was $448.7 million and $278.2 million, respectively.

XML

Net Loss per Share

6 Months Ended

Jun. 30, 2020

Earnings Per Share [Abstract]

Net Loss per Share

10. Net Loss per Share

The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders:

	Three Months Ended June 30						Six Months Ended June 30
	2020			2019			2020			2019
	(in thousands, except share and per share data)
Numerator
Net loss	$	(67,581	)	$	(34,380	)	$	(116,520	)	$	(63,534	)
Denominator
Weighted-average number of common shares    used in net loss per share – basic		33,265,778			30,069,048			33,243,931			29,950,241
Dilutive potential common shares		—			—			—			—
Weighted-average number of common shares    used in net loss per share – diluted		33,265,778			30,069,048			33,243,931			29,950,241
Net loss per share – basic	$	(2.03	)	$	(1.14	)	$	(3.51	)	$	(2.12	)
Net loss per share – diluted	$	(2.03	)	$	(1.14	)	$	(3.51	)	$	(2.12	)

The number of weighted average options that were not included in the diluted earnings per share calculation because the effect would have been anti-dilutive represented 4,793,680 and 3,845,874 shares as of June 30, 2020 and 2019, respectively.

XML

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements.  In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.  Operating results for the six months ended June 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020.  The consolidated balance sheet at December 31, 2019, has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements.  For further information, refer to the annual consolidated financial statements and footnotes thereto of the Company.

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

The significant accounting policies used in preparation of these condensed consolidated financial statements for the three and six months ended June 30, 2020 are consistent with those discussed in Note 2 to the consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, except as noted below with respect to the Company’s liability related to sale of future royalties and as noted within the “Recent Accounting Pronouncements – Recently Adopted Accounting Pronouncements” section.

Liability Related to Sale of Future Royalties

Liability Related to Sale of Future Royalties

On June 10, 2020, the Company entered into a Development and Commercialization Funding Agreement with an affiliate of Blackstone Life Sciences, LLC (BXLS) that provides funding for the development and commercialization of bardoxolone for the treatment of CKD caused by Alport syndrome, autosomal dominant polycystic kidney disease (ADPKD), and certain other rare CKD indications in return for future royalties (Development Agreement).  The Company accounted for the Development Agreement as a sale of future revenues resulting in a debt classification, primarily because the Company has significant continuing involvement in generating the future revenue on which the royalties are based. The debt will be amortized under the effective interest rate method and, accordingly, the Company is recognizing non-cash interest expense over the estimated term of the Development Agreement. The liability related to sale of future royalties, and the debt amortization, are based

on the Company’s current estimate of future royalties expected to be paid over the estimated term of the Development Agreement. The Company will periodically assess the expected royalty payments and, if materially different than its previous estimate, will prospectively adjust and recognize the related non-cash interest expense. The transaction costs associated with the liability will be amortized to non-cash interest expense over the estimated term of the Development Agreement. See Note 5, Liability Related to Sale of Future Royalties, of Notes to Consolidated Financial Statements contained in this Quarterly Report on Form 10-Q.

Fair Value Measurements

Fair Value Measurements

The Company categorizes its financial instruments measured at fair value into a three-level fair value hierarchy that prioritizes the inputs used in determining the fair value of the asset or liability. The three levels of the fair value hierarchy are as follows:

• Level 1 - Financial instruments that have values based on unadjusted quoted prices for identical assets or liabilities in an active market which the Company has the ability to access at the measurement date

• Level 2 - Financial instruments that have values based on quoted market prices in markets where trading occurs infrequently or that have values based on quoted prices of instruments with similar attributes in active markets.

• Level 3 - Financial instruments that have values based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset.

The Company has determined the fair value of the liability related to the sale of future royalties is based on the Company’s current estimates of future royalties expected to be paid to BXLS, over the life of the arrangement, which are considered Level 3. See Note 5, Liability Related to Sale of Future Royalties, of Notes to Consolidated Financial Statements contained in this Quarterly Report on Form 10-Q.

Recent Accounting Pronouncements

Recently Adopted Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board (FASB) issued Topic 842, amended by ASU 2018-11, Leases (Topic 842): Targeted Improvements. The new guidance requires a lessee to recognize assets and liabilities for all leases with lease terms of more than 12 months and provide additional disclosures. Topic 842 requires adoption using a modified retrospective transition approach with either 1) transition provisions at the beginning of the earliest comparative period with its cumulative adjustment recognized to retained earnings at the beginning of the earliest period presented or 2) a cumulative-effect adjustment recognized to the opening balance of retained earnings on the adoption.  We adopted this standard on January 1, 2019, using the cumulative-effect adjustment approach. We elected the package of practical expedients in transition for leases that commenced prior to January 1, 2019 whereby these contracts were not reassessed or reclassified from their previous assessment as of December 31, 2018.

In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808) (ASU 2018-18).  This update provides clarification on the interaction between Revenue from Contracts with Customers (Topic 606) and Collaborative Arrangements (Topic 808) including the alignment of unit of account guidance between the two topics.  This update is effective in fiscal years, including interim periods, beginning after December 15, 2019, and early adoption is permitted.  The Company adopted this standard on January 1, 2020 and its adoption did not have a material impact on the Company’s consolidated financial statements and related disclosure.

In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. This update requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to defer and recognize as an asset. This guidance should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. The Company adopted this standard on January 1, 2020 and its adoption did not have material impact to the Company’s consolidated financial statements and related disclosure.

XML

Liability Related to Sale of Future Royalties (Tables)

6 Months Ended

Jun. 30, 2020

Liability Related To Sale Of Future Royalties [Abstract]

Schedule of Activity Within Liability Related to Sale of Future Royalties

The following table shows the activity within the liability related to sale of future royalties for the six months ended June 30, 2020:

	Liability Related to Sale of Future Royalties
	(in thousands)
Transaction date balance	$	294,454
Non-cash interest expense recognized, net of transaction cost amortization		664
Balance at June 30, 2020		295,118
Less: Unamortized transaction cost		(884	)
Carrying value at June 30, 2020	$	294,234

XML

Other Income (Expense), Net (Tables)

6 Months Ended

Jun. 30, 2020

Other Income And Expenses [Abstract]

Summary of Other Income (Expense), Net

	Three Months Ended						Six Months Ended
	June 30						June 30
	2020			2019			2020			2019
Other income (expense), net
Investment income	$	501		$	1,705		$	2,555		$	3,502
Interest expense		(5,644	)		(2,413	)		(11,512	)		(4,810	)
Non-cash interest expense on liability    related to sale of future royalty		(664	)		—			(664	)		—
Other income (expense)		—			7			—			7
Loss on extinguishment of debt		(11,183	)		—			(11,183	)		—
Total other income (expense), net	$	(16,990	)	$	(701	)	$	(20,804	)	$	(1,301	)

XML

Leases (Tables)

6 Months Ended

Jun. 30, 2020

Leases [Abstract]

Summary of Supplemental Balance Sheet Information Related to Operating Leases

Supplemental balance sheet information related to the Company’s operating leases is as follows:

	Balance Sheet Classification	As of June 30, 2020
		(in thousands)
Non-current right-of-use assets	Other assets	$	7,653
Current lease liabilities	Other current liabilities		3,452
Non-current lease liabilities	Other long-term liabilities		5,212

Schedule of Maturities of Lease Liabilities

Maturities of lease liabilities by fiscal year for the Company’s operating leases:

	As of June 30, 2020
	(in thousands)
2020 (remaining six months)	$	2,063
2021		4,142
2022		3,500
Total lease payments		9,705
Less: Imputed interest		(1,041	)
Present value of lease liabilities	$	8,664

XML

Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Stock Based Compensation Expense

The following table summarizes stock-based compensation expense reflected in the consolidated statements of operations:

	Three Months Ended June 30				Six Months Ended June 30
	2020		2019		2020		2019
	(in thousands)
Research and development	$	7,527	$	1,659	$	19,044	$	3,350
General and administrative		7,269		2,824		15,060		5,360
	$	14,796	$	4,483	$	34,104	$	8,710

Summary of Restricted Stock Units

The following table summarizes RSUs as of June 30, 2020, under the Second Amended and Restated Long Term Incentive Plan (LTIP Plan) agreement and standalone option agreements:

	Number of RSUs		Weighted-Average Grant Date Fair Value
Outstanding at January 1, 2020		50,000	$	72.70
Granted		24,751	$	184.00
Vested		—	$	—
Forfeited		—	$	—
Outstanding at June 30, 2020		74,751	$	109.55

Summary of Stock Option Activity

The following table summarizes stock option activity as of June 30, 2020, and changes during the six months ended June 30, 2020, under the LTIP and standalone option agreements:

	Number of Options			Weighted-Average Exercise Price
Outstanding at January 1, 2020		4,038,949		$	41.24
Granted		973,999		$	203.19
Exercised		(47,351	)	$	37.51
Forfeited		(171,917	)	$	94.68
Outstanding at June 30, 2020		4,793,680		$	72.27
Exercisable at June 30, 2020		2,240,699		$	33.31

XML

Net Loss per Share (Tables)

6 Months Ended

Jun. 30, 2020

Earnings Per Share [Abstract]

Computation of Basic and Diluted Net Loss per Share

The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders:

	Three Months Ended June 30						Six Months Ended June 30
	2020			2019			2020			2019
	(in thousands, except share and per share data)
Numerator
Net loss	$	(67,581	)	$	(34,380	)	$	(116,520	)	$	(63,534	)
Denominator
Weighted-average number of common shares    used in net loss per share – basic		33,265,778			30,069,048			33,243,931			29,950,241
Dilutive potential common shares		—			—			—			—
Weighted-average number of common shares    used in net loss per share – diluted		33,265,778			30,069,048			33,243,931			29,950,241
Net loss per share – basic	$	(2.03	)	$	(1.14	)	$	(3.51	)	$	(2.12	)
Net loss per share – diluted	$	(2.03	)	$	(1.14	)	$	(3.51	)	$	(2.12	)

XML

Collaboration Agreements - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Dec. 31, 2009	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Nov. 30, 2021	Dec. 31, 2019	Oct. 31, 2019
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payable to collaborators, net of current portion		$ 70,055		$ 70,055			$ 66,862
Collaboration revenue		3,073	$ 7,833	4,426	$ 15,603
Current portion of deferred revenue		4,688		4,688			4,701
AbbVie
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payable to collaborators		150,000		150,000			$ 100,000	$ 330,000
Interest expense		1,600	0	3,200	0
Payable to collaborators, net of current portion		70,100		70,100
AbbVie | Collaborative Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue		0	6,600	0	13,200
Current portion of deferred revenue		0		0
AbbVie | Forecast
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payable to collaborators						$ 80,000
KKC Agreement | License Agreement Terms
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue		1,200	$ 1,200	2,300	$ 2,300
Current portion of deferred revenue		4,700		4,700
Upfront license fee received	$ 35,000
Collaboration revenue, total milestone payments received in 2010, 2012, 2018				45,000
Collaboration revenue, potential milestone payments		52,000		52,000
Collaboration revenue, additional potential commercial milestone payments		140,000		$ 140,000
Deferred revenue, expected timing of recognition				2021-12
Deferred Revenue		$ 7,100		$ 7,100

XML

Term Loan - Additional Information (Details) - USD ($)			1 Months Ended	3 Months Ended		6 Months Ended
	Jun. 24, 2020	Dec. 20, 2019	Jun. 30, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Oct. 09, 2019
Debt Instrument [Line Items]
Repayment of outstanding principal amount						$ 167,170,000	$ 0
Loss on extinguishment of debt			$ 11,200,000	$ 11,183,000	$ 0	11,183,000	$ 0
Amended and Restated Loan and Security Agreement | Term Loan A
Debt Instrument [Line Items]
Maximum borrowing capacity								$ 80,000,000.0
Amended and Restated Loan and Security Agreement | Term Loan B
Debt Instrument [Line Items]
Current borrowing capacity								45,000,000.0
Amended Restated Loan Agreement | Term Loan B
Debt Instrument [Line Items]
Maximum borrowing capacity								$ 75,000,000.0
Proceeds from long-term debt		$ 75,000,000.0
Amended Restated Loan Agreement | Term Loan
Debt Instrument [Line Items]
Loam principal amount		$ 155,000,000.0
Repayment of outstanding principal amount	$ 155,000,000.0
Debt instrument, exit fee	6,700,000
Debt instrument, prepayment fee	5,400,000
Debt instrument, accrued and unpaid interest	$ 1,000,000.0
Loss on extinguishment of debt				$ 11,200,000		$ 11,200,000

XML

Liability Related to Sale of Future Royalties - Additional Information (Details) $ / shares in Units, $ in Thousands		3 Months Ended	6 Months Ended
	Jun. 24, 2020 USD ($) Account $ / shares shares	Jun. 30, 2020 shares	Jun. 30, 2020 USD ($) shares	Jun. 30, 2019 USD ($)
Liability Related To Sale Of Future Royalties [Line Items]
Proceeds from issuance of common stock, net			$ 55,399	$ 0
Number of units of accounting related to consideration received | Account	2
Liability related to sale of future royalties, net	$ 294,200
Transaction cost of liability related to sale of future royalties	800
Transaction consideration allocated to common shares	$ 55,500
Effective interest rate including transaction costs	13.70%
Common Stock A
Liability Related To Sale Of Future Royalties [Line Items]
Issuance of Common Stock, shares | shares		340,793	340,793
Development Agreement
Liability Related To Sale Of Future Royalties [Line Items]
Proceeds from royalty agreement	$ 300,000
Purchase Agreement
Liability Related To Sale Of Future Royalties [Line Items]
Proceeds from issuance of common stock, net	50,000
Purchase Agreement | Common Stock A | BXLS
Liability Related To Sale Of Future Royalties [Line Items]
Proceeds from issuance of common stock, net	$ 50,000
Issuance of Common Stock, shares | shares	340,793
Shares issued, price per share | $ / shares	$ 146.72

XML

Liability Related to Sale of Future Royalties - Schedule of Activity Within Liability Related to Sale of Future Royalties (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2020 USD ($)
Liability Related To Sale Of Future Royalties [Abstract]
Liability related to sale of future royalties, Transaction date balance	$ 294,454
Non-cash interest expense recognized, net of transaction cost amortization	664
Liability related to sale of future royalties, Balance at June 30, 2020	295,118
Less: Unamortized transaction cost	(884)
Liability related to sale of future royalties, Carrying value at June 30, 2020	$ 294,234

XML

Other Income (Expense), Net - Summary of Other Income (Expense), Net (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Other income (expense), net
Investment income		$ 501	$ 1,705	$ 2,555	$ 3,502
Interest expense		(5,644)	(2,413)	(11,512)	(4,810)
Non-cash interest expense on liability related to sale of future royalty		(664)	0	(664)	0
Other income (expense)		0	7	0	7
Loss on extinguishment of debt	$ (11,200)	(11,183)	0	(11,183)	0
Total other income (expense), net		$ (16,990)	$ (701)	$ (20,804)	$ (1,301)

XML

Other Income (Expense), Net - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Other Income And Expenses [Abstract]
Loss on extinguishment of debt	$ 11,200	$ 11,183	$ 0	$ 11,183	$ 0

XML

Leases - Additional Information (Details)		3 Months Ended	6 Months Ended
	Oct. 15, 2019 USD ($) ft²	Jun. 30, 2020 USD ($) ft²	Jun. 30, 2020 USD ($) ft²
Lessee Lease Description [Line Items]
Operating lease right-of-use asset		$ 7,653,000	$ 7,653,000
Operating lease liability		$ 8,664,000	$ 8,664,000
Weighted-average remaining lease term		2 years 3 months 18 days	2 years 3 months 18 days
Weighted average incremental borrowing rate		9.60%	9.60%
Cash paid for amounts included in the measurement of lease liabilities		$ 1,000,000.0	$ 1,900,000
Operating lease, expense		$ 1,000,000.0	$ 1,900,000
Plano Texas
Lessee Lease Description [Line Items]
Operating lease, existence of option to extend			true
Operating lease, option to extend			through April 30, 2022
Lease expiration date			Apr. 30, 2022
Operating lease, renewal Term		3 months	3 months
Plano Texas | Office Space
Lessee Lease Description [Line Items]
Area of real estate property | ft²		122,000	122,000
Plano Texas | Office And Laboratory Space | 2019 Lease Agreement
Lessee Lease Description [Line Items]
Area of real estate property | ft²	327,400
Lease initial term	16 years
Lessor, operating lease, existence of option to extend	true
Renewal lease term, option one	two consecutive five-year renewal periods
Renewal lease term, option two	one ten-year renewal period
Operating lease right-of-use asset		$ 0	$ 0
Operating lease liability		0	0
Leasehold improvement maximum amount funded by landlord	$ 31,300
Leasehold incentive obligation included in other long-term liabilities		$ 1,700	$ 1,700
Irving Texas
Lessee Lease Description [Line Items]
Operating lease, existence of option to extend			true
Operating lease, option to extend			extend through October 31, 2022
Lease expiration date			Oct. 31, 2022
Irving Texas | Maximum
Lessee Lease Description [Line Items]
Operating lease, renewal Term		6 months	6 months
Irving Texas | Office And Laboratory Space
Lessee Lease Description [Line Items]
Area of real estate property | ft²		34,890	34,890

XML

Leases - Summary of Supplemental Balance Sheet Information Related to Operating Leases (Details) $ in Thousands	Jun. 30, 2020 USD ($)
Leases [Abstract]
Non-current right-of-use assets	$ 7,653
Current lease liabilities	3,452
Non-current lease liabilities	$ 5,212

XML

Leases - Schedule of Maturities of Lease Liabilities (Details) $ in Thousands	Jun. 30, 2020 USD ($)
Leases [Abstract]
2020 (remaining six months)	$ 2,063
2021	4,142
2022	3,500
Total lease payments	9,705
Less: Imputed interest	(1,041)
Present value of lease liabilities	$ 8,664

XML

Income Taxes - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Income tax receivable as per CARES Act	$ 22.1		$ 22.1
Effective income tax rate	0.00%	0.00%	16.00%	0.00%

XML

Stock-Based Compensation - Summary of Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 14,796	$ 4,483	$ 34,104	$ 8,710
Research and development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	7,527	1,659	19,044	3,350
General and administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 7,269	$ 2,824	$ 15,060	$ 5,360

XML

Stock-Based Compensation - Summary of Restricted Stock Units (Details) - Restricted Stock Unit (RSUs)	6 Months Ended
	Jun. 30, 2020 $ / shares shares
Number of RSUs
Number of RSUs - Beginning balance | shares	50,000
Number of RSUs, Granted | shares	24,751
Number of RSUs, Vested | shares	0
Number of RSUs, Forfeited | shares	0
Number of RSUs - Ending balance | shares	74,751
Weighted-Average Grant Date Fair Value
Weighted-Average Grant Date Fair Value - Beginning balance | $ / shares	$ 72.70
Weighted-Average Grant Date Fair Value, Granted | $ / shares	184.00
Weighted-Average Grant Date Fair Value, Vested | $ / shares	0
Weighted-Average Grant Date Fair Value, Forfeited | $ / shares	0
Weighted-Average Grant Date Fair Value - Ending balance | $ / shares	$ 109.55

XML

Stock-Based Compensation - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020	Jun. 30, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense		$ 34,104	$ 8,710
Total intrinsic value of outstanding options	$ 448,700	448,700
Total intrinsic value of exercisable options	278,200	278,200
Performance-based Restricted Stock Unit (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of performance-based restricted stock units, performance targets not met		4,200
Time-based Restricted Stock Unit (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	300
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 2,900	$ 10,000
Performance-based Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Performance-based stock options which have not met performance targets	303,000	303,000
Unrecognized compensation expense	$ 34,100	$ 34,100

XML

Stock-Based Compensation - Summary of Stock Option Activity (Details) - $ / shares	6 Months Ended
	Jun. 30, 2020
Number of Options, Abstract
Number of Options, Outstanding - Beginning balance	4,038,949
Number of Options, Granted	973,999
Number of Options, Exercised	(47,351)
Number of Options, Forfeited	(171,917)
Number of Options, Outstanding - Ending balance	4,793,680
Number of Options, Exercisable	2,240,699
Weighted Average Exercise Price, Abstract
Weighted-Average Exercise Price, Outstanding - Beginning balance	$ 41.24
Weighted-Average Exercise Price, Granted	203.19
Weighted-Average Exercise Price, Exercised	37.51
Weighted-Average Exercise Price, Forfeited	94.68
Weighted-Average Exercise Price, Outstanding - Ending balance	72.27
Weighted-Average Exercise Price, Exercisable	$ 33.31

XML

Net Loss per Share - Computation of Basic and Diluted Net (Loss) Income per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Numerator
Net loss	$ (67,581)	$ (34,380)	$ (116,520)	$ (63,534)
Denominator
Weighted-average number of common shares used in net loss per share – basic	33,265,778	30,069,048	33,243,931	29,950,241
Dilutive potential common shares	0	0	0	0
Weighted-average number of common shares used in net loss per share – diluted	33,265,778	30,069,048	33,243,931	29,950,241
Net loss per share – basic	$ (2.03)	$ (1.14)	$ (3.51)	$ (2.12)
Net loss per share – diluted	$ (2.03)	$ (1.14)	$ (3.51)	$ (2.12)

XML

Net Loss per Share - Additional Information (Details) - shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Earnings Per Share [Abstract]
Weighted average anti-dilutive shares excludes from computation of earnings per share	4,793,680	3,845,874